<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-415-03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LANOXIN 0.125MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DIGOXIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.125
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        16.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ASPEN" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ASPEN
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASPEN
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C01AA05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1. What Lanoxin is and what it is used for</strong><br />Lanoxin contains a medicine called digoxin. This belongs to a group of medicines called &lsquo;cardiac glycosides&rsquo;. They work by slowing down the rate while increasing the force of your heart when it beats.<br />It is used to treat certain heart problems, such as:<br /><strong>&bull; Heart failure</strong><br />This is when your heart muscle can&rsquo;t pump strongly enough to supply blood around your whole body. It is not the same as a heart attack and does not mean that your heart stops.<br /><strong>&bull; Certain types of irregular heart beats</strong><br />These include &lsquo;atrial flutter&rsquo; or &lsquo;fibrillation&rsquo;. They are caused by problems in the way the upper chambers of your heart send electrical signals. They cause your heart to beat too fast or in an uneven way.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2. Before you take Lanoxin<br />Do not take Lanoxin if:</strong><br />&bull; You are allergic (hypersensitive) to digoxin, digitoxin or any of the other ingredients of Lanoxin (listed in Section 6)<br />&bull; You have been told that you have any of the following heart problems:<br />- &lsquo;Second degree&rsquo; or &lsquo;intermittent complete heart block&rsquo;<br />- Certain types of &lsquo;supraventricular arrhythmias&rsquo;<br />- &lsquo;Ventricular tachycardia&rsquo; or &lsquo;Ventricular fibrillation&rsquo;<br />- &lsquo;Hypertrophic obstructive cardiomyopathy&rsquo;<br />Your doctor should have checked your heart problem and decided that this medicine will help you. If you are not sure, talk to your doctor or pharmacist before taking Lanoxin.</p><p><strong>Take special care with Lanoxin</strong><br />Check with your doctor or pharmacist before using your medicine if:<br />&bull; You have recently had a heart attack (myocardial infarction)<br />&bull; You have been told that you have low potassium or magnesium levels in your blood (hypokalaemia or hypomagnesaemia)<br />&bull; You have been told that you have high calcium levels in your blood (hypercalcaemia)<br />&bull; You have a heart problem caused by a lack of vitamin B, known as &lsquo;Beri-Beri disease&rsquo;<br />&bull; You have kidney problems<br />&bull; You have a lung problem<br />&bull; You have thyroid problems<br />&bull; You have digestion problems.<br />If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking this medicine. Your doctor may change your dose or you may need a different medicine.</p><p><strong>Taking other medicines</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines obtained without a prescription and herbal products.</p><p>In particular tell your doctor or pharmacist if:<br />&bull; You have taken either digoxin or digitoxin in the last 2 weeks. Your doctor may need to change your dose.</p><p>Taking Lanoxin with other medicines can change how they work or how Lanoxin works. Tell your doctor or pharmacist if you are taking any of the following:<br />&bull; Medicines for stomach problems, including indigestion, diarrhoea and being sick (vomiting)<br />&bull; Medicines for heart problems, including high blood pressure (hypertension) and irregular heart beat (arrhythmia)<br />&bull; Medicines for breathing problems, like asthma<br />&bull; Medicines for cancer<br />&bull; Medicines for epilepsy<br />&bull; Medicines for anxiety or depression<br />&bull; Medicines for bacterial infections (antibiotics)<br />&bull; Medicines for fungal infections (antifungals)<br />&bull; Medicines for high cholesterol<br />&bull; Medicines for preventing organ transplant rejection<br />&bull; Medicines for problems with your immune system<br />&bull; Medicines for preventing blood clots during kidney dialysis<br />&bull; Water tablets (diuretics)<br />&bull; Laxatives<br />&bull; Steroids<br />&bull; Anaesthetics<br />&bull; The herbal remedy St John&rsquo;s wort (Hypericum perforatum). This should not be taken, when taking Lanoxin. If you already take St John&rsquo;s wort, speak to your doctor, as soon as possible, before you stop taking St John&rsquo;s wort.</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking Lanoxin.</p><p><strong>Taking Lanoxin with food</strong><br />Lanoxin can be taken with most foods. However, you should avoid taking it with foods that are high in fibre (e.g. brown bread, cereals, fruit, vegetables and pulses), also known as &lsquo;roughage&rsquo;, as the amount of Lanoxin absorbed into the body may be reduced.</p><p><strong>Pregnancy and breast-feeding</strong><br />Talk to your doctor before taking this medicine if you are pregnant, might become pregnant or are breast-feeding.</p><p><strong>Driving and using machines</strong><br />You may feel dizzy, tired, have a headache or get blurred vision while taking Lanoxin. If this happens, do not drive or use any tools or machines.</p><p><strong>Important information about some of the ingredients of Lanoxin</strong><br />This medicine contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking Lanoxin.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3. How to take Lanoxin</strong><br />Always take Lanoxin exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.<br />Your doctor will have decided how much Lanoxin is right for you:<br />&bull; It depends on what heart problem you have and how serious it is.<br />&bull; It also depends on your age, weight and how well your kidneys work.<br />&bull; Your dose may go up or down depending on how you respond to the medicine. Your doctor will do checks to see how well the medicine is working. These may involve blood and urine tests.<br />Taking this medicine<br />&bull; Tablets should be swallowed whole.<br />&bull; You usually take this medicine in two stages:<br />Stage 1 - loading dose<br />The loading dose gets your Lanoxin levels up to the correct level quickly. You will either:<br />- Take one large single dose and then begin your maintenance dose or<br />- Take a smaller dose each day for a week and then begin your maintenance dose.<br />Stage 2 - maintenance dose<br />After your loading dose you will take a much smaller dose every day, until your doctor tells you to stop.<br />Adults and children over 10 years<br />&bull; Loading dose<br />- Usually between 0.75 and 1.5 mg (6 and 12 tablets) as a single dose.<br />- For some patients, this may be given in divided doses 6 hours apart.<br />- Alternatively, between 0.25 and 0.75 mg (2 and 6 tablets) may be given each day for a week.<br />- You may take a higher strength tablet for the loading dose.</p><p><strong>&bull; Maintenance dose</strong><br />- Your doctor will decide this, depending on your response to Lanoxin.<br />- It is usually between 0.125 and 0.25 mg (1 and 2 tablets) daily.</p><p><strong>Children under 10 years</strong><br />&bull; Loading dose<br />- This is worked out using your child&rsquo;s weight<br />- Usually between 0.025 and 0.045 mg per kg of body weight.<br />- This should be given in divided doses between 4 and 8 hours apart.</p><p><strong>&bull; Maintenance dose</strong><br />- The doctor will decide this, depending on your child&rsquo;s response to Lanoxin.<br />- It is usually a 1/5 (fifth) or a 1/4 (quarter) of the loading dose, to be taken daily.</p><p><strong>If you use more Lanoxin than you should</strong><br />If you take too much or if somebody else takes your medicine by mistake, go to the hospital immediately. You may get any of the side effects and symptoms listed in Section 4, but these can be serious.</p><p><strong>If you forget to use Lanoxin</strong><br />&bull; If you forget to take a dose, take it as soon as you remember. However, if it is almost time for the next dose, skip the missed dose.<br />&bull; Do not take a double dose to make up for the one that you missed.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4. Possible side effects</strong><br />Like all medicines, Lanoxin can cause side effects, although not everybody gets them. In general, the side effects tend to happen if the dose you are taking is too high, your doctor may adjust your dose.</p><p><strong>Tell your doctor immediately if:</strong><br />&bull; You have palpitations, chest pain, shortness of breath or sweating.</p><p>These can be symptoms of a serious heart problem caused by new irregular heart beats. If these happen, tell your doctor immediately.</p><p><strong>Other side effects that you should tell your doctor about, include:<br />Common</strong> (affects less than 1 in 10 people)<br />&bull; Slow or irregular heart rate<br />&bull; Feeling sick, being sick or diarrhoea<br />&bull; Skin rash that may be itchy<br />&bull; Drowsiness or dizziness<br />&bull; Visual disturbances, with blurred or yellow-green sight.</p><p><strong>Uncommon</strong> (affects less than 1 in 100 people)<br />&bull; Depression.</p><p><strong>Very Rare</strong> (affects less than 1 in 10,000 people)<br />&bull; Bruising or bleeding more easily than normal<br />&bull; Stomach pain caused by lack of blood supply or damage to your intestines<br />&bull; Mental disturbances, you may feel confused, indifferent or unable to judge clearly<br />&bull; Weakness, tiredness or a general feeling of being unwell<br />&bull; Breast enlargement in men<br />&bull; Loss of appetite<br />&bull; Headache.</p><p>Lanoxin can very rarely cause serious irregular heart rates. Your doctor may do regular checks to make sure Lanoxin is working safely for you.</p><p>If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5. How to store Lanoxin</strong><br />&bull; Keep out of the reach and sight of children.<br />&bull; Do not use Lanoxin after the expiry date on carton or bottle label (Exp.). The expiry date refers to the last day of that month.<br />&bull; Store below 25&deg;C<br />&bull; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.What Lanoxin contains</strong><br />&bull; The active ingredient is digoxin, each tablet contains 0.125 mg (125 micrograms).<br />&bull; The other ingredients are lactose, starches, hydrolysed starch and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                b.What Lanoxin looks like and contents of the pack
Within the carton is an amber glass bottle that contains 500 white tablets. A white, round, flat tablet debossed ‹DO12» on the one side and plain on the other side.
OR
Carton containing blisters in 100 or 500 tablet.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong><br />Aspen Pharma Trading Limited<br />3016 Lake Drive,<br />Citywest Business Campus,<br />Dublin 24,<br />Ireland<br />Service-Tel: 0800 008 7392 (+44 1748 828 391)</p><p><strong>Manufactured by:</strong><br />Aspen Bad Oldesloe GmbH, Industriestrasse 32-36, D 23843 Bad Oldesloe, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in {08/2014}; version number {1}
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>1. ما المقصود بالعقار لانوكسين؟ وما دواعي استخدامه؟</strong><br />يحتوي لانوكسين على مادة دوائية تُسمى ديجوكسين. تنتمي هذه المادة الدوائية إلى فئة من الأدوية تُسمى &quot;الجليكوزيدات القلبية&quot;. تعمل هذه الفئة الدوائية<br />عن طريق تبطئة نبض القلب وفي الوقت نفسه زيادة قوة القلب عند النبض.</p><p>ويُستخدم هذا العقار لعلاج اضطرابات معينة في القلب مثل:<br /><strong>&bull; فشل القلب،</strong><br />تحدث هذه الحالة عندما لا تستطيع عضلة القلب ضخ الدم بقوة كافية لإمداد الدم إلى بقية أعضاء الجسم. تختلف هذه الحالة عن النوبة القلبية ولا تعني<br />توقف القلب.</p><p><strong>&bull; أنواع معينة من اضطرابات نظم القلب</strong><br />تشمل هذه الأنواع ما يُعرف بحالة &quot;الرفرفة الأذينية&quot; أو &quot;الرجفان&quot;. وتحدث هذه الحالات بسبب مشكلات في طريقة إرسال الإشارات الكهربية من التجاويف العلوية للقلب. وتسبب هذه المشكلات سرعة نبض القلب بشكل مفرط للغاية أو بطريقة غير سوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>2. قبل استخدام العقار لانوكسين</strong></p><p><strong>يجب عدم استخدام لانوكسين في الحالات التالية:</strong><br />&bull; إذا كنت تعاني من فرط الحساسية تجاه مادة ديجوكسين أو ديجيتوكسين أو أيٍ من المكونات الأخرى في العقار لانوكسين (المذكورة في القسم 6).<br />&bull; إذا كان الطبيب قد أخبرك أنك تعاني من أحد اضطرابات القلب التالية:<br />- إحصار القلب من &quot;الدرجة الثانية&quot; أو إحصار القلب &quot;التام المتقطع&quot;.<br />- أنواع معينة من حالة &quot;اضطراب النظم فوق البطيني&quot;.<br />- &quot;تسرع القلب البطيني&quot; أو &quot;رجفان القلب البطيني&quot;.<br />- &quot; اعتلال عضلة القلب الانسدادي الضخامي&quot;.</p><p>ينبغي أن يكون طبيب القلب قد فحص حالتك وقرر أن استخدام هذا العقار سيكون مفيدًا لك. إذا كنت غير متأكد من شيء، فاستشر الطبيب أو الصيدلي&nbsp;<br />قبل استخدام لانوكسين.</p><p><strong>اتخاذ العناية الخاصة مع لانوكسين</strong><br />ينبغي استشارة الطبيب أو الصيدلي قبل استخدام هذا العقار في الحالات التالية:<br />&bull; إذا كنت أُصبت مؤخرًا بنوبة قلبية (احتشاء عضلة القلب).<br />&bull; إذا كان الطبيب أخبرك أنك تعاني من نقص مستويات البوتاسيوم أو الماغنيسيوم في الدم.<br />&bull; إذا كان الطبيب أخبرك أنك تعاني من ارتفاع مستويات الكالسيوم في الدم.<br />&bull; إذا كنت تعاني من مشكلة في القلب بسبب نقص فيتامين ب وتُعرف بداء &quot;بري-بري&quot;.<br />&bull; إذا كنت تعاني من مشكلات في الكلى.<br />&bull; إذا كنت تعاني من مشكلات في الرئة.<br />&bull; إذا كنت تعاني من مشكلات في الغدة الدرقية.<br />&bull; إذا كنت تعاني من مشكلات في الجهاز الهضمي.</p><p>إذا كنت لا تعلم هل أي من الحالات المذكورة أعلاه تنطبق عليك أم لا؛ فينبغي استشارة الطبيب أو الصيدلي قبل استخدام هذا العقار. قد يقوم الطبيب بتغي ر ي<br />الجرعة التي تأخذها من هذا العقار أو قد يصف لك عقارًا آخر.</p><p><strong>استخدام أدوية أخرى</strong><br />يُرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول حاليًا - أو تناولت مؤخرًا - أي أدوية أخرى. يشمل هذا الأدوية التي تحصل عليها دون وصفة طبية بما في<br />ذلك الأعشاب الطبية.</p><p>ينبغي إخبار الطبيب أو الصيدلي في الحالات التالية على وجه الخصوص:<br />&bull; إذا كنت استخدمت العقار ديجوكسين أو العقار ديجيتوكسين في الأسبوعين الماضيين. قد يلزم الطبيب القيام بتعديل الجرعة.<br />إن استخدام العقار لانوكسين مع أدوية أخرى يمكن أن يؤثر على فعالية تلك الأدوية أو العكس. ينبغي إخبار الطبيب أو الصيدلي إذا كنت تستخدم أي دواء<br />من الأدوية التالية:<br />&bull; الأدوية المستخدمة لعلاج اضطرابات المعدة بما في ذلك عسر الهضم والإسهال والقيء.<br />&bull; الأدوية المستخدمة لعلاج اضطرابات القلب بما في ذلك ضغط الدم المرتفع (فرط ضغط الدم) وعدم انتظام نبض القلب (اضطراب نظم القلب).<br />&bull; الأدوية المستخدمة لعلاج اضطرابات التنفس مثل الربو.<br />&bull; الأدوية المستخدمة لعلاج السرطان.<br />&bull; الأدوية المستخدمة لعلاج الصرع.<br />&bull; الأدوية المستخدمة لعلاج القلق أو الاكتئاب.<br />&bull; الأدوية المستخدمة لعلاج الالتهابات الجرثومية (المضادات الحيوية).<br />&bull; الأدوية المستخدمة لعلاج الالتهابات الفطرية (مضادات الفطريات).<br />&bull; الأدوية المستخدم لعلاج ارتفاع الكوليسترول في الدم.<br />&bull; الأدوية المستخدمة للوقاية من رفض الأعضاء المزروعة في الجسم.<br />&bull; الأدوية المستخدمة لعلاج اضطرابات الجهاز المناعي.<br />&bull; الأدوية المستخدمة للوقاية من الجلطات الدموية أثناء الديال الكلوي.<br />&bull; أقراص الماء(مدرات البول).<br />&bull; الملينات.<br />&bull; الستيرويدات<br />&bull; عقاقير التخدير<br />&bull; عشبة القديس يوحنا الطبية. يجب عدم استخدام هذه العشبة الطبية أثناء استخدام لانوكسين. إذا كنت تستخدم عشبة القديس يوحنا بالفعل؛ فيجب<br />عليك استشارة الطبيب في أسرع وقت ممكن قبل التوقف عن استخدام هذه العشبة.</p><p>إذا كنت لا تعلم هل أي من الحالات المذكورة أعلاه تنطبق عليك أم لا؛ فينبغي استشارة الطبيب أو الصيدلي قبل استخدام لانوكسين.</p><p><strong>تناول لانوكسين مع الطعام</strong><br />يمكن استخدام لانوكسين مع معظم الأطعمة. ولكن يجب تجنب تناوللانوكسين مع الأطعمة الغنية بالألياف (مثل الخبز البني (الأسمر)، الحبوب،<br />الفاكهة، الخضروات، البقول) - وتُسمى هذه الأطعمة أيضًا &quot;الخشائن&quot; - لأنها قد تقلل كمية لانوكسين التي يمتصها الجسم.</p><p><strong>الحمل والرضاعة الطبيعية</strong><br />ينبغي استشارة الطبيب قبل أخذ هذا الدواء إذا كانت المريضة حاملاً أو تنوي الحمل أو إذا كانت تُرضع رضاعة طبيعية.</p><p><strong>قيادة المركبات واستخدام الآلات</strong><br />قد يشعر المريض بدوار أو تعب أو يُصاب بصداع أو تغيُّم الرؤية أثناء استخدام لانوكسين. إذا حدث هذا؛ فيجب على المريض تجنب قيادة مركبات أو استخدام<br />أي أدوات أو آلات.</p><p><strong>معلومات مهمة عن بعض المكونات في العقار لانوكسين</strong><br />يحتوي هذا الدواء على اللاكتوز. إذا كان الطبيب قد أخبرك أنك لا تتحمل بعض أنواع السكر، فينبغي استشارة الطبيب قبل تناول لانوكسين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>3. كيفية استخدام لانوكسين</strong><br />يجب استخدام لانوكسين حسب إرشادات الطبيب دائمًا. ينبغي استشارةالطبيب أو الصيدلي في حالة عدم التأكد من كيفية الاستخدام.</p><p>إن الطبيب هو الذي يقرر الجرعة المناسبة لك من لانوكسين على أساس:<br />&bull; نوع الاضطراب القلبي الذي تعاني منه ودرجة خطورته.<br />&bull; سنك ووزنك ودرجة سلامة وظائف الكلى لديك.<br />&bull; قد تزيد الجرعة التي يصفها لك الطبيب أو تقل حسب استجابة جسمك للدواء. سيقوم الطبيب بإجراء فحوص عليك للتعرف على درجة فعالية الدواء في جسمك قد تتضمن هذه الفحوص اختبارات دم وبول.</p><p><strong>تناول هذا الدواء</strong><br />&bull; يجب ابتلاع الأقراص كاملة.<br />&bull; يجب عليك أخذ هذا الدواء على مرحلتين:</p><p><strong>المرحلة الأولى:</strong> جرعة التحميل</p><p>جرعة التحميل هي الجرعة التي تجعل مستويات لانوكسين تصل إلى المستوى الصحيح في جسمك بسرعة. وستأخذ إما:<br />- جرعة فردية كبيرة واحدة ثم تبدأ في جرعة المداومة، أو<br />- جرعة صغيرة كل يوم لمدة أسبوع ثم تبدأ في أخذ جرعة المداومة.&nbsp;</p><p><strong>المرحلة الثانية: </strong>جرعة المداومة</p><p>بعد جرعة التحميل؛ سوف تأخذ جرعة أقل كثيرا كل يوم حتى يخبرك الطبيب بالتوقف.</p><p><strong>البالغون والأطفال فوق 10 سنوات</strong></p><p>&bull; جرعة التحميل<br />- تتراوح عادة بين 0.75 و 1.5 مجم (6 أقراص و 12 قرصًا) كجرعة فردية.<br />- قد تُعطى هذه الجرعة لبعض المرضى على جرعات مقسمة كل 6 ساعات.<br />- أو، يمكن إعطاء جرعة تتراوح بين 0.25 و. 75 مجم (قرصان و 6 أقراص) كل يوم لمدة أسبوع واحد.<br />- يمكن أن تأخذ قرصًا ذا تركيز أكبر لجرعة التحميل.</p><p>&bull; جرعة المداومة<br />- سوف يقرر الطبيب هذه الجرعة على أساس استجابتك للعقار لانوكسين.<br />- تتراوح هذه الجرعة عادة بين 0.125 و 0.25 مجم (قرص واحد وقرصان) كل يوم.</p><p><strong>الأطفال تحت 10 سنوات</strong></p><p><strong>&bull; جرعة التحميل</strong><br />- يتم تحديد هذه الجرعة على أساس وزن الطفل<br />- تتراوح هذه الجرعة عادة بين 0.025 و 0.045 مجم لكل كيلو جرام من وزن الجسم.<br />- يجب إعطاء هذه الجرعة على جرعات مقسمة كل 4 و 8 ساعات.</p><p><strong>&bull; جرعة المداومة</strong><br />- سوف يقرر الطبيب هذه الجرعة على أساس استجابة الطفل للعقار لانوكسين.<br />- عادة تكون هذه الجرعة 1/ 5(خمس) أو 1/ 4 (ربع) جرعة التحميل، وتُعطى بصفة يومية.</p><p><strong>في حالة أخذ جرعة زائدة من لانوكسين عن الجرعة الموصوفة</strong><br />في حالة أخذ جرعة مفرطة للغاية من هذا العقار سواء بواسطة المريض أو شخص غيره, يجب الذهاب إلى المستشفى على الفور. قد يُصاب المريض بأي<br />من الآثار الجانبية والأعراض المذكورة في القسم 4، وقد تكون خطيرة</p><p><strong>في حالة نسيان جرعة لانوكسين</strong><br />&bull; في حالة نسيان جرعة من هذا الدواء، ينبغي تناولها حال تذكرها على الفور. ورغم ذلك، إذا كان وقت الجرعة التالية قد اقترب للغاية، فلا تتناول الجرعة<br />التي نسيتها.<br />&bull; ينبغي عدم تناول جرعة مزدوجة لتعويض الجرعة الفائتة.</p><p><strong>في حالة التوقف عن استخدام لانوكسين</strong><br />يجب عدم التوقف عن أخذ هذا الدواء لأن مرض القلب الذي تعاني منه قد يتفاقم. إذا كنت ترغب في التوقف عن استخدام هذا الدواء؛ فينبغي أن تستشير الطبيب.</p><p>إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، فاسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>4. الآثار الجانبية الممكنة</strong><br />مثل كل الأدوية، يمكن أن يسبب لانوكسين آثارًا جانبية وإن كانت لا تحدث في جميع الأشخاص الذين يستخدمونه. عمومًا؛ يُتوقع حدوث الآثار الجانبية إذا<br />كانت الجرعة المأخوذةكبيرة أكثر من اللازم، وقد يتعين على الطبيب تعديل الجرعة لك.</p><p>يجب إخبار الطبيب على الفور في الحالات التالية:<br />&bull; حدوث خفقان، ألم في الصدر، ضيق التنفس أو تعرق.<br />يمكن أن تكون هذه أعراض مشكلة خطيرة&nbsp;في القلب بسبب عدم انتظام نبض&nbsp;القلب مؤخرًا. إذا حدث هذا؛ فيجب إخبار الطبيب على الفور.</p><p>تشمل الآثار الجانبية الأخرى التي يجب عليك إخبار الطبيب عنها ما يلي:</p><p><strong>الآثار الشائعة</strong> (تؤثر في أقل من مريض واحد من كل 10 مرضى):<br />&bull; بطء نبض القلب أو عدم انتظامه<br />&bull; شعور بالغثيان، قيء أو إسهال<br />&bull; طفح جلدي قد يكون مصحوبًا بحكة<br />&bull; نعاس أو دوار<br />&bull; اضطرابات في الرؤية مع تغيم الرؤية أو رؤية يغلب عليها اللونين الأصفر والأخضر.</p><p>الآثار غير الشائعة (تؤثر في أقل من مريض واحد من كل 100 مريض):<br />&bull; اكتئاب.<br /><strong>الآثار النادرة جدًا</strong> (تؤثر في أقل من مريض واحد من كل 10000 مريض):<br />&bull; كدمات أو نزيف بسهولة أكثر من المعتاد<br />&bull; ألم في المعدة بسبب نقص إمداد الدم أو تلف بالأمعاء<br />&bull; اضطرابات عقلية؛ شعور بالارتباك، لامبالاة أو عدم القدرة على الحكم على الأشياء بوضوح.<br />&bull; ضعف، تعب، أو شعور بتوعك عام<br />&bull; تضخم الثديين في الرجال<br />&bull; فقدان الشهية<br />&bull; صداع.<br /><strong>في حالات نادرة جدًا؛</strong> يمكن أن يسبب لانوكسين اضطرابات خطيرة في نبض&nbsp; القلب. قد يقوم الطبيب بإجراء فحوص منتظمة عليك للتأكد من سلامة مفعول لانوكسين على صحتك.</p><p>إذا زادت خطورة أي من الآثار الجانبية، أو إذا لاحظت حدوث أي آثار جانبية غير المذكورة في هذه النشرة، فيُجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>5. كيفية تخزين لانوكسين</strong><br />&bull; يجب حفظه بعيدًا عن متناول الأطفال ونظرهم.<br />&bull; يجب عدم استخدام لانوكسين بعد تاريخ انتهاء الصلاحية المكتوب على العلبة الكرتونية أو ملصق العبوة (بعد الرمز Exp).يشير تاريخ الصلاحية إلى آخر يوم&nbsp;<br />في الشهر المطبوع.<br />&bull;يُخزن في درجة حرارة أقل من 25 درجة مئوية.<br />&bull;ينبغي عدم التخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لا تحتاج إليها. ستساعد<br />هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ.محتويات لانوكسين</strong><br />&bull; المادة الدوائية الفعالة هي ديجوكسين، ويحتوي كل قرص على 0.125 مجم (125 ميكروجرام).<br />&bull; المكونات الأخرى هي اللاكتوز، نشاء، نشاء هيدروليزد، ستيريت ماغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>ب.شكل أقراص لانوكسين ومحتويات العبوة</strong><br />يوجد داخل العلبة الكرتونية عبوة زجاجية لونها عنبري او اشرطة معدنية تحتوي على 100 أو 500 قرص أبيض اللون. الأقراص بيضاء اللون ومستديرة<br />ومستوية ومنقوش على أحد جانبي كل قرص الرمز &quot; DO12 &quot;، والجانب الآخر مسطح.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>الشركة صاحبة تفويض التسويق:</strong><br />أسبن فارما تريدينج المحدودة، 3016 ليك درايف، سيتي ويست بزنس كامبوس،<br />دوبلن 24 ، أيرلندا</p><p><strong>تم التصنيع بواسطة:</strong><br />أسبن باد أولدسلو المحدودة, المنطقة الصناعية 32 - 36 , د- 23843 باد أولدسلو,<br />ألمانيا.<br />لأي معلومات عن هذا الدواء، فضلا الاتصال بالوكيل المحلي لمالك حقوق التسويق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في 08 / 2014 رقم الإصدار (1)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lanoxin 125 Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Digoxin Ph Eur       0.125 mg/tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. Its therapeutic benefit is greatest in those patients with ventricular dilatation.</p><p>Lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation.</p><p>Lanoxin is indicated in the management of certain supraventricular arrhthmias, particularly chronic atrial flutter and fibrillation,.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The dose of Lanoxin for each patient has to be tailored individually according to age, lean body weight and renal function. Suggested doses are intended only as an initial guide.</p><p>The difference in bioavailability between injectable Lanoxin and oral formulations must be considered when changing from one dosage form to another. For example, if patients are switched from oral to the i.v. formulation the dosage should be reduced by approximately 33 %.</p><p><strong>Adults with chronic cardiac failure in the absence of supraventricular arrhythmia:</strong><br />No loading dose is required. The usual daily dose is 125 to 250 micrograms (0.125 to 0.25 mg) for patients with normal renal function. A lower dose of 62.5 micrograms (0.0625 mg) should be considered in the elderly.</p><p><strong>For the management of atrial fibrillation or flutter in adults and children over 10 years:</strong></p><p>Rapid Oral Loading:<br />If medically appropriate, rapid digitalisation may be achieved in a number of ways, such as the following:</p><p>750 to 1500 micrograms (0.75 to 1.5 mg) as a single dose.</p><p>Where there is less urgency, or greater risk of toxicity eg. in the elderly, the oral loading dose should be given in divided doses 6 hours apart, assessing clinical response before giving each additional dose. (See Special Warnings and Precautions for Use).</p><p>Slow Oral Loading:<br />Digitalisation may be achieved more slowly with doses of 250 to 750 micrograms (0.25 to 0.75 mg) daily for 1 week followed by an appropriate maintenance dose. A clinical response should be seen within one week.</p><p><strong>NOTE: </strong>The choice between slow and rapid oral loading depends on the clinical state of the patient and the urgency of the condition.</p><p>Maintenance Dose:<br />The maintenance dosage should be based upon the percentage of the peak body stores lost each day through elimination. The following formula has had wide clinical use:</p><p><img alt="" width="500" height="357" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAkACQAAD/4RD6RXhpZgAATU0AKgAAAAgABAE7AAIAAAAQAAAISodpAAQAAAABAAAIWpydAAEAAAAgAAAQ0uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEFobWFkIEFsWmFocmFuaQAABZADAAIAAAAUAAAQqJAEAAIAAAAUAAAQvJKRAAIAAAADNTEAAJKSAAIAAAADNTEAAOocAAcAAAgMAAAInAAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADIwMjA6MDU6MjEgMTQ6NTU6MjAAMjAyMDowNToyMSAxNDo1NToyMAAAAEEAaABtAGEAZAAgAEEAbABaAGEAaAByAGEAbgBpAAAA/+ELImh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjAtMDUtMjFUMTQ6NTU6MjAuNTA4PC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPkFobWFkIEFsWmFocmFuaTwvcmRmOmxpPjwvcmRmOlNlcT4NCgkJCTwvZGM6Y3JlYXRvcj48L3JkZjpEZXNjcmlwdGlvbj48L3JkZjpSREY+PC94OnhtcG1ldGE+DQogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgIDw/eHBhY2tldCBlbmQ9J3cnPz7/2wBDAAcFBQYFBAcGBQYIBwcIChELCgkJChUPEAwRGBUaGRgVGBcbHichGx0lHRcYIi4iJSgpKywrGiAvMy8qMicqKyr/2wBDAQcICAoJChQLCxQqHBgcKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKir/wAARCAKWA58DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6RooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorwr4veGU0HxfZ+NfCljDa6ho8DaldpbxiP7WglVZC+Bydrtk9SM17Ro+q22t6LZ6pYPvtryFZo2/2WGaFrDm/r+t/uE3aXL/X9aou0V4BrlpB4v/aH8K3WtwR32k3kV2lpZ3CB4jFCrAOVPB3Plvpsr2XU/Emi+HGhsbh5Fl8rdHaWNnLcSLGON3lwqzKg6ZwB2o+ypPr/AMH/ACG/icV0NokAZPAFV7HULPU7VbrTbuC7t2JCy28gkQkHBGRxwQRWfD4s8P3Xhptfj1a0OkKCXu2kCxrzghs9DnjB5zxWfp/izwXp3g1NZ06/06w0DzXSOZEEEJfeQ20YGSWDdBz1560bXuG+x1FFche/FbwRpv8AZn27xFbQHVI0ltQ6vlkcZVmGPkB9XxUPxC+IUPguLSo1tLy5m1O9ht0lhtXkjjVmG45VSC23O1Bliegp2d7edvmH/Dna0VmjX9P/ALJj1GV5reCVtqLc20sMrNnAUROofcccDbk9qq6Z4y0HVnu47a+MU1knmXMF5DJaywp/faOVVYL/ALWMe9IDcorkZfir4Ii0O41h/Edp/Z9vP9neddzBpNobagAy5wwPy5/Q1t2PiTRtS8Orr1lqVvJpTRGX7Xv2oqjqST93GDnOMd6A8jTorn9P8deHtS1aHTYLyWK7uFL28d1aTW/2hR1MRkRRIMc5Unjmh/HnhaPWbvSn12zF5YwvPdR+ZxbohAYu33VxuHBOfyNAHQUVgeFvHHhvxrDcSeGNVivxbPsmCKysh7fKwBwcHB6HHFJqXjnw7pMrLf37Rxxv5ctyttK9vC3TbJMqmNDkjhmFHWwHQUVVvNTs7CzW6urhVhcgRkfMZCegUDJYnsBkmqGjeLNG1+6ntdOun+124BmtLm3kt50B6MY5VVse+MUAbNFQXtjaalZS2eo2sN3azDbJBPGHRx6FTwa8U+EHgnwtf6x45j1Dw7pd4lpr0sFutzZxyiGME4VdwOB7Chatryv+KX6je1/O35/5HuVFeP8AxCguvhO1l4v8JzzRaNHPHb6povmFrcxH5Q8anIjI4Hy4HT3z6dd+IdMsdPt7y5uQI7pQ1ukaNJJPld2EjUFnOOcKCaN1f5C2djSorJ0TxPpHiF7iPSrsvPbEC4tponhmhJ6b4pArrntkDNRT+MdCtbi4iuL1o0tQ3n3Jgk+zxkHBUzbfLDA/w7t3tR5AbdFUtR1ey0q3Sa9lZRJkRxxxtJJKcZwkagsxwCcAE1W0PxPpHiP7QNJu/Mltm2XFvLE8M0J7B43Cuue2QM0Aa1FFFABRRRQAUUUUAFFFFABRSOwRGY5woycAk/kOtc5/wnmkf8+fiD/wnNQ/+MUAdJRWHYeL9N1G+jtbe21lJJDhWuNDvIEHGeXkiCr+JFblABRRRQAUV4z4g8IeG5f2j9Chl0DTZIbzS7me5he0QpNIGPzspGGbk8kZqXXk/wCFffGTwha+E1NrpuvNLb3mkwcW424PmpGOEI3EkgDp9aI+9y+f/BX6A9Oby/yT/U9horE1fxhouhvIuoXE37n/AF7W9pNOtvxn960asIxg5yxHHNWpvEGkQaGusyajbjTXVWS6EgKOGOF2kdckgADqTR0uBo1Xh1Gyubya1t7yCW5gAaWFJVZ4wSQCyg5GSD19DWXpHjDRNc1KXTrK5lS/ij8x7O7tZbWbZ/fEcqqxXnqBiuH+H1jZ6X8bfiJbadaw2luq2LCKCMIoJjYkhRxyST9TTSu9e1x/Zb7WPVKhuru2sbdp724it4VGWklcIo+pPFZGgeM9G8T3E8OjPeytbsyytLp1xAisp2su+SNV3A/w5z144rn/AI1abY3/AMI9elvrO3uJLW0eW3eWIM0L/wB5SR8p9xUTbjHmHFXlyndxSxzwpLC6yRyKGR0OQwPIIPcU6uD0r4k+D9HttD8P6lr9pb6nLZQAQMSdpMa4DMBtQnIwGIzmuy1DUrPSrT7TqNzHbw7goZzjcxOAo9STwAOTWklZszg+aKZaorF0nxfoutahJp9ndSR30aeY1neWstrNs/viOVVYr/tAYqbVvEWl6NIkN9LK88il1tra2kuZmXOC3lxqzbeeTjFSUXINQsrq6mtra7gmngAM0Ucqs0ec43AHIzg9fQ1Yrx34dXWiaJ8QPiTd6bDHBpEDWUipYWrMqr5TFtscak9c5AGeua9E8LeNNC8aWMt54bupru2iba0zWc0SE+il0UMRjnGccZ607afJP7w6v1N6isrQvEum+I1uW0prphaymKX7RZTW+1x1X96i5I74zjvUmqa/p+jSRR3skpmmyY4La3kuJXAIBYRxqzYGRk4wM80gNGiuX8R+PdK0HwfqGv24m1OGy3I6WUTSYkAyVYgYQDPJbAHIPPFT+E/FMGv+FbfU5/tFuy20cly91Zy2yAlAzFTIqhl6/MuR70dG+36h1S7nQ0Vz8Pjrw9NqUFl9ueKW6bbbPcWssMVycZAildQkh9lY07U/G/hnRtai0jU9btLfUJeVtmky4GC2WA+6MAnJwKAN6isDR/HPhrX9IudU0jVobixtZzbyz4ZVEnHyjcBuzkYxnORjNSaX4w0TWNUk0y0upY7+NPMNpeWstrKU/vKkqqzL7gEUeQG3RWLc+LtEtLy4t7m8ZPsoJuJzBIYIMckPNt8tDyPlLA+1bEcizRJJGdyOoZT6g0dLgOormT8QvDY8YJ4Wa7ul1lyQlq2n3A3AZ+YMY9pXg/Nnb71e07xVpWq69faNZSXL32nnFyj2U0aRnjA8xkCHOQRgnI5HFC12Dbc2KKxPGl/e6V4F1u/0pS17bWM0sGBn5whIOO9eX6V5ehXnwv1DRsLfa/F5eqFWy1+rQB2klPV2VuQTyM46U4q7+78b/wCQPRX9fwPa6KyNRdtUvf7It2IiUB76ReyHpGD6t39Fz0JBrWVVRAiKFVRgADAApALVe71Cy09Ua/u4LUSMEQzSqm5iQABk8kkgY9SKdd3dvYWct3ezx29vCheSWVgqoo6kk9BXj/xa1PQNbXwzdWsGdRh8QWaRz3NjJBK0Rc58tpEUvHnHK5XpQtZJd2l97sO2jfk/wR7NRWVq/ibStDmigv55TczKXjtrW2kuZmUdWEcSs20ZGTjAzTLLxZoOoeH5dctdVt20yEN51w7bFi2/eDhsFSO4OCKOlxF+01Kx1C1a5sL23uoEZkaWGVXVWU4YEg4yD1Hals7+z1GJ5NPu4LqNHMbtBIHCuOqkjoR6VjaDJ4U8SeGZ18Pwafd6LcSypLHFbAQTNn58qVAbJ6nBB964L4N6tp3hj4S6jfah5kFhaatd7jBbvL5ah8fdjUnA9cYAo6tPtf8AFf5g+lu9vz/yPXqKxfD/AIt0fxTojavoU1xc2K5xKbOaPzMddgZAX9PlB5461PoPiHT/ABLYNe6Q1w8CyNGWntJbclh1wJFUnB4yBjII6g07PYLlq41Gxs54YLu8t4JbhwkMcsqq0jHoFBPJ4PA9Ks15T8TtPs4/ih8O9QjtIFvJdVMUlwsYEjoEyFLdSBk4HbNej6pren6MiG/nKvLnyoYo2lllwMnZGgLNgegNJaxv52/L/MH8VvK/5/5F+isvRPEmk+IlnOk3Yle3fZPC8bRSwt6PG4DofqBVd/GWgxTTpJelI4CVkuWgkFuGDbSgm2+WX3cbQxbPGKA8zcorN1PxBp2k3ENvdyTNPNykNtbSXEm3ONxWNWIXJ5YgAetWNP1Ky1W2NxptzHcwh2jMkTZXcpwwz6g8H0IIoAtUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc5e28V547W2uUEkM2jzRyIw4ZTKgI/KvMPBuoXnhtta+ExlkS+jvCmlTYIIspsu0gPqi7j/vECvS38GTv4qGvf8ACVa2swUxi3AtfJERcMY9vkZxkAZzux/FWqfD+mnxOPEH2Zf7SFr9k87HPl7t2PzojZJX87/e2v8AL5sT3du6t9yX9fI828SWsNj+0L8PLW1jWOCDT7uONFGAqiMgD8q3o7i0b4qa1/wi9s95rf2S3h1Oa5n2WtogyUAABZnIJO0ccDJXPMurfDCLWPGNr4mn8U6/FqNlvFoYWtQlurZyqqYCCMHHzbj6k1ox+BbO38VT6/ZanqVrd3kSRX6wvGI73YuFZxsyrAd0K009Ffz/ABbf66g0ru3l+Fv6RynwUEqeHfFkNw8bvF4ivVYxoUUn5c4BJIGc8En61ieBgP8AhkvURjj7BqP/AKFLXe6R8NdL0CHWl0bUdVtJdYmeaSYXIkaBnILeWHVlGcckqWPrwMUNO+EljpfgS78I2fiTXl0q6JDKZLcuitneit5PAbPPfjgjJypawcfJL7lY0hJRkn/ev+ZzWpWFqP2SCBbxjdoMMzfL1cIpDH34HPtUnxEJbwX8NixJJ1vTCSe/yGunm+F1rP8AD1fBsniPXTpagJkPbiUxADEW7yfu5Geme2ccVa1D4b6bq/ga28L6rqWp3UFmyPbXhlRLmFk+4VZEUZUcAlT75rSUv3jmu6f3O5nFWST7SX3pIw/HF1Mfi94R06TV7vSLe5trsQXFssLE3HyYX96jrnbuA4zzgHk1sW3gG0svHll4p1DxFq1/qqQNZxC5+zIkiEM20rFCmccnr2qzrHw48Pa94Uh0HVYri5hgbzIrqS4ZrlJf+enmklt3ufyxS+HPAdt4bt5RFreuajdvG0cd7qd8bmWAH/nmGGxe38POBnNQtF6X/H/h7eg3r8/6/wCD6nLfBy1ga+8dTtChl/4Sa7j3lckL8vH0rm/DS+H4vgN4gtPEzXMelNrdzAIrM4lY+eNkae5bA5455r0Hwx8NYfCX9q/2V4m11jqrvNOZ2tnxM3WZf3PDe3K+oPFUtP8Ag3oll4V1Dw7NqusX2n3032krczRb4Z9wbzUdI1IbIB5JHt1o6r0S+63+TsOTvK6/mb/P/MxPGj6vJ41+HVzqNra2EY1cxxWyOZZVBjP334UHA5UA8/xHHNy5tobj9qK38+JJAnhneoYZwwuOD9RXQ6t8N9P16PSP7a1fWbufSZxPDc/ahFIxAIw3lqoHXqoVj61H/wAK0tl8ep4ti8Qa1HfRxC3SFWt/JWAHPk7TDnb753e+eacXaWvd/jG35k9H6Jfc7nLXLT2Hxl8dz6Uuy7/4RmOZNg+9KN2047ngVv8Aw0h0jxP8EdHtJo472zurHybyNjnfJ0l3d8ltxJ65Oau2Pw6gsPHtz4tXxBrM19dJ5U0MrQGF4h92PaIgQo4xgg+pOTmjF8HNAs9fm1HSdS13SoLmQy3Gm6fqTwWsznqWVcN+AYDjpUx+Hlf9at/r+A3vdf1ol+n4mT4kaG1+JPgjRNP1W50XSzZXUFjLaLE2JUCKqfvkcfcBAOMnPB556K28A2ll48svFOoeItWv9VSBrOIXP2ZEkQhm2lYoUzjk9e1aXijwNoPi/QY9I1izzbwENbvC3lyW7AYDIw+6R+VR+FfA9p4Wy41XWdYuNuxbjV79rl41/uqDhVHToATgZpp999fx/wCHsJrSy8vw/r7zpa8p+C3/ACHPiF/2Mc39a9PvbeS6spYILyaykcYW4gCF4/cB1ZfzBritC+Fi+Gp9Qm0Xxh4it5NSuDc3Rb7HJ5kh6t89ucfhiktG35W/FP8AQp/Dbzv+D/zMX9oW7E/w8j8OWg8/VNcvIYLS2Tl3IcMTj0GBz70zQlfTfj3ZaJqBylj4Vjj0/d0yHUSFfc7fyFdtpfgXSNN1z+3Jzc6nrPliL+0NQl8yRV9EAASMHnIRV6mpfEfg/TfEtxZXly1xaajp7F7PULOQJNASMHBIIIPdWBB9Kcfd+9/lYmS5vu/VP9LHH+K7WW2/aA8FXuljbPeWt3Bf7R9+BFDLu+jNx74rI1B/FvwzstSeWyt/F/ge4lmuJRG+y6tIpWZpAc8SINx9zn+EV6dpfh2DT7039zd3Op6i0Xkm9vCnmCPOdoVFVFGeu1RnAznFZ8/ga1ntHsP7V1VNLm3/AGjT/PVo5w5JYFmUyKCSflR1HOMY4papJLz9NXcq93d+Xrocheak2tfGnTLa312+0i2u/Don02W2jgJmLSbnX99G4ztCHgA/LXTaP4Fs9F8dS+I59e1TUNWvbT7M4ujAqSRqQc7Yok5HHPvVjxZ8O/D/AIw0u0s9Rt5LZrDBsbqyfyprQgYHlsOnQcEEcDjirXhjwja+GIGCahqmq3Lja15q169zMVznaCeFHsoHvTVlt0v+N/8AOxOvXy/C3+VzeooopDCiiigAooooAKKKKAEcFkYBihIwGGMj35rnP+EX1f8A6HvxB/340/8A+Ra6SigDDsNA1K0vo57jxdrN9Ghy1vcQ2YR+O5jt1b34YVuUUUAFFFFAHk3jCxm1D9onwxDbald6ZJ/ZFywuLQRlxhumJEdcH3Wux0zwFp9j4k/4SLULy+1rWVjMUN5qDoTAh6qiRoiL35C55PNUL/4ZpqHjKHxQ/ivX4tSt0eK3MRtQkMbEkoFMBBHP8WT0yTXbAYUAkkgdT3oWkV31/Fv/ADB6yfbT8Ev8jyT4Y2l74p8JXrv4u1ezuhqN3HqFlBFZssUhlYkEyQM3KkdWPtwMVPf+GfCfgvwhoHhxrjVtTFrrcb6ZbLMnmy3QJcISFVdg3EnOMeua29X+Emhal4nfXrG/1nQr24IN2dGvjbLd4P8Ay0wP1BB59ea09Z8AaRrOj6dYeZeWTaXOtzZXdtN+/hlGfn3OG3E5OdwOc8007Wfp+H9aA9W/n+N/6ZyFwdV/4aG8MzaslnBJPo90vk2xZ9gBBwZGxu5PZV/GuZ1fVdZ0b4nfEW90e0kubeJtNbUhbSbbhbXyj5hi4+9jvwQM455HqF78OtL1LxLpevajfancX+nRvGrm52LOGxneqADHH3V2qcnINQaJ8N7fQ/GN/wCJIfEOtXN5qQAvI7g25inAGFBVYQRt7bSOnOeaUdEvn+d1/wAEafxedv0/y0Oh8PXmlah4dsbrw88T6bLCGtzF93b/AI+uec5zXPfGD/kj3if/AK8HqTwZ8PLbwPNcf2VrmrT2lxI8z2NyYDArscllVIlKfRSB7V0eraVZa7pF1peqwC4s7uMxTRFiNynqMjBH4Uqi5otLqEHyyV+hwnibQ9JvP2fLi3vbaBYItE+0IfLH7uUQ7g4/2t3f3rmrW91CLxZ8IbTxEX8uTTZHYSjrdCABS3+0AfzNeh2ngO0gtI7C71XVNS0qHb5OnXskbxIF+6CQgdwMDh2YcCtDxL4V0rxXp8Vpq8TnyJVnt5oZDHLbyL910YcgitHL33Lu7/n+Ov4IzUfcUH0Vr/d+Gn4s4r4u2sqa74F1PSxjVIteit42UfM0LqfMU/7OF5qb4c6sNS+Ivj+O+b/iZW+oxxLG55W2VMR4H93O4/Vveus0/wALx217b3up6lfa1d2oYW09+Yswhhg7ViRFyRxuILYJGcGsfxJ8LdC8R+JItfFzqekaqgCSXekXZtpJ0H8DkDkdsjBwBzxUrTT1/G3+X4st6/h+F/8AP8DF+H6xp8Z/iUsQUAz2RIX1MJz+tQaVqC/Djx54g8POh/s/U4m1fR4geDKeJYF9CXwQP9qum0r4feHfCniK/wDE1tPd20s6A3BlvWWAKqBcsuQGwAW3PuOWJzVe5/4Rvx74q0O50y5stXGhzPdtdWsqzRxMV2rGWUkZJIfH/TMH0o0ul5Wf3f8AAv8AgD6vzuvX+tPmdRomnHStFtrR23you6Z/78jHc7fixJ/GuR8a6H4qXxRa+JfAl7ZyX9rafZrnSr0kR3MRfcCGB+Rsg4PQ468YrvayNS8PJf35v7fUb/Tr3yRAJ7SReEDE8o6tGxyTyykjtjmk9XcFtY841TxXH4p+CXjmSbRpdF1W1gnh1KykO7ZN5Y5DdwVA5/8A1mH4hXstl8AfDbc/YZG01NQI/wCffClgfYkKD9a9Hh8HaSmh6lpk8clymrB/7Qmlf97dFl2lmZcYOAANoAGOAKo6H8OdD0XwrceHpDearY3Mfky/2nctMxjH3YweAqrngKBjr15p3t/5L+G69BW1T/xfjbX1X5md8ZLG0v8A4Oa40m0C3tvtNu68FJEIZCp7cjH41zniiOa+1T4Sf2/Ekl29yGuVkUEeZ5AJ6/7Qz9a7Wx8BWlrZw2F1q2qalpduymDTr2SNoo9pyg3BA7gYGA7MOB6VF4q+HkHizXtN1a51/WLKXS5PNs4rNoBHFJ3fDxMWJ/2iR7daFo7run936/5IHdq3k195jfFC9lt/FPgi3k1KfS7G51KRZLyAREpL5REQxIrLyWPVT+Bwa0p/h9bN4r0fxHrPifWb690t2S088WqKfM+UqRFAhYH61ua/4U0rxV4bbRfEcJ1G2ZV3PJhXLDo4KgbW9wAOemOKzPCnw7sfCsqyjWNd1iSIEQHVtQadbcYxhE4VeOM4zgkZxRHR/wBf1/wBy1XyscbqY8ZfDmXV76xtLbxb4Pu7ia7uLYPsurQOxaUDqHQfNxyfpg16joeoWmraBYahpu77HdW8csG4YOxlBGfwrJn8FQSwz20Or6tbWN08r3VnHOpSbzCSw3MpdASTxGyda3rO0t7Cyhs7KFILeCMRxRIMKigYAA9MUL4bPy/r/IJayv6/1/mcN8UvD0+rW+m3/ht/J8WadKZ9LdQMuAP3iPnjyyODnjJUd8HU+HOvWHiLwlHfWYdLsyMuoxTf62O6HEiv7g9O2MYwOK0LTw19l8XXmvnWNSne7hWE2crRGCNVORsAQMMEk/e5zznjGRoPw4t/D3jC/wDEVn4g1mSfUpPMvLaVoPImOMDKrEMY9QQeOSeckdNH1/B/8H8wlrr2/r/hjsWUMpVgCCMEHvXLf8I5ofhi4ju9F01f7RkBtrGJ5pHSHdyVjVmKxJxubYBwOhOBW5qur22jWq3F5HeSIzhALOymunzgnlIlZgOOpGOgzyK59fFuhjU3vmtfEbymMRIG8OX+I1zk7R5HGTjPrgelLqBk+L7m70jUPCnhmzup4v7e1B11C/iYpJIqoXcBxyjNwARyAMLjAqx4D1m8PjLxd4Wubia7t9FngNpNO5kkWOWPd5bO2SxBB5Yk4PJp2v614b8R2sEd5a+JYprWdbi1uYPDt+slvKvR1JgIzyeCCCDggim+H9W8N+HEu2trfxNcXV9N593eXPh2+MtxJjG5ttuFGAAAFAA7CnF2vf8Ara33Wf8ATYS6W/re/wB91/SRS+MGrDTZPCEN45j0u61+Bb1icKVXLKG/2dwBP+7UfxuWI6R4Wdwu5fEtlsJ6jk5xWp4k1fwn4t0KfSNe0nXrqzmHKnw5qAKkdGU+RkEeorjx4R8ES6JBpmo3Hj7Ukt7hJ4przTdSeSPaDtRD9nGxec/IASQOeKUdLeTT/L/Ifn5Nfn/mdZcT2X/C2rxvDtrJfeIl02KC9aefy7W0gLllzwWLnJIUDkLyVzmsz4NJNDd+Ooblo3kXxJOXMSFVLFVyQCSQPxNOjTwxa+JV1zTZfGlldtbJa3Pl6JfyC8RRhfNMluzFh/fBDe9R6Ta+FNCu9au9IfxpbXOsStLJKdEv5PIdhgtGr25Xcf7zBj744oWi+TX4pg9fvX5WLfwMGPh1MBwP7UvP/RzVB8CEWT4e36OoZW1i8BUjII31B4TttB8GaDe6Ro+q+OjBdMzq9x4fuXe3dvvOh+x9T/tbh7daTwjd+E/hfol4qap4ubS97TyHVdCuvLhY/efeLVSM98nFGl9e1vy/yJd3t/Nf8/8AMj8M6jL4Iv8AxH4CRsSwyC50AN0MNw+0KPZJGOfavUdOsYtM022sbYERW8Sxpk5OAMcn1rzSPxh4L8X+NNL8TaZFqWpx6TBNFHe2uiXsyiSTaNuViPIUMef7wx3rsP8AhPNI/wCfPxB/4Tmof/GKf2Vff/LYfV2/ruct8Uf+R/8Ahv8A9hl//QKdpV68n7SWu2uo/fi0WD+zg3/PItmQr9XPP09qq+KrbQPFviHTdYutS8cWU2lP5lnHZ+HrlY4n7vh7NixOB1JHt1rQ1y58M67eWOoSR+K7PVtPBW21O08PXyToD94HNuUYHurKR7ClHTV93+KsEtb+i/B3K2s2ktp+0h4eutLG03+k3CakF4DRxkbGPvuYDNYtzc+KvhdpE8OrWUHi3wMzsxuYG23VpDIxJ3Do6jd1H1yO3XaXrmgabdSXssfijUNRmjWKS+u/Dl75jIOQuEt1VRkk4VQM81myf8I5LYjTJJ/Gb6OV2y6Y+hXzxSjOSGZrYyhf9kOFxxjHFC0SXb/NsNG235flYn8VaZ4rTxLD4w+Ht3Z3sjWMcF3o96dq3EQZnRkbPyv8xAzgfyra+Hnim38V6HdXKaXLpF7b3kkGoWMpyYrgYLc9wcg5wM5rLvtW0O4vGvLCbxfpV20KQebZ+H73AjQkgeXJbPH/ABHkrnng1r+D7jRIvtFjottq6SzO93cz6jpd1bmeQkBmaSWNVLHI+UHoOBgcNWV1933/AJfqDu7d/wDgf18jqKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAMlhjuIXhnjWWKRSro6gqwPUEHqKh0/TLHSLNLTSrK3sbZPuwW0Sxov0VQAKs0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFVpNTsYb6KylvbdLqYkRQNKokcgZOFzk8AnjtVmvLfFdjaWv7QHgGa2tooZJotQMjRoFLny85OOvJJ/E04q8kv62bB/C32PUqyo9R0DxIl5pkV5purKgMd3aLLHOF9VkTJx9CK4z4061c2Xh3SdFsZpLeXxDqkGnPLG21kiY/Pg9sjj8TUXxfYeEPBemeItEjW1m8P3kAiES7QYGYI8Rx/CQRx6gHtSSvv3t+X+aHqtu1/z/AMj0FU03QdJwi2um6fap0AWGKFR+QUU/T9TsdXs0u9Kvbe+tn+7PbSrIjfRlJBrzjU9V/wCEl+Pei+H3Ytp2l6Y2rNCT8sszHbGWHfaDke5z2qbV9Rk8NfH7Q4LYlLTxNZSxXUQ+600I3JJ/vbTtz6Y9BVJNtX63/C/+TJdkm10t+Nv8z0qiiipGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeaeMv8AkvXw8/65ah/6KFel1y+p/Dnw5rGvx63qEOoPqMWfJuE1a7jMORgiMLKAgPcKAKcXaSf9bWB/C0cv8cNPkbSvDeuqpaDQ9bt7u6I/gh3YZvoDj6CpPjrDJrHw8t9CsD5l3rWo21tbopzv+feT9AFJJr0ia3huLV7a4iWaGRCjxyDcHUjBBB6/jWTpfhHRdHvRd2Vo/nopSJ57iSbyEPVIg7ERrwPlTA4HFC00fe/5f5Du912t+f8AmcI+mNoP7SOmX84xa6roLWMEhPBmiYMV+u0ZA78+lTeJbGTXP2h/CiW2Wj0OwuLy6I6R+Z8iA+5I6egNeharo9hrdoLbU7cTRqwdCGKPGw6MjqQyMOzKQRTNI0LTtDikTTYCjTNvmlkkaWWZsYy8jks5xxliaE3dN9L/AI3/AMyWtGl1t+Fv0RoUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGDL468JQXzWU3inRY7tJPKa3fUIhIr5xtK7s5zxjrS3vjnwnpt7JZ6j4o0W0uojtkgn1CJHQ+hUtkVwfxOsYfD3xM8G+OhAnlRXX9m38m0fKkoKo5P8Asktz7iq3xzFjoOreEPGTQo11pmqIsuI9xa3P3icf3TjBPQt70R15fN2f9fNDe7S7XX4/5Hquoa1pek6et/qupWdlZsQFuLmdY4znp8zEDntWPD8RvB11qtrptj4l029vLx/LhhtLhZyzYJ/gzjoeTirXieRbrwzLawlXOphbSI4DD978u7B6gKS30WuJ+IMNlo/jH4bRxrFa2lpfyqvRVjRYT+Q4oW+vewvs3XZs9RorkNE+Jej634tk8OrZatp975ZltzqNi9ut2g6tHu5IHuB7Vp6l4oWzmuIdO0rUNamtCPtMeniLMORuAJkdAWxg7VJbkccijpcOtjcorjLv4q+GbXwWPFCPfXWnZZHNtZSO0TrwVkGMRnOB85AyRzV3RfHdhr2ptbWWnastqLUXI1SezaOzccfKsp4YjOeMjrgmgDpqK5HUviLp2kWsWo6hp2pQ6JKVA1gxJ9nG44Uld/mhScYYpjkHOK2dX11dKhspY9P1DUkvLhIVOnweb5Yb/lo/Iwg7tQBq0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHM/EXw2PFnw91jRwAZZrctAfSVfmQ/99AVwvhJX+Lvw3nuNVRgW0c6SGkXB+0dZZBn/aWLn1U17BVPS9JsdEsfselWy21v5jy+WmcbnYsx59WJNK2jXf8A4K/Jju9Gun9fml+J5v8ABvWrjxT4d0xNQSRZ/DUT2NyJF63IOwHPcrGvP/XSrfxK2f8ACwvhz5mMf2tL19fK4/Wu80zR9P0dLhNMtY7Zbm4e5mCfxyucsx9zWN4h+HvhvxTq1tqWuWt1Pd2uDbyJqNxEISO6KkgCn3AzwKuUm5KXo3+b/ElJJNLzS/JHNeMcD4+fD3HBMOoA+48oVk+A7XS9W8V+LdF16/1O31231ieb7PBrV3bCWByCjrHHKoIxgZA9M9q7jUfhv4Z1XXrbWr+2vpdStFC29z/al0rRADHy4kAGe+OuSTkk07xR8N/CPjS5huPEuiQXs8IASbc8b4HQFkILDk8HIpLRL5r73cb1/D8E1+pxvjvw94f8M/BPxnZeGLd4YmBkuS1xJNumJTcdzsxzjGeevvXReLIrq6+BeoR6UGaeTRP3Yj6sPKGQMe2a1dU8BeGtY8Nw+H7zTdukQ/csrWeS3j+hEbLuGecHPPPWtLRNDsfD2lx6dpYuFtY+I0nupZygwAFDSMxCgDgA4FS1eMl3t+A07Si+1/xt/kcB4c8P+B/HXw8tr2W71K906a2T7Vbz+Ib1442ABZHQzYG0joR2r0TSoraDR7OGwjeK1jgRYUcksqBRtBzk5xjrzXND4TeBV8SHXh4as/7QL79+G2bs53eXnZnPOdua3tY8PaXr7WJ1a1+0GwuVurb94y+XKucN8pGep4ORVt3d+5CVlbsaVFFFSUFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGBdePPCFjdy2t94q0S2uIWKSwzajCjow6gqWyD7Vo6Xrela5bmfRdTs9RhBwZLS4SVQfTKkivO/GKL/w0T8P32jcbW+BOOTiPj+Zqj8TE/sn4x+A7/wAO7Ytavrpra7ji4Nxa/LuLgdQAWIJ/pTir8t+un4tfoEtHK3RX/C57BRWHqXihbOa4h07StQ1qa0I+0x6eIsw5G4AmR0BbGDtUluRxyKrW/wAQPDdz4Mk8UR3+NMiJWRmjYOjg7fLKY3b8kDbjJyKQHS1jaf4v0DVfEFzommarb3eo2ilriCFtxiAYKQxHAIJxjOaoWnju0k8SWmhappepaNfX6NJZLfJFtuQoy21o3cAgc7W2nnpXO2A/4yZ1b/sXIf8A0caaV5Jd7/gn/kTJ2i36fi0v1PSqq6lqmn6NYteavfW1haoQGnupliRSTgAsxA5NY+ieLW1zV7uzg8P6tbwWszwvfziAW7svHyFZSzDtkLweDggiuhYBlIYZBGCD3qXtcrrY5z/hY/gj/ocvD/8A4NIP/iq37a6gvLdLiznjnhkGUkicMrD1BHBry79n6KMeA9Xj2KI/7bu1K4GMZUYx6Yqp4BWO3+Pfiy38JEf8Iz9mR7tYMG3S9+XITHAbG7IHfOegqkrtLur/AIX/AK8xdG+zt+Nj2GiubuvGlukl0NJ0vUtaSykMV3Lp6RlYHABZfndS5GeQgYjpjPFXdK8U6LrPhoa/p9/E+meW0jTsdojC/e3A8qRg5B6Uulx9bB4i8V6F4SsVu/EeqW+nwuSEMrcuQMkKo5Y47AGtWKRZoUljOUdQynHUGvJPjF4nTUvg7rYOk6la2txFEbW8uYkWOfMiEYUMXTj/AJ6Kue3aum8QfEG38FW2iQX2h6vepqAit4J7JIWjMrDAjJeRSpPuMe/XDS/Ow2tE15/hY7eisXXvETaDpltdto2o3zXEscP2e08kyRs/ABDSKDycHaTjr0ya2EYvGrMjIWAJRsZX2OMj8qQjP1PxFomiSxRazrGn6fJOcRJd3SRGT/dDEZ/Cr0c8M3+plST5Q3ysDweh+hwa8Y8D+N7Dwx498S6D8Qv+Jdrl9qLzQX92MR3VueIkDngKAOAeOcdcivSdN8P2fhabWtQ0DTldNQK3JtLQohklCkHbuIUbvl7gZyaPsqXl/SD7XL/XqdFRXAfC/wAb6r4w0u5vNV0S6tFa7nAuPNhaCMI20RDEm8kY5OwAnJzWndfEOwg0+TVLfTNTvtFi3ebqtrEjQoFJDMFLiR1GD8yIw75o2DudZRXJeI/iX4e8M6Baa1dSXV1p94qtDc2ds0sRBIAzJ9xM5/iYfpVnTPG9hqdxqQNhqljZafGJW1K/s2gtpk5yY3bG4DGc4xjkZFAHSUVyd78QrDSrm0/trTNT02wvZFit9TuYkEDu33VIDmSPP+2i9K1L/wARpa6sNNs9PvNTu1RJZ0tBH/o8bEhXcyOowdrcLljjpQBsUVS0nVbbWbD7ZZeb5XmSRYljMbBkcowKtgjlT1q7QAUUUUAFFFFABRRRQAUUUUAFFI5KoxClyBkKMZPtzXOf8JRq/wD0IniD/v8A6f8A/JVAHSUVh2Gv6ld30cFx4R1mxjc4a4uJrMonHcR3DN7cKa3KACiiigDnpviB4NtriSC48W6FFNExSSOTUoVZGBwQQW4IPat23uIbu2iuLSaOeCZA8csTBldSMggjggjvXlfia3hf9p7we7RIW/su5bcVGcgNg/hmvWKF8Kf9aNr9BP4mu36q4UViaj4ogtNSl02wsrvV9RhjWWW0sfL3RIx4LNI6IucHALZOOBSaB4v0nxHaXctnK8Etg5jvba6Xy5bVxyQ6np9RkHsTR0uM3KK4qT4paRBaWupXGn6nFod3MsMGstFH9ncscKcB/MVSeAzIB78iuk1fXLTRYoDc+ZJLcyCK3t4E3yTvgnao+gJJOAACSQKAK0njDw/F4oi8ONq1udYmztskbdIMIX+YD7vyjPOO3qKsnXtNXxGugm5/4mb2xulg8tuYg20tuxt6npnNeaa5qp1P48eABPp15ptzHDf77a7CbwDEMHdGzIQcHoxx3xXcWvjrSrzx1L4Tihvl1GG3e5dprVooyisFyrNjcCTwVBBwefVpaLzv+Fwe7+X4nSUVxMfxW0Ga+1eygtNXku9J2CS2XTpPOmZ92FjixvY4XOSoGCDnHTU8G+NtL8b6XPeaXHdWz2sxgurS9h8qa3kH8Lrk4P4mkD0dmdFRXH3XxJ0u2sZtUSw1K50O3Zln1i3iRreMqxVjt3+aygjG5UYe/Wt/Q9esfEWni+0v7UbdiNr3FnNb7wQCColVSykEfMOPegHoQap4v8NaHefZNa8Q6Vp1ztD+Td3scT7T0O1mBxweajsvHHhPUrkW+neJ9Gu5yCRFBqETsR9A2a4b9oeNH+HFqXRWK6tbbSRnGWINejapoum67pL6drFlBeWkqbWhmQMuPb0PuOlCvyt+dvwT/UH8SXlf8Wv0L9FeRfC7VLvw58QvEnw41C8lu7XTFW70uWdyzpbsFPllj1C71x+NdjdfEOwg0+TVLfTNTvtFi3ebqtrEjQoFJDMFLiR1GD8yIw75odrJrZhZ3afQ6yisqbxLpcXh+HWo7kXNjceX5D243+cXIVFUDqSSBTNP8RJeahDYXem3+m300LzrBdIh+RGVSd8bOmcsvAYnnkCnZ3sHS5sUVy+q+PLTS7ObUF0vU77SrYuLnUbSONooQhwxwXDuBzkorDg+lb+n6haatptvf6dOlxa3MYkhlQ8OpGQaW6uBZooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8k+IWnQar8ePANpdtcLE9vekm3uZIHBCAjDxsrDp2Nd7pPgrQdF1R9Ts7N5NRddhvby5lupwv90SSszAewOKo6l8MvC+r6+mt6hb38upRsWiuRq92jQ56iPbKAg56LgV1SII41RdxCgAFmLH8SeT9TTTtFLrr+LbB6yb6aHkHgO10vVvFfi3Rdev8AU7fXbfWJ5vs8GtXdsJYHIKOsccqgjGBkD0z2rQ8RWHgnwT4Ku9PstDa/gvdXhj+yS3crrNfOVKlpXZiuCoLHnp0OcV1Xin4b+EfGlzDc+JdEgvZ4cBJtzxvgdAWQgkcng5FXbvwf4evvDA8O3Gk239kqAFtI18tUwcgrtwVIPOQQc0lol5WX3W/y+8HrJvvd/f8A19x574tg1K3+Lfw6uNa1CGWZ7m8HlW8IjihXyugJyxOMAknBxkKOlZfi6DW7/wCNGvxeEbmFdQPhqCRI2z/pCCfLRhwRsLDjcOme3UemXfw98L6g2nvqWlLfSaa++2ku5pJnU4wNzOxLj2YkVHF8OfDUHixvEsVteDWGOWuv7TuSWGc7Cpk2lP8AYxt9qa6eV/xQS1X3fg7j/AXifS/FPhW3udHgFmLf/R57ArtazlXhomXtj+VdKehrmtM+H/h3R/Elzr2m213DqN3IZLiX+0bllmY5++hkKsBk4BGB2xitrU9Nt9XsHs7trhYnxuNtdSW78f7cbKw/PmlLXUSVtDx74JeEPDeueE9Wuta8PaVqNz/bV0nnXdlHK+0EYG5lJxz0qwLqXwx+0HZ+FfBiJDpF9pjzX2nW6gQWsg3lZVQcRk4QHGM5Ge1dnpnwq8K6Lbtb6NDqunwu5do7TXL6JWY9SQswGfetjQfCOheGWmfRNNit5p8edcEmSab/AH5GJdvxJo008lb8Lf8ABH383f8AG/8AwDjPgJcs3w4bT7wkanp+oXMN+j/fEplZiW+obrXnmtWt5pfw3+It5p0cj6PJ4nEgjTo8Syr55H+yWG0/7pr3G88E6Deay+qtaS299KAJp7K7mtjOB0EvlMokH+/mtWHTbKDTRp0NpClksflC3WMBNmMbdvTFNt35uv4bp/oPTbpe/wCf+Z5v8Ydb0vVfgBqV9YXcMttewQm2ZWB3/vEOB7gA5HbBrp/EnhuLxl8M5NJ3hXuLNHtph/yzlUBo3H0YA1VtPhD4DsYL+G08N20ceo4FyN7neAwbaMt8q5UHauBx0qxf+IfCHw3g07RXQaal1vFlZWNhLJ5hBywVYkPOTnnrmk7NNLqCukvK/wCn+Rj+APEsnjy20uW9j2XWixsupRMOUvRuix+QkbH+2teiVieF9MWwsLm5a0FpcandPezxAAFWfGAcfxBQoPvmtuqk7/116kry2/Q5K+0fwt8U/DO3V7GC+gWWSLOf3lvKjFWCuMFSCPxrlPhVpuqeEfG3iTwYNSn1TQdNihmspZ23NbFwf3JPrjnA44zgZrt38C+HvnNrYyac0rmSWTTLqWyeVj1LtCylyc/xE5rU0rR7DRLQ22l2ywRs298Es0jHqzMclmPqSTUrS/mN6qx5N4EFzP8AAbxFZaXKF1OSfU4rdFbDmXLkADrnvXX/AAovrLUvg3oRjKGGKwW3nU/wsg2uCO3INbOj+B/DWga5faxo+j21pqF+SbidActk5OMnCgnkhcAnk1EfAPhv7fcXcentCbpi1zBBdSxQXBPUyQqwjcnPJZTmjeLXdL8L/wCY+t/Nv7zxOeym079lVFuNwtX1dJbQP2tzdAofoRk/Q16n8ZftX/CotWksVkcxLFLKsTFWaJZFZwCOR8oPStzxN4G8P+MLGCy8Q2ctzaW/+rt47uaGMemVjdQcY4yDjtWpp+l22maalhbefJboCALm4kuGIPYvIzMR9T04pt3i153/AAS1+7USSU+b+t29PvOGHhXwD4u8Hx6ncXeo6ro0iCbE/iC9mjBHOCrTEbgeMdQaTxP4O1e68TP4j+H3iD+y9chto4Lqyu08y3uYwCyK46qeSNwz36c1rab8J/A2j+IDrem+G7OC/wB29ZBuKxt6ohJRD7qBWzqPhfSdUuZLq4gliupFVHurS5ltpmUdFMkTK20c8ZxyfU0Py0/r8RLs/wCv8jK+HPia78UeGJLjVdPi0/UrS8ms72GE5j85GwzKfQk57/U9a6yq1hp9ppdklpp1vHbwJkrHGMDJOSfckkknqTVmh6ggooopDCiiigAooooAKKKKAEdQ6MpyAwwcEg/mOlc5/wAIHpH/AD+eIP8Awo9Q/wDj9dJRQBh2HhDTdOvo7u3udZeSM5VbjXLydDxjlJJSrfiDW5RRQAUUUUAeV+JDj9prwfn/AKBV1/Jq9Nvr2DTrCa8u3EcECF3Y9gK5e8+FvhW/15dbu7bUX1NCfLu/7ZvBJGDnIQiX5ByeFwBmppvhz4euWhN6NVvFhlWZI7vW72ePepBUlHlKnBA6ihfCk/P8W3+ofab9PwVjmPhneSRfEnx/p2qBo9Qkv47yNZeGe3ZMJj1CgAccAmqk4ttJ+MnjjXbiNm0W38Pxf2oiLnzZcE4928tf/Hh616FrHhLRdevIbzULVxewArFd2txJbTop6qJYmV9vtnFW7bRNOtNOlsYbSP7NOG85Hy5m3DDFy2S5Pckkml0XdK34W/L8R9X5u/43PE/H8d3P+zvBfQeRpGkAWclhpdsPMZIzKuzzJnyScEH5QuCPvNzXSeJdfg0n48eEZdWnRNMuNOuLa2ndvkS5ZhuBPQEgKv411jfDPwk/h2TQptKM2mOci2muppFi5BxHucmMZHRMCr2q+C/DmteG49A1PR7abS4lCxWwXYsQAwNhXBU47gg1blrdd2/vVibaWfa343OK8Y3Vuf2gfh/EJozKkV9uUNyu6Ibc/XBqRyP+Go4hnn/hFz/6UV0EPwr8DwW+nwL4bsmh07d9mjkUuqFipZiGJ3Mdi/M2Tx1qVvhz4abxaPE5tbv+2Aci6GpXIIGc7Nvmbdn+xjb2xRFpcvlf8b/5jvo/NL8Gv8jmfBW0/Hr4iHgsI7AZ7/6o074dxxyeOviXESFRtUjDFTjGYeT/ADro9L+G/hnRvEE+t6dbXsWpXOfPuDql05myMfOGkIb2yDjjGMCqsHgbRPBVvq+t+FdIu7jVJoJJHgbUriX7bJgkBhJIysxPcgnk1Dty6/y2/L/IqV5S07r8rHK+G9M1q3+E1x4P0nTRq1rcQ3NtYayJoktmhcth5FLeYCMn7qMDgHPNekeF9FHhvwnpeirMZ/sFrHb+aRjftUDOK8FsLL4CXkkVtrGiX1tr0oBn05rbUEmEhG4qI4/lHsBxiva/A2ix6FoL2tnBd2mnmYtZWl3K0klvFtUBcsSQMhiFJJAbHHQaa63/AOHt/wAOR2S8/wAf+GOQ/aF/5Jtbf9ha1/8AQjXp8k0dvbNNPIsUUabndzgKAOST2Fc94n+H/h3xlIjeJLW6vFjIKRDULiOJSM4YRpIF3cn5sZ96afh34cljEV5Df6hABj7PqGq3V1CfrHLIyH8qhXUWvO/4JfoN/En5W/F/5nlOk2Go+M/EfxH8daCsgt7rTZdM0eUDa1wyxgF09soMH39q9G+FF9Zal8G9CMZQwxWC286n+FkG1wR25Brs4LeG1t0gtYo4YY1CpHGoVVA7ADgCsA+AfDf2+4u49PaE3TFrmCC6liguCepkhVhG5OeSynNH2eRbWX4X/O7Hdt8z3v8A5flZHnfgLwfDrXwHttF1W9udPgutQebS7iJtskIExaFlPuRkeoPuK0tJ1bxvoPimLwj4vlstYa/sbhtK1m3j8qUsigssidB1HI9Bye3pN9pGn6lYrZX9lDPaoVZYXQFVK/dIHbHUehAI6VW03w1pek3j3drFNJcuCvn3V1LcSKpOSitIzFVyB8q4HtQ9bro/8rff5i8/63v9x5j8KdG8NeLfhvbWt5d6s17axNaanYnXrxBG6kqwaJZgqqeuMAc4r03wvp2k6T4btbDw7CYdMgDJboZGcbdx5DMSSCckHPSsfV/hV4H17XxrWreHLS4v87mkO5RIfV0BCuf94GusjjSGJY4kVEQBVVRgKB0AFU3fXuKw6iiipGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFeRanq+qa5d/EK8XVL3T38LqE01ILhoo0ZYTIXkUHEm48YcEYxgA813mgeJ/7R+H+leILyIpLe2cUxhQctI6jCKPcnA+tC1V/T8dg6/f+G50NFUtLt7mG1L38pkupm8yUBiUjJH3E9FAAHvyTyas3MCXVrLbymRUlQoxikaNgCMcMpDKfcEEUMCSivF/BOkNqnxY8c6NqOt+Iriw0mS3FnCdevF8oOpZvmWUE9O5NavjufxB8L7ODxNoep3mp6DbOqajpWoSm4ZY2bHmRzPmTIJxhmI5HpRokm+tvxCzu0uh6nRWcPEGlDw/Drc9/b22mzQpMtzcSrGgVhkEsTgdam07VdP1izW70i/tr+2YkLNazLKhx/tKSKbTTsJNNXLdFYek6X4eS51o6K8Rnv5t+om3u2ZvMKAZOGzGduMYx61598Ibyx0C38dSanqC2tjZ+IpovtN/dcIihUUNJIcnsMk+lJa/df8l+pVna/nb8/wDI9dorO0vxFomt280+i6xYajDAcSyWl0kqx8Z+YqSBx607Sde0jXoZJtC1Wx1KKNtrvZ3CTKp64JUnBoEX6K8q+P6XOm/Dy417SdV1XTtQt5YYkey1GeFCrSAEGNWCE/MecZ6c16B4d0eHR9JjiguL64Miq7yXt9NcuW2jJzIzED2GB7U0rpvzsD0aXc1aKbLLHBE0szrHGgyzucBR6k1R0rX9H16J5ND1ax1JI22u1ncpMFPoSpODSA0KKpXOtaXZahb2F5qVnb3lznyLaWdVklx12qTlvwqW51CysrB768vILe0Rd7XEsqrGq+pYnAHvR5gWKKr2eoWWo26T6fdwXUMiB0kglV1ZT0YEHBHHWrFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUjusaM7sFVRksTgAetc5/wsfwR/0OXh//AMGkH/xVAHSUVh2Hjfwpql9HZ6Z4n0a8upTiOC31CKR3OM8KGJPArcoAKKKKACivP/jVPqWnfC/VtU0jV7zTrm1jTYbZwucyKp5xuBwTyCMda7jT2Z9MtWdizNChJJyScChapsHpbz/r9SxRXmHxt8S6vpngPVR4Zu3s5rRYmu7uIkNGHkVRGjDo5BySOQB/tA16VaktZwliSTGpJPfimldXG1axLRRWXpGpzaheavFMsarZXv2eMoCCV8qN8nnrlz6dqS1/r+u4noalFFcB4m8W3998QbLwH4XuRa3ksBu9RvwgdrSAcAIpyN7EjBIIGQcGjd2QdLnf0VzbeC4o45ZLHW9dt751OLp9TlnCsec+TIzRdewQDsMU/wAP3Vxo3hWzj8YapF9vR3hlurhliE7+YVDAHAG75cAeoFAHQ0VUttV0+9vLm0s7+1uLm0IW4himVnhJ6B1Byv41Ba+I9EvtTl02x1jT7m+h5ktYbpHlT6oDkflQBpUVQ1bXtI0GFJtc1Wy02KRtqPeXCQqx9AWIyai1PxJo+j+H5Nc1DUbeLTY03/afMBRh22kfeJ7AdaV0lcdm3Y1KK5Xwx408P+OvC7XMN/ZSJNCTdWq3Kl4EckASAHKEj1xzmtLSToGgeFLRNLurW30S2hCwS/aQ0Sxj/poxOR15JqnpuJa7GxRVCXXtIgvrWym1Wyju7xd1tbvcIJJx1yi5yw+lVfEdjoF+liviR4FWG7jmtRNcGL9+GATGGG47iBjnJI4pdQNmiq82o2Vvdw2txeW8VxcHbDC8qq8hwThVJyeATx6GorLWdL1K6uLbTtSs7ue1bbcRQTq7Qn0YA5U/WgC7RWfqniDRtD8r+2tXsdO844j+13KRbz6DcRmr6OsiB0YMrDIYHIIoAWiuO+JHjg+C9DtvsMKXWsancrZ6dbucK8rHG5v9kZ5/Ad6s2fgxpIYZte13WL7UQAXmg1Ga1iDZzhYYmVNoJ4DBjgDJNC11B6HUUV59qWgatHoXi2013WdQ1Gy+zC40+cSG3khCo52Fotu4hlByeoIzmrPwZYt8G/DbMSSbTJJ7/M1C1v5W/G/+Qm7Ned/wt/mdxRWba+I9EvtTl02x1jT7m+h5ktYbpHlT6oDkflT9W17SNBhSbXNVstNikbaj3lwkKsfQFiMmgZfoqBL60lslvI7qF7Vl3LOsgKEeobpiq0fiDRpp7SCHVrGSW9QvaxrcoWnUdSgz8wHqM0eQeZoUVmL4m0F9YOkJrenNqSnBshdxmYf8Azu/Src+oWdrcQwXN3BDNO2yGOSUK0jc8KCck8Hp6UAWKKpWmtaXf39zY2OpWdzd2uPtFvDOryQ56blByv403Vde0jQoUl1zVbLTY5G2o95cJCGPoCxGTQBfopkcsc0SywyLJGwyrqcgj1BqhY+I9E1O+mstN1jT7y7g/wBdb290kkkf+8oOR+NHkHS5pUUVyDakfFXja+0KCRl0vRkT+0Chx9oncZWHcD91V5Yd9yg8ZBFq7B5nX0V59rniu/1r4kR+A/C919ha3tvteq6jGqu9vHxtijDAgO2RyQcA8D025fBax28zaTruuWV/Ip23UmpS3IVs5z5MzNHjPYKOOBijpzB1sdNRWT4Xj1KHwvYQ65K0+oxRCO5mYY8x14LY9DjI9jWtTejAKK4/xdft4Mmi8TRSP/ZzTxw6rbkkqEchBOo/hZSVzjquc8gV0eragNO0W5vUHmGOItGoP+sY/dUfUkD8aXS4dbF2ivOvGniDSPB/hzR/DWr+In0STU/3MmoQsVlQAZkkVgDtZmIG48DcT2rQ8CeFLDTM6xpnjTxB4mtrqLbE2o6t9qhAz95QABnjGecU117C7Ha0UUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcrrPw/wBK1m+v7h7i8s01SNY9TgtZFWO+RRgCTKkjg4yhUkcEkVHdX1rpmgXfiH7Oo0jRLN30+3jGAyohzIB6EfKvtk/xV0epWTahai284xROw84KOZE7oDnjPQn0z06h91Y217ps1hcxK9rNEYXixwUIwR+VJ35WkNW5k2ea6b4x17Tz4K1LWr5bu28WMI5rUwoi2Ujx74/KKgMR2O8sT1BHSvUq4bSvhv8AY7zQxqOrG/0/w4CNKtvs/lsh27Q0r7iJCq8LhUx3yea7W5WdrWVbSSOKcoRG8sZdVbHBKgqSM9sj6irk108/u6Eq99f6Z5Z8O/8AkuvxM/662f8A6LNbPxv1C30/4N6+bhgDcQC3iXuzuwAA/n+FVdD+HfinQfFmueIbXxZpct3rbI1zHNobmNdgIXYBcgjg9ya1ZPh9/bWuWOreNNVfWZdPbzLazjgFvZxSZ4k8rLMzAYALO2KmSUoxi+yT+7UpO03LzOV0jTLfRNP+HX9r3F3Pq2m6a/2fQYIhJJPI0YBc7iAmwZG5iAM4yO8/gJJf+F0fEC3u7KK1S4is5pLVZBIuWjYEngDJHXr9TXV654MuL7xvpvirR9UWw1Czt2tJUmtvPingY7ipUOpU55DA/gar6d4BudO+IOqeKU8QXEjalbxxyWjQIELxjCsxGCVH90bfcmqcuaXM+t/xdyUrR5V5fhb/AIJifCOytdO8RePbPT7aK1todc2xwwoERB5a8BRwB7VD8H4Irm5+IMFxGssUniW6V0cZDAgZBFbPg7wJr/hXVtfv5vE1pqB1qZrl0OlNGIpyMAjExygHBXqcD5h3d8P/AAHq3grUNYmvPEFvqkOrXT3s0a6cYGWZiMlW81htx2I9OfVLs/5Uvnp/kU3o7fzX/P8AzMLwPfR+ALjxN4LmT5NLZtQ0mMAbp7aY5CD1KyHZ+Ir0XQdLGj6Jb2nBlALzuAB5krHc7cerEmud17w1p2u/EzQL9t32zSYpJptjYDRkjy1fHX5xuAP9w12dF7xV9/8ALT/h/MT+J/1v/WnqeXftF/8AJF9Q/wCvm3/9GrXpdp/x5Qf9c1/lXHfEvwLqnxB0NtFh1220vTpCjyA6c08rOrbhh/NUAdONueOtXotK8cRWaQL4m0I7ECCQ6DLu4GM/8feM/hihP3GvO/4IJatehz3jPVFvPjD4M8OXTq+nSG4uZYc5WWeNMxqw6HbncAe+0+lQfFSF9E8XeDfE2jL5epSatFplx5Ywbm3lzlGx94DbkZ6da2bz4bJqWgabDqGsXDa7p1017DrUMSpIJ2YljsORsOQuzOMADPFakHhi8vNRsL/xVqNvqU+mu0lolrZm2iVyu3zGVpJCXAJAO4AZ6Z5pxsreT+/+lp6CfXzVv6/P1OK13U/EPgDxNr+oat4bbxH4V1eVZpLiyAe4tFEaoUeM/eTjI7Dkk84q9rVve6p4G8Kaz8MEt9TtdJdLm3sbltguoREyBAT0cZ4zjBHtXVXGhayk11/ZevRxQXkxkkiu7IT+UCMEREOm31+feMk8Y4qOy8GR6Loekab4e1CewTSVYRFlWQTbhyJAeoJJOFKnOMEdKlX5fu/D/Ib+L7/6+Zj+AfFuj+J/EGrN/Y93oXiSOKJNSsLyPaxVS21wR98ZYjdwenGMV3tc9o/heS08RXHiHWLyK91ie2W0MlvbmCFIlYsAqF3OSTySx6cY6V0NN9Ba3YUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACPuKNsIDY4JGQD9K5z7D43/6GHw//AOCGf/5MrpKKAMOwtPFcd9G2p61o1xag/vIrfSJYXYY7OblwOf8AZNblFFABRRRQB5/8c/8AkiviD/rlH/6NSuj1PVLjRfAkmo2Nhcajc29mrRWttGZJJW2gABRyaofETwjqPjjwzNoVnrFvpdpdAC5Z7E3EjYZWG0+YoXpzkHPtW7otrf2Okw22q3dveXES7TNb2xgVgOB8hd+fXn8BSXwtFN/D5X/T/I8E+JPjwXnwg1LR/wDhDvGVnLOYnm1DVNJ8mJpPNVmZ23HGSMAY9AOK9t8H+IP+Ek8Px3v9kappO0+V5Gq23kSnAHzBcn5Tng1D4+8Jf8Jx4JvvD/237D9r2f6R5XmbNrq33cjOduOtdBDH5UKR5zsULn1wKtP3WvP/ACJeyt5mXqujX2o3Sy2niXVNKQJtMNnHasrHP3j5sLtn8ccdK5bw94b1STUfEATxprkRTUtrFIbHMh8iI7jm2PPOOMDgcZyT6BVe2sbezluZLaPY91L50x3E7n2hc89OFA49KlaN+n6oT1t/XRjrOCS2s4oZrqa8kRcNPMEDyH1IRVXP0AFeQaCj6Z+1l4iXUBtOp6UklkzfxqojBA/FG/KvZa5zxX4J0/xW1ldSzXFhqenSeZZajZsFmgY9QMghlPQqQQaE7TUvX8UO14uPp+DudHXlXx10rTb7w7pN5JawPeR6zaQLdKoE0aNJ8yrIPmX6A12+n6b4mjzHqviGzuoMYV7fTDBP17sZXQ8ccIPwrG+IHgG+8ZaPY6Xpmtw6PaWtwlyd1ibiR5EOVO4yLgZ5PBJPej7UX5r8w6NeT/IzPiPZ6Z4I+H93N4a0/T9Ga+ura2u7qC1C/u3lCs0hTaWGCw+8D8x5BOad4j+Hmv8AiO30r7T4l0awGkXKXVrPYaJJE8ewfdDG6YBCOoxXX6j4ej8ReE5tE8VmC/W6iMdw9vC0CtzkMql2KkcH7x5Fcz4c+Heu6KyWWoePNR1TQoQFh06W0iVig6JJNgu69OBt446cU46P53v/AF/Wont/X9f8MPlNlafFXULu0kuNb1ebT4YDp0SLssI9xJZpGOED5B2/eO0kBu3L/DLzI/hZ45tJIo4Ba6nqUSQxOWSIbc7VOBwCTjgfQV20Hgm603x5qfiLRtYW2j1hIxf2ktr5pZo12q8b7xsOOxDA+lQeFPhyPDSeIIZ9butQtdauZrgwPEiLEZfv9B8zH1PHHCjnMtXg13i187p/5/1oWrKSfZp/hYxPDOnWWp/s0WEGpWkF3ENFMgjnjDqGVGKsAe4PIPauc1TT7O9/ZAtZby0gnktdJjlgeWMM0L5A3KT904JGRXYaP8NtZ0TwLeeG7TxjNOskLWtpJdWKslpA2cqEVlLvg/fZjjHAA4qtL8Ltcl+Ei+BD4rtRAFEJvBpJ3mEHITHn4zkfe9OMZ5qqj5nNrrb9f8yafu8l+l/0/wAjnviv4X0ay+DcWvW2nQLrMLWUq6l5YNxu3oOZPvYwemcDjA4rW+M2n2bTeCdSa0gN8PEVlCLryx5nlksdm7rtzzjpmtTxR8Ote8U/Dy08K3fim0hEewXF3HpLbphGVKYUz4U/Lyec9tvQu8YfD/xD4usdChm8U2do+k3Md4ZI9JZvOnQna2DP8q4P3eecnPYXzJST7Sv8tP8AIUdIq/8AK18+hjfEDRtPm+OPgGT7LHHNem9S5miXZJMqwjAZxyQASOvAJpz6BpPhr9ofw8nh7TrXTI7zSLoXEVnCsSSbSCCVUAZ9/YVs+IvAPiLXfGOheIU8UWNrNoit5MI0hnSR3ULIW/fg4OOADwO5PNS6p4F13UPiZp/i2LxJaQrp8LW8NkdLZgY3+/ufzgSx7HAAwODzmI6cvlf8b/5jqe8tOy/B3MPwQfEHiux1+9t9V0RPP1S6tbqC90iS4kVUcqkbMLhBgJtwNoxnuSTXWfDrwlP4H8JroVxrH9rC3mcxSeT5XlI3Ij2l24GTjnoaxtQ+F17B4rutd8EeLLvwzJqDh9Qt0tY7mGdu7hH4Vj64P0rttJ03+y7EQPczXkzHfNcz7d8z92O0ADoBgAAAAClHSPyS+7+vUJav5tnk/wAbUez8efDrWbkf8S211Xy53P3UZmQqT+Cn8q9lrN8QeH9M8U6HcaRrlstzZXC4dCSCO4II5BB5BFY2k+HfE2iRw2dt4qivdOhAVRqenGa5Cjt5ySoDxjkoTxzmiOkeXzv94S1fN5W/P/M1fFLr/wAInrCbhu+wTHbnnGw815LaavcaN+yxoEtrOtt54traWd1LLFG8+1yQCDjaSDgjr1HWvUtc0C91Hw1f6dpupraXl9EYpb64tvPIUgg4QMgHBOOw64OTnG0D4cLZ/DM+CfEt9DrOnCIwxvHam3cJnIz87ZYHkEY6Dikuvy+dr3/MOsfn8r2/yM7xH8PNf8R2+lfafEujWA0i5S6tZ7DRJInj2D7oY3TAIR1GKuSmytPirqF3aSXGt6vNp8MB06JF2WEe4ks0jHCB8g7fvHaSA3Znhz4d67orJZah481HVNChAWHTpbSJWKDokk2C7r04G3jjpxWjB4JutN8ean4i0bWFto9YSMX9pLa+aWaNdqvG+8bDjsQwPpVdfv8Ay/X+u4un3fnc8/8AAOm2uofCXxvp2r6daSw2WraiIrZ1E0cDKuRs3KPuknBAHrgVu/DHwv4fj+Eei6vLZ2dtqB0ssdXkiUzwAqQWErcqADwM4A46Vd034YajoukeJLPTPFMmdcuZpwbmyWRLfzfvnarKXcjoScDHC9c3/DngC40v4by+DNc1eLU7BrVrSOWC0NvIsbAg7iZHDHnggDp3pP4XbtH70mmV9pdry/Fpo808beTa/ACyg0K0kvLDS57WSHWrhRB57+cAZYk5c7iep25DZDN36r4k6TYz/En4f3Rto47q5vpIZrmJdkroIiQpcfNjk454ycVoaj8L9R1f4ZDwZqPicGCFY47a5h08IwSNlKCQFzvI24yuzPpUniH4da9rOseHr628XJCdBfzovtOmec88pGGaQrKgwRwFVVwCfbFtrm/7ev8ALT/Ii2nya/y/MxdW8P6R4Z+Pngc+HtNtdMF7bX0dytpCsQmCxgjcFAycnqea2fhpep4h1Hxhf6iEmvl1mawcMM+Xbx4WOMA9F6nHckmp9f8AAevaz4/0bxPD4ls7U6Orrb2p0pnVt6hZNzeeCc9sYxx16mHVvhheDxdc+IvBXiq58MXd/t/tCOO1juYbgj+LY/Ct78/Tk1KtZJ9mvxv+RUt3byf4f19xl+MdMtvh58OLTQvD128Nlea1DBK94TMlvFNLuZSAVPl8bcZGQSM85rR1/wCH2v69faLfX3iXSLJ9EuluYJbDRXhfaBgxlmuWAQjgjFdFqPgnT9b8H3Wga/NPqSXgzcXUpVZXk4w42gKpGBgAADHSsfw14B8QaRIltrXju/1rSYCPIsZLSKMlR0EsvLyDp3XOOcg4ojo/ne/yX+X4hLVf11/r8Du68t+CMslyfG9xc8zP4mugxI7AKAPwr1KuD8P2A8H/ABK1y0l+Sw8SSi/spD937QFxNFn+8QA4Hcbv7poj8T81+qf6A/h+f+f+Zy/gpW0z9prxva6gNs+oWsVzalh/rIhtBwfbp+Br2Sub8UeCLHxNeWWorc3Omaxp5JtNSsyBLGD1UhgVZT3Ug1Pp+neJFUx6zr1ncxcYaz01reU/Vmlcc+yj2xSXwqPbQH8Tl3NS81Kx0+xkvL+9t7W1iz5k88qoiYODlicDmojrelC1gujqdmLe5UvBMbhNkqhSxKnOCMAnjsM1y3jaTUdAvtB1jS9EudZ03TmlW5sbFBJOm9AFljQ/eIwwxnOHNc5cW1lP4s8FahZ+ENT01Ptd1POk2mu7wpKj8yMgdU3SNnaW4zkgULUHornTfFV4L34M+JJYZEnhk0ySSORGDKw25BBHBHQ5qLw3cT6x4U8FWl2CZJLGG+ug3cRxrtz7+YyH/gJpfiNYf2p4Wi8F6OqwTauyW4SJMLb2qsDK+BwFCjaO2WUd66bTdFi026eWJ8oLeK2hjxjyo4wcD3JLE547elONld+a/C/+a+5ifT5/jb/J/gXri2gu4Ggu4Y54nGGjkQMrfUGvOfDPhgeCPi9eaf4fUw6Bq+nNfPZL/q7W4SRVyg6KGDdPb0HHU6vo3iG48QW2o6H4mFhbpH5c+n3NgtxDLzncCGRlbtncR04rVs9OS2uJbqVzPdzALJMwA+UZwoHZRk8e/JNKOjv6/wBfr8hva3p/X6FyisywsdVt9Z1G5vtY+2WVwyG0s/sqx/ZABhhvHL5PPPStOgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiuL8ReMrz/AITO08GeFUgfWJ4Tc3NzcKXisYAcbyoILMTwFyOoJOKvS6H4ltreabTvFs91eFSY4dSs4Gtg2c4xEiSAdvvnA9aOlw62OmorJ8L3WoXvhewn1tUTUmiAu1jGFWUcOB7ZBrWptWdgCiis6DSPI8QXWq/2hfyfaYUi+xyT5t4tufmRMcMc8nPOBSA0aKKKACqupabaaxpdzp2pQie0uo2imjJI3qRgjI5H4VaooavoxptO6Mjw34V0Pwhpn9n+G9Nh0+2zuZYwSXPTLMclj7kmteiim23uLYKKKKQBRWToniTTvENxqUelTrcJp1z9lllRsqZAoZgD7bgPrmpdN0j+zbzULj+0L+7+3T+d5V1PvS34A2RDHyrxnHPJoA0aKKgvrX7bYT2vnzW/nRsnnW77JI8jG5T2I7Gh7AT0VW02y/s3S7ay+03F39niWPz7qTfLJgY3O3dj3NWab3AKKKKQBRRRQAUV5j4ivNV0/wCP3hKzi1u/bTtShupJbAuqwqY4sDAVQSMnPzFuemK9Op291Pv/AJ2DrYKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFZNl4k07UfEuoaJZTrNdadFG91sbIjLltqn3wuce4oDpc1qKKKACivN/i9dappkfhy90vWr6ySXWrW0mtoGVY5kd8ncdu/PygcNjGQRzXpFC1V/O35f5jejt/X9aBRWVB4j0+68U3Og2syy3lpbrPcqjZ8oMcKD7nk49MetatHS4utgoorO15dTk0W4h0GRINQmXy4Z5FDLATx5hU9do5x3IAoA0aK8j8R6F8TPD/h271NvisbhoE/dwDw5aqZpCQEQHPBZiB+NdL4h8T6jocnhjwzbzx3PiDWWET3UqDbGsaZmmKDAJ9BwMn0GKe4Hb0VxB8QXvhTxzpHh3W9Qm1S01uOQWd7cRxpLHPHyY28tVUqykYIUEEYOc8dldQvc2csMdxLbPIhVZodu+MkfeXcCMj3BHtS6XDrZktFee/BzUdR1Hw7rJ1fUbnUZrbW7q2Se5fc2xCFUcYA6dAAOTxXoVPt8n96uJO9/n+DsFFFFIYUV5t4KudVi+MPjDR7/W7/VLWzt7R7cXbL+73hmbCoqqOTjOM4A9K9Jo6J9xvRtBRRRQIKK85+M9zqmmeGbLUtI1q+09kv7eCSG2ZVSZXlUHcdu/OPRgOTnNejULVX+X5f5i62/rr/kFFFFAwooooAKKKKACis7SdI/sp71v7Qv737XctcYvJ/MEOQBsj4G1Bjge5rRoAKr31ha6latbX0CTxEhtrDoQcgg9iDyCOQa4L45XOqaZ8Mb7VtF1q+0ye0KDFoyKJQ7qh3MVLDAJxtZefWvQLUlrOEsSSY1JJ78U1qr+Y3pbzJQMDFFZV94j0+x8RabokkytqGo7zFAG+YIili5HpwB9TWrSF5BRRRQBXhsLW3u57qGBVuLjHmy9WfAwBn0HYdBk+tWKKKACivP9c1/xBpnxg8K6KNQhbS9WW7eWFLYK37tMqNxJPcHIxyPQ4r0Cn0T7/wDDBs7BRXOeLbDxPqsdtZ+FNbTQCGMlxftZpckjGBGqPxyTkntgetceul/ELRvGHh+0v/iOdXhvbljPajQ7eDMEalnJcZIGdq8f3xzSWrsD0Vz1OiuR8UaX431mV18MeIrXw3DCfkZrBbqS5OO5Y7UXPHAJ4z7UfDXxFq/iXwm8/iO3ih1K0vJrKdoARHK0T7S6Z7EjH1BoWoPQ66iiigAqlqdzfwQhdJsYru5bJVbicwxDH95wjkdeMKf61drm/GnjvQvAmmR3Wv38VqZ22QIwZi57naoLbRnJIBpMaLvhvXf7f0+aWW0eyurW4e1ubdmD+XIh5ww+8pyCDxkHoDxWvXK/D/xDoHiPQprnwveSX9us7efeNA8Qmnb5nIDgHuO2AMAdKwvjPcappnhuy1PSNbv9PZL+3gkgtmRUmV5VB3Hbvzj0YDrwap7pd7fiTfRvtf8AA9HooopDCiioL23e6sZoIrqa0eRCqzwbd8ZP8S7gVz9QRQBPRXn/AMG9R1HUvB99Jq+oXGo3EWr3UAnuW3MVR8AccDp0AAr0Cjon6fiJO9/n+AUUUUDCiiigAooooAKKKKACiiigAooooAKKKKAPGvAn7v8AaY8fJejbcyW8LQburRYTke33a9lrj/FHgV9U8RWXifw9frpXiCyQxLO8PmRXER6xSoCCR6EEEVp6fL4rnUx6tZ6PZdP39peS3Bb1/dtEm3/vpvxoXwRj20B/E5dzdorgfFesaXpPiTTdD8RarNo+j3VnLKt39ta0E1wrr8rTqVKnBLY3DdnnPSs+Z7q68UeD9Pt/Ft9qOnahZXsctxaTLGtxsT5ZQ6DJbDY3BiMqCADRur/11/yDqenV5h4Rso9P+Pni63gkuHi/s+1kAnuJJipZmZsFySBk5wOB2r0u2h+z2sUPmSS+WgTzJWyz4GMk9ya4DRPDPi+y+Lur+Jr+LRf7M1OCO28qG8laaJI/utzEAxPORkYz1OORfH9/5A/gfy/NHINr2laNquqaR8UNMuNE1a+nnitPFCoSssMjsY1WdfmjCjA2Z2gDnGTXuERUwoUYMu0YYdCPWuL13w54j13w1deHNQOk3lpepJG9/K0iy26tnbiHawkZQcbt6cjOO1dZpljHpek2lhCzPHawpCjOcsQqgAn34pr4bMH8V/X+v62OIspbbxr8S/FGk67BFeadoaW0ENhOoeGRpFMjSuh4Y/dAznGDjrRc+A4tC8E+JrMarfSadIJLuxtY55IPsGIyRGjowJQMMhfugYGKj8TeBPEcHjh/GHw81OwtNSuoVgv7PU0c210F+6xKfMGA9PQcjnOveaT4rufB+oRXE2k3mu31ubfAMltaQqQQdvEjk85568fdrOV3Tdt7W+f9a+Radpq+1/6/rqcd8P8Aw5o9h8LdD8cX8dzfatpmkPPBNNdSbYl2MSixhggGOPu5PUknmq0PhrX/ABx8PrTUBoegNq9/ZrPb6++sTC7gkcbgykW2UAJ/1avtA4z3rt/h54d1nQvANt4a8UxafILSD7MstlcvIJ0Oc7g0abeCBwWz7Vz/AIf8FfEHwXL/AGL4Y17RbjwyHZoDqtvLJc2ikk7ECFVcA92YfTtW07Ocu3T8fu6GULqC79f68i1rmmaiNJ8JJ451qxa0tNy6xaAO41WXyyqKiBQZecsU28+hxWb4EFvbfF7xRoVhp02n6JLp1vcx6bNGEiUsSrMsWSEDdxhT1yK39d8GaufFnhvxBodxa3c2kRzQzW+oyNGswlHzSK6q218/7OOccUll4P8AEMHxcu/FMmoaetheWEVtLAkTmXKMSFBJwB6tyTz8q9alO8rvre/4/wDA/IJX5bLpb8/+HOa+DXhrQxqHjG4TSLGO4tfEV3b208duqSW8W0DZG4AZBgnhSOtXvhdpkK6p8QNKMl09surmBS93K0oTygMCUtvyB0O7I9a0/C/gzxJ4X8Xa/Na6jp0mhanfSaisBicXBmccoW5VUyByAxPtUHgjw1408Oaz4ovtUt9CmGs3LXsMdvfTDy5MYWNiYfu4xlhyMfdOeBO+/wDKl89P8n/TLl8Ta/mv8tf+Acx8OvBGl+L/AAZ4g0/xDJe3ljDr15HHAbyVRlWAVmYMGkIAGNxI46Z5o8OG41n9lu8fU728ln0+3vDDOl1JFJmEyCPLKwLAYHByOBkcV0vw+8MeNPCGi63a38OhXU97eTX9s0N9MqiSQglHzDwo5O4ZPbHeszQfAnjfR/g/qfg6RNAluroTRxXQvpggWbcXJXyM5XPA757Y5mV3Br+6vvWg6dlJN/zP7tf+AYnjW0SX9k3SrzzbiOa10yz8sxXDop3+WrBlUgOCpIwwPWr3xQ8L2uh6Zo/jOyub0eILfULRPtjXchBjdwrRiPdsVcHooHvnJq7rPgLxrqvwRtPA6poMd1FHFby3RvpihjiKlWA8nO47cEdBjOTnA0fHnhbxr4u8EaZpFtDoVrdxTxT3ckl9MyZibKhMQ5O7AJzjHTnrW05Jzcl/Nf5aEb01Hyf/AAPxH67f6jr3xMu/DlvpWmarZWGmxzyWWpXrwRStKzAsyrDIJAAoGGAA3E8nGJ/AXhTxJ4a8T6vLdLplj4dvEV7XSbK8knW0lGA2zdEgVW5OB37VH4n8EeI9R1nTvF/hm/stI8U21t9muYJWaazuY858tm2hsA8htoPsOtdL4bsvEYX7X4xvNOmvtmxYdLikSCIHBPLsWYkgcnHA4HWs46L7/wA/69Alr+H6Gd8UPEF14c8ESXGny/Z7i5uYLNLjvD5sgQuM9wCSPfFM1D4baa95pmoaBMdF1KyuI5Zb63jDS3sY4aOZicyBh3YnB5rX8Z+FLPxr4TvdB1FmjiulG2VPvRODlXH0IBxXOeGtD+I9uiaX4p1vQ7nSoVEYubW3l+2XKDjDEkIhIxkgMevfmiO/nf8Ar+vMctvL+v68rGb4x/5OG+H3/Xtf/wDouh59R8Z+MPE1k+gaLrmn6VcR2cdtqt+8aR/u1cv5QgkUksx+YnI24GOc2vE3hTxdqXxY0LxNpsOinT9FjljSG4vZUlnEq4YnEJC47DJ6deeF1/wN4nsPG1x4r+HOqWFreahGkeo2Gqo7W1wVGFfKfMGA9Pz60lbljfz/ADuvw/MH8Tt5fkZ1j4S8aaJ8PfFGmXOvadpMU8hk0yYXskq6bATl4zKyIQoXhSBx7Vl6kdH0f4geBrvwZp0thDe37Wl3eQQfZ4r9TGfvZw0pzlg5Ug8ndzz1nijwPr3izwHdWGp6tZHWppIZg0MDpaDyn3LHsLMxUnOSSSc9OAKj8U+E/Fvie48L36T6Np13o98LmWLMs8eNpUlWwhbrwpC/71NN8yfmvu/q/wCfUUtYtLs/v/rY53UfDFlqH7RsmmXFzqP2K78PyXFxCNQm+dmnAZQ27cinavyoVHygdMitzWvC+iaJqWgafdy2w8KWdtNFFoEgkuXupyQVIiO4yhRuODnHXHcLJ4V8Yr8YovFscWiy2MWn/wBm+W99Kk0ke/d5pxAVDd9g47bu9aeq+FdZT4pWfi7RnsrlBYHT7i0vZXj8tC+7zI2VG+b1BAzjqKFa0V6/+3W/NenyKk7tv0/S/wDXX5nNfDWJLjxP8QPDP2e8sdIguIDbWJmMRtkljJZU8tsxg4yApGM9AcisjwB4G0vxl8JruDxHLe3kMV/e+TEbuRVVhI2Hbaw8xuBy+enTrnr9H8H+KdE8eeKfEMN7pVzFrCQvFakSRFpI02gM+G2JzngMTx93vX8B+FvGvhHwNqWj3cWg3V5JLLPayx3syxlpWywcGHIAySMZz0461MtY6b8q+/QFpLy5vw1OZ8M+KtTu/hR8PtOur+YSa7fmxubsSESmGNn+UN1BYIq564JxzzXoY+H1hY+LtP1zw5IuiCHzBfWlnCqx6grDjzAMfMG53EE9a4zSvhFrU3wnsvCuu3llZalo9z9r0vU9OmeXZJvZgWRkTH3sdTnrxiuu8M6f4+kZF8dajobwQMCq6VBKJJyMEF3cgDnkqq88c4yK1k05trvf5NL/AIOhmlZJdLW/F/8AA1OYsDf/ABAuvEE114a0HXrO31Saxhj1XUnT7OIvl+WMW8gVjktvB3Hd6AV1Xw20LxJ4c8Myab4svbe8kjuXNo8Nw85SA4KozuqlivIzjpisK+8C+L/D3jDUNb+G+raXHb6vL519pmsRyGES4wZUMfzZPpx356Ad5o1nfWlmW1e7ju76Zt80kMZjjBxgKikkhRjuSep71EdI/Jff/XUuXxfM5jx5rE0fiTwp4bjlkgg1u9kW5kjcqxiijLmMEcjcdoJHbI71bt/AFjpfjK01zw7KNGgSKSO906zhVIb3d912UYAcHndjJ6ZpvxD8Dt410m0+w6g2matptwt1p96q7vKkHqO4P+fSjwzY+OZWRvHd9obJCwKRaRDKDKR0Z3kPrztVRyBz2pR/H+v6t8wl+n6nPeCYtP8AiWniHVPFVnBqkcerTWVraXaCWO1jiAUbVPAc5JLdecZwBWNpf2lk+IXgfUr2/uLPQUF1p1wLyVJo43jZ1jMisGYKcYDE++eK6zT/AAfrXhDxPq9/4QOn3em6zP8AarjTr6d7fyJz9545FSTIbupUexqabwhqVnofiOXTPsN3r/iBibiW5keGFBs8tVG1XbCL2xyc8jPEy+DT+W3z0/q5UX72ve/y/wCG0sc78MvAGh6v8P8AwzrerC+utTGnbIrj+0J4jCjggqgjdQvB6gZ7k55rL+FngjR/EOkapNr/ANtvxpviO6NnHLfTBYjGyhWOGG9uBy+48fWu6+H+i+JfC3w/t9E1WDS5rzToPKtXt72Qxz4yRvJhBj7DgP6+1UPhf4W8U+EY9VtPEKaTJb39/NfrLZXcrtG0hB8vY0Sgjg/Nu/CtpP8AeScezt96f+Zik+SN/n9zRz2i2+pfEjw3catd+GtB1dbu5uBbXN9qssc1qqyMiiNRbP5RAUcq2SeTyand/FPhrwp4P8JeKNWSe/1TVPsVzqFrO5ZrcBnCh2VW3EAIWxnGec81cg8C+NfCHiG9f4e6vpB0TUrlrmaw1mKVvssjHLtEY8E59CQOn1rY8WfD2TxZ4RhsrrVWh1q2uVvrfU4o8CO5XoQmeExxjJ4xyTzUJ2Sfpdem/wCvqay1bXrb57FofD6wsfF2n654dkXRBD5i31pZwKseoKw48wDHzBudxBPWuM8G+GdBb48eOy+iac32I2M1rm0j/cO0ZZnTj5WJ5JGCTzXXeGdP8fSMi+OtR0N4IGBVdKglEk5GCC7uQBzyVVeeOcZFVI/BfiHT/ivqXiLRtT0+LStZjgF/FNC7zq0QwBHzt5Gck5x6HrTWj+T/AMxacr+X5nNaLb6l8SPDdxq134a0HV1u7m4Ftc32qyxzWqrIyKI1Fs/lEBRyrZJ5PJqa5uPFHhTwP4U8KeJtWjn1XVtUTTptRtp3LC3yWOHKq28qAm7rznOeauweBfGvhDxDev8AD3V9IOialctczWGsxSt9lkY5dojHgnPoSB0+ta3jD4dSeL/CENjdaq0WtW1yt9BqUUe0R3A6EJk4THGM5wByTyUmkk+ml16b/r6jldt287fPb9DmPiz4X0jRdP8ADU+jWMVgz+JLPzhbqEE5LH5pAPvN/tHJ688mvYK8n1vwN8RPFvh3TrfxFrmgxX1hqMN1EbOCXy2EeTvfdyzE4+UBAOeTxj1K0W5SzhW/kiluQgErwxmNGbuVUsxA9iT9aF8LXn+i/wAhPVr0/VnlWh+F9Am/aE8UCXQ9NcQWNpcxBrSM+XKSSZF44YnksOaveEDZfEjWPFlz4ntIdRttP1Z9OtLG7QSwwJEo+cIeN7Ek7sZ6DOBWjd+DvEcHxWm8S6Bqen29hqNpHbX8dxAzzL5ZyDFg7ckHGW4Ho1LD4P1nwx4y1XW/B7WFzaa0yy3umX0zwBJgD+9jkRH691K++e1KNrJPs/vv/loN7try/LX8dTP8AXd9o3xI8UeCpp5rnTLFIr3Tmmcu0EcnWLceSoPQHoBXpdc/4e8NHS9X1bWr6RJtU1aRDO0YISKNF2pGueSAMkk9SScDgDoKfRX3F1djlfEv/E18W6BoY5iSVtTuhjI2Q4EYP1lZD/wA1yXiRZF/af8AB7yH9y2lXKx5P8YD7se+CK73TdGuIPFWsaxfPEzXQigtQjEmOCNScHIGCXdzxnjbzVXxZ4T/ALeudK1OxmjttX0a58+0nkTcpBGHjbvtZeMjkHB7YoWji/X8Vb8Fb7gkrpr+tHf8zjvi9vfxt8N4bcfvzrgcEHnYAN36V6rXJWvhi+1XxdZeJfFS2cdxpsLxWFlZytNHCz8PIZGVCzEAADaABnrnNdRdNcJaStZRxS3AQmKOaQxozdgWCsQPcA/SltG3m3+X+Qbyv5W/P/M8I8D69Ztaal4NvNkP9v8AiHUomuLqDdCUDDdGuRtaRs8A8Dqc8Ke78V6CvgP4R61H8NtKisbyO2BU2kf71gCAzk9XcJuIJya57SPhX4gfwV4i0HxPBo9w1/ezanYXFpfyq1tcuQV5MOVAIzuGT2281uyDxxZfDWbTPEmpaTb63IkdpZalZzySG5lZsAMjIm1iONysepbjFD+C3Wy+em3yfT7gjpO72u/zv+RzfjTSNGh8JeGNV8FM1tqepX1pGk2nXDwz6lG/+sWSSNg7/LliScjHUV7HZ2sdjZxW0LTNHEu1TNM8rke7uSzH3JJryvTvDvxR0i+a+stE+GVvO4Amltre5illUdi4X09c16Zot++qaHZ30sIgkuIVdo1feFJHIDdx6HvVN6O3f+vyJS29Dy+08PWfiX44ePNP1V7g2T2diJoIJ2h84eWeGZCGx7AgHvmoPDbzfDDxz4o8M2ctzd6Ba6MdasreeQubbaSGiUnnBI4+nrk11svhXXdH+IWqeKfDr6ffLq0MMNxY30r2/l+WCAySor5/3Sn41raV4VWLU9U1fWXju9R1WNYJti4jigUELCueSPmJJPJJJwBgCNeXTs1+dv0ZpJpyu/L9L/k0ct4O8M6Z46+G+n6z4liW/wBW1OFrg6iw/fWzMTgQv1iC8ABSOn1rltM+IWtt8MrLTNRvH/tWXxGPDkmo5wxQP80oP97ZkZ9ea7fwr4V8TeBrB9B0SXTdQ0VZHezmvJ5I57NWJOwoqMJQCePmQ1HrHwk0/UvhsvhiG9lguorg30WohfnF2WLGUj3LHgHp0PFXePNdL3dNPmv0uvMhJ2s99dfk/wBbMwPjF4U0bR/BNtdaRZR2Mp1az85oBtNz+9HMp6uc87myffk5l+LnhPSNP1XSPiE2kW1y+lXkZ1RGhDCe3b5N7DHLR8EE9h7Cna34E+Ivi3wauk+Jde0Nbm3uoZIJbOCQCQIwJklJ6txwqhRnqfT0ebTzf+GZdP8AEb29z59s0V40MZjjcEENhSzEDHqTU6xXMt07/gv8gVnKz2as/vf+Ziapo+jeLPGGlSXdjZ3yaTD9sWWSEOQ0nEQDHtgM2PUIfSuk1DTrPVtPmsNTtorq0uEKSwyqGVx6EGuY+F3h+Tw94Ds7e5upLyWQbxNKMExD5YhjtiNU49c12FOSXw9Ai3ueReDND0HTPBfizwZqmk21xDpN/IGhaJS1ykgD27HPV8EKGPOVHPFUPh7Y28Xwp1XwJqmn2j39lqjabPE0KusrSMGSYgj5iEO4E8/u/au/ufBss3xMi8RxXCJZSWaxXlt3mljfdC3TGF3N3zkLTYvAqw/FefxbFOq29xZqktqP47hcqsp+kbFfxpp3+Lqtfl/nZ/ehvy6O6+f+V/wOf1Uyf8J3a+BtB0bS7nStP0f7SdNu7traCTfIUGVWKTeAAflIxl8nJAqx4Q8F+IdF8WarJNFpuleGNQtdg0jTNQmcW83d4j5UflggnO3HODV3x14G1XWNc0/xP4O1WLS/EOnRtCjXCFoLmInJjkA5Az3GcZPGcEaug2ni4Wz3niu40i41FImW3tNNWWK3Vj3Z3LMScAZ28DPBqU9LvfW/zv8AeDWtltp8rWOU+CcQto/GdusksiQeJLiKMzStI21VRVBZiScAAZJNUPD1jpnibw/4ru/HKINcsL+6WS5ufll05AMxGFjzGu0KQVxk881u/DXwx4m8JXXiF/Ev9j/ZtUv5dSElldSM0TvjKEPEoK4H3s9unPHNx+HvH+r3H9r6fbeANbtpLiS50/UdZtJ2ufLZsqQVyFAG0DB6AUS1t/hS9HZf5MptXbX81/lr/mYmt29+P2SZ7/Wpb+TUr2KCSdr29mnLf6Qu1gJHbZlcEhcDnpW38TvDNroWn6P40srm+/t+31C0jN013Jh43cK0fl52KmOwAz3zk1d8VaT4+8eeA9S8JX1r4dt9T3xfaLuG8mFvs3B12KY2bd8uCGIwMEZzxe8c+FvG3i3wRpmkQQ6DbXcNxFPdSSX0zITEwKhMQ5O7GTnGOnPWrcvev/eT+WhH/LtR8pff0/Ez/Gnh3RdQ+P8A4QS/0ewukvLK8a5We1RxOVVdpfI+bHbPSvWYoo4IUihRY441CoiDAUDgADsK4HxT4S8U6x4h8MeJtFudJsNX0pJYrmC58yeApKAG2sAjMRjgELnPUY57y3SSO2iSeXzpVQB5NoXeccnA4GfSpWkUvX82xfab72/JHnPhx7T4g+MfF6eI7eLULHSL1dPtdPukEkKBRlpChyCzN3IyAAB3rO0S3ex+Ivib4eXE93JoMmnpqViiXUkb2ilgrRLIrBwm7oucADHQ10T+D9W0Dx1qPiXwe9lMmsIg1DTb6V4UaRBhZUkVHKnHBG0g+tXrfw5qNld6z4gRLO68Q6lFHCkUkzx28MafdjDhGYjJZi23k9gOkfZ+Wvrb/PUv7Xz09L/5aHB/BTwbpOt/D/Qtf1r7XfahZ3VxLavLeShYWEz8hAwUknJJYEnPXGBXs9cJ8JvC/iHwV4RTQPEK6bIlu7vDcWV1I5fe5Ygo0a4xnqCc+gru61m03psLq2eaeMv+S9fDz/rlqH/ooV6XXnfibw14v1P4m6F4j0600Q2eiLOkcU+ozJJcCVApJxAwTGOnzfWuy13+3P7Hb/hGRp41Lcu0agXMOMjdnZ82cZx71P2I/P8ANg/i+40q5XSP+Jv8QtZ1M8w6ZEmmW5x/GcSzEfnGv/ADXUfvPJ6KZNvTOBn/AArI8J6NNoXhyC0vXjkvXZ57uSMkq80jF3IJAOMsQMjoBQt7/wBf1a4dP6/rew3xZY+IdR0SS38Kata6VespHn3FqZu3G35gFOe5DfSuX+D2v6vqOh6joniW1hg1Xw/dmyne3Xak3GQ/1OST69cDNdEZfGUeu3CraaFcaSzfuJTdTQzxrj+JPLdXOc9GWrXh/QI9DjvJDJ597qFw11eXG3b5khAHA5woUBQMngdScmlHS77r8f6uEunl+X9WM/4jafFqHw91nzZbqFrezluIntrmSFldEYqSUIyM9jke1eWaj4QsdR/Zv0/xDdXN9/aml6LHdWE0V3JGtsyJkbUU7cnuxBbk8jjHrvjSw1fVfCGoab4fjsmu72B7fdezvGkaupUt8qMSRnpgfWuM/wCEO8Z/8KR/4QpodCN99kNh9p+3TeX5W3G/HkZ3dtvTvntU68srb6W9df8ANF3Xu387+mn/AATmfiDoNvqHwWtvH91dXzeJbextrq3vVu5F8hnKZVEBCAfMecZPc17Zpcz3Oj2c8pzJLAjsfUlQTXm+ueC/GerfBW38FJDoUd4LeO0muTfTGMJHs2so8nJY7TkHAHqc8d94bh1O28OWVtrsdrHfQRLFJ9jlaSNtoxuBZVPOM4xx0yetayteVtr6GSvyxvvZ3/D/AIJqV5t8dgT8O4Qp2k6rZ4I7fvhXpNcz8QPCUnjXwq2lwXq2Uy3EVzFM8XmKGjYMAVyODjHWs+qfmvzKeqa7p/kef/FPwbB4O0mT4heGby/h8QadLHJcTy3kkgvIy4VkdWJULz91QAPTpW5BqKeNPi1qOgavGJNK0rS4ZTp8oDRzyzclpF6OFUgAEYySa277w/rXi2zh0/xdFp1rp8c6TTxWFw832zYwZVbfGnlruAJA3E4xkVDrvgy/Tx1beMvCs9tHqS232O7tLtmSG8hzkAuoYoynodremKpWVk9rv8v8/u3B6rTf/gr9L/eYEbt4B+NOn6JpOYvD2vWM0w09P9XaTQjcWjXoikYyo4yat/D+3074ieFl8V+ILSK9u725me2Mo3GxRZCiLEf+WZAUEsuCSc5ro7Hw3c3filPEviJbZb6K0Npb2ttI0kVurHLneyqXZsAZ2rgDGOprlPD/AMPvGHgnWrmx8I65pg8K3lw05gvoHe4si33hDtwp9txwPQ85FtZ72/V/pb7rA+rXdfl/n/mUPhf4X03xP8J9Z0PXYReW0us3qFpQCwYPgSA9mHXIqX4cy2Wh/DPW/DFzptn/AGhotxJYXVt5Khb534hd1/i8wFRk5zXR/DPwbrXgqx1Cz1TUrO8tbm8luoUhibzELtk7pCQG4xwFHJPJplz4Tin+NMOt2twyINODahbLjbLIr4t2b35kP/ABQukXs0k/kv8AgNfNdhapNro2183/AMH8DpPC/hvT/Cfh620rSraGCOJQZDFGE8x8Dc5A7k1r0UUN3dwSsgooopDCiiigAooooAKKKKACiiigAooooAKKKKAKep6RputWn2XWdPtdQt9wbybqFZUyOh2sCM1BL4b0OfUIL+fRdPkvLZVSC4e1QyRKpyArEZUA8jFadFABRXPeO/FI8G+D7vWPLWWWMpHDG2drSOwRc47ZOT7Co7bS/FVp4mt7j/hII9Q0iVG+12t3bokkTY+UwtGq8Z6hyxwOpoWoPQ6WiiigAooooAKKKKACiiigAooooAKKKKACiuB+LXinxJ4I8JT+ItAk0uSC1MaSWt7aSOzlnC7g6yqB1HG09+a37TU9Q0rwbPrHiq6s53gtmu5DY2zwoiBNxXDSOSeDzkZ44FK/uuT6Ds7pLqb9FcHpUni/xFoug+JtI1uCEXyxXF1pV1bobcQPyQjqvmCQKepYqSOgrvKpxa0ZN77BRRRSGFFBztO3g9sivPPh94j8Q6n488ZaL4iv7e8TR5beO3NvaiBRvVmJxlm9Byx6U1q7fP8Ar7weiueh0UUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqrqep2ukWD3l/KsUKEDJPViQAo9ySAB70AWqKztcs9Sv9LaDRdV/sm6Lowuvsyz4UMCy7W45GRntnNaI6c0AFFFZxs9SPiNbwarjTBbGNtO+zLzLuyJPM+90429O9AGjRRRQAUUUUAFFYmv68dNubHTLBEn1XUnK20Tn5UVRl5XxztUenUkDvms3XvFN1o+r6J4YsDDd65qyyFJrkbYokjXLyMq8n0CAjPqOtG4bbnW0Vys+o+K9HvdMhv4NN1S2vLpYJ721R7Y2wPQ+UzSbgcYzvGCRxXVUdLh1sFFFc9p2t3Ft4kbw7rjI11JE1xY3SLtW6iBwwI7SLkZA4IIIxyAbuwdLnQ1k+JfDGleLtHOma7bGe33rKu12R43X7rKykEEeorWoo3DY4TSvhPp+n3W+88S+KdYth92x1LV3ktwOwKLt3D2bIrulUIoVQFUDAAHAFLRRcAooooAKKKKACub1nwTa674gi1K+1bWhAkQjfTIb947ObBzl41xu64IJwRwQa6SijrcBAAqhVAAAwAO1LRVTTdTtNWtnuNPmWaFJXhLqcgsjFWwfYgj8KALdFFFABRVTUNTtdLjhe9lEYnnS3iBPLu7BVA9ev5A1DrFnqV6lqNJ1X+zWiuUknb7Ms3nRA/NH833d394cigC/JGk0TxSqHjdSrKwyCD1Feex/BjSLO6VtF8ReKtGslbd/Zun6w8Vv1yRjBYA57MPbFeiUUdbgU9K0qz0bT0s9PjKRLySzl3c92ZmJLMfUkmrlFFG4BRRRQAUUUUAFFFFABRRRQAUUUUAFFFIwJUgHBxwfSgBaK56S08Q6f4MuIjr0F3q8avIt/PYAIRuLAGJHUcL8uc+5z0rN+EviLUvFfww0rWtbmWe9uvNMjqgQcSsAAAMcAAfhTte/l+v/DA9LeZ2dFFcD4f17xC/xh1vw7rOoW11ZWunx3VutvaeTt3uRg5ZiSAMZzg+gpLV2/ruD0V/63sd9RSOGMbCMhXwdpYZAPuOM1wHw18Q6/rGveLtP8R30F42kagltC0FsIU27Mkhck89eWNC1dv6/rUHor/1/Wh6BRRRQAUUUUAUNc0n+3NFuNON/faf567ftOnz+VNHznKvg4NQ+H/D1p4csPs1rNd3UjEGW6vrhp55iBjLuxyfpwB2ArVrG8VeKdN8HeH5tX1h2EMZCpHGNzzOeFRR3YmjYLXNmiuXs38balDDeO2j6MkgDGwntpLqUDOcNKssaq2MZAVgDnk1P4b1rWdQ1bVtP1/S4NPlsGj8poJzKlyjg/vASqkDKkbSOCDyadhXOhooopDCiiigAooooAKKKKACiiigAooooA8s1fxppum/E690vxzqGo6HEPLOi3IuJILSVfLG8sVIRmDE8SZUccesfxIivtJ8I+HdSg1/UZL9dStLd7u2v5I47qN5OS0aMIzuB67fYcV1ev297qMd/p2t+FY/EGl3EoFskUsJKrtGTIspQLhgcFSzcjjiuUvvhprUPwS0/wAOafPDcatpd0l7bxvIfLJWUyCHeecAHaCcdB0ojok30a/PX8N+45a3S6p/lp+P3Fj4ry3WmeJ/BF5p2o6havea7BaXEcN9KkUsXJKtEG2HPc4yeh4qnqMGv3fx4l8OxeL9Yt9OutEe8KxmINATMF2xYTaMBQAzKzAFucnNJ4s0fx/4xt/CuoyeHrGwu9M1aO8k09tRVwqopOXlC4GTgAKrYzkk9rTWfir/AIXrD4lfwldnTF0r+zZJYry2bLmTeZFDSKxT6gNj+HPFVFLRPvL8Y6fiK+jfkv8A0r/IzvjL4Xg034RQRyanq9/LZ3NtCtxd6jKzShp1yZFUhHbnhiuRxg11+v6Lqmm6Tp1j4Yu7qGymv0bVbu71OSWaG2xl9kkzsy5wBweMkjHWs34z6b4h8QeEV0XwxoE+pzS3EM7TC5gijjEbhtp3uGJOOwxz17UnjDT/ABH4kj8NalF4euWt9Ov/ADdQ0G4ubcPcLjCuCJDG21vmAZhn2NKLuv8At7/L8BNWl8v8/wAexR8M66Lb40nQdD1i91HQLzRjeoLq4lulWUSBd0c0pJZCvozLn0rV0BpPiNZatqN5qGoWdtHfzWlhFY3klsYRESnmMY2BdmbJw2VAwMdSYLvRPFE/xq0vxJa6Tbx6aNJeylea6XdBmTdyi53N6BSR/tCs7T9F8dfDrxJqkPhbRLbxL4f1a8a8jjk1BbWSxkc/OCWByuf7oJ4/MWqSfZ/fzafhsxy3dvL8tfx3NPU9Y8T+D/A2jafrV0NW1/UNQXT1ubFEV3UljuAkKp5nlr3IXce/ejJD4xtPF2kXvhjQvEcFlJc7NXg1nVre4haEn78YNzIUZck4QAHpjtWz4z8G6x4w8GxKbuCw8QWt3HqNmyMXht5k+6m4gErjILYHJJx2p3hvVPiDqzJaeJ/DNloiREeffxaks32jB58uJQSobH8TZAPQmmt7ve/4af8AB/QUttNrfjr/AMCx3FeReI31O18P+I9Q8Ta9eaf4gje5n0a107UJAEt4x+6YwRHDg4BYyK2N3OOg9dPTivKvD/hnxPYeC/FGg3+jifVdQa6I1h7qPZfCQEIScmQFQQu1lAGODispXs7b2f8AXqaRtdX7r9fw/wCAZnjbX/EF18B9C8U2OvXun6hNDaecttsSOZpWRWLfLvHU42svWug8RC/8B2EuqprutazqWt3dvYxW88sRigd3wTBEQqIdu7G5sEgbieTXMa74Y8cXPwH0fwpF4Z87VIRbhlhvYNkKwspy7O65ZsdFDAc/NXd+L/Dd58Qfh+LQxT6DqsciXNr9pMbtbzxtlSTGzLg+oJOD+FbTtdtbc34abfiZRT0v2/HXf8Dnb+HxnbeINJvvCWheJYR9rUapDrGrW08E0B+8VU3L7HHUbAo9u1bGswXdx4s1M+LtVn0zQRHDFo6WGpSW0s8pVjIxETB3YHACnIwM4PWl8Oap8R9SK6d4m8NWOlLHhZ9Vh1JZBOB1MUKqSpOP4mGM5wcYpmk6Pr+k/FDxDqV5pJ1S31IR/wBn6iLmMC0jVcGFlY71XdzlFbOeany9f6/y+fkVfd+n9f5knwd1/UPEPgHz9Xupby5tr24tTPNHsd1RyFLDAOcYzkA+orvK85+GujeKvCvhvXLfVNIt/M+33V1ZxR3gLXRdtyjONqDtk5PPIXHPdaTc3t5pFrcapYf2deSRhprTzhL5Ld13rw2PUUPVJ+S/IS0v6v8AM8+/aF/5Inq//XS3/wDRyVq/EDToNQ+D2pNO9yht9JklTyLqWEFhCeGCMN6/7LZB9KofGvS9f8TeBbrw74b0C51Ge7MT/aFuIIoo9sgYg75AxPy9lxz1q14im8Q6p8Kb3TrTwjqA1S7s3sRayXVoNhaPb5hcTbdmTjj5uPugc1D1pSXn+hrFpVIN/wBak/wl0i2sPhvoN1BJePJdaZbtIs99NMinYD8iO5VBz0UAflUnxE8TXehw6Lpuly+Rfa7qUdhHcFA3kKeXcA8Fgo4zkZI4qX4aJq9l4H0zSNe0O50q6020it2Ms0MiTFVxlDG7HsPvAdeM1H8SfBtz4v0SzbSJ47fWNJvI7+wkmzsMiH7rY52kentW1Vp1b9L/AIX/AMjGCfJbrb8bGB8Qzf8Aw30mLxdoOpajcQWtzGNTsb28kuY7mF22kqJGPlsCwI2bR7YFN1S41uT43abp+n+JL6Ow1PSJrkQuEKW5yoyihQCccjfuwSTz0rW13TdY+IXh+PQtZ0GbRbaSeF9QknuIZFkRGDlYfLdidxUDLhMA5wTxWdqll4lHxx0vWrPwrdTaLY2D2DXKXVspJds71Qyg7RgdcHrx0zEd0n3f3cv+exTel15fn/lv8iLwh/a3hv40ap4TuPEGp63p0+lLqUbapMJZYpDJsIDAABfYAAelJ4AjWb4wfE+JywV57RSUcqwBhboRyD7jmpYrLxMvx8m8RN4WvP7GbTBpi3IurbJIk3+Zs83Ow/8AfXt2pvw/03xLY/E7xbqus+GLvT7HXZYpLeZ7q2k8sRoVw6pKSCeOgP8AWnGzSv8Ayv8A9K0/AU9L27r8v8xPA1tc+Gfitr3h3WNX1fUTNAt7pMl/qM06/ZycOm1mK7lYD5sZx3656rwppoOoarrYvNQljvbl1t4Z7+aWKONTtJRHYqu5lZhgcAgDA4rI+J/h691GTQNX0C4W11mw1BIYZSud0U37uVcd8Kd3/Aa7iytIrCxgtLZdsMEaxovoAMCkvhv20/r5W9dRve3fX+vnqcR8UPEbeHE0ebUF1GPw9LO6apdaczrJCuz5Msnzqu48lSDwOecFyeKLDSvBeueKtF1z+3tJtrMSWsZuPNMTorZQsfmOSV5clvU9K6bWJdVhuLdtPsI9Qs9kgu7cyqkjdNuzd8rHqMMVHPXiuH0n4ZW9zceLJW0w+H9M8R2aWx0xWRmjcBt0xEbNGpO4YCk9M55xUa8rQ9LpsztZTxpe+H4dR8N6P4qj8SBY5EuJ9TtBZzcgsrQC6KBSCQMJu6c55p3iyfxOPiV4HtY/EGo6X/baT/a7FDE0ds6QchML8xyzH5y4yAcYAFXvCknxQ0G3t/DWo+H9N1K3tEEMOvnUhGhjHClodrOzAduAcde9R+MdL8Ty/ErwfqWl+Hb7VLLQBN9pulubZGn8yML8ivKpyMHOdvt61r7vMrbX/R/cKN+V33s/6/r5mb440G68Ep4Wm0/xR4mvLi78SW0E8t7q8riSJySYzGpWPbx/d9ula/xElutN+JPgWaw1HULcX+pG3uoI72UQzIEyAYt2zr3xz3rU+KPhrVvE3hjT59AgR9U0rUINSgtJ5AgmaMnMZboDyec4yOtYHiXR/HnifUvB+ttoFhaXGl3rXMunPqIYRjbj55gvJPoqsBjqc8Snt5S/DT/ghPWOnWL+/X/gDgNfPx41Dw+ninUjYz6GbtBJ5ZNsXmCny1ChMgDCsysRk9areGrfxDD8QPE3gOTxfqtxYxW8N5Dfzskl5Cr53IsjDAySOdpAAwAOovW9n4q/4X0/iOXwpdJpEmmDTDOLu2YhhJu83b5udn4bsfw54pdDsvE0Pxw1nxBd+FL2DStQso7SOdru1ZlMfO5kEpOD2xk9MjrgVrRXk7/e7foEr+815fpf9RfhbearYeNvGPhHUdZvdZtNFlt2tLnUJPMnCyoWKs/8WOP/AK1dh458S/8ACIeB9V10Rec9nAWjjPRnJCqD7ZIzXG+B9O8TWfxc8Vazqvhe7sNN13yPJmkurZzF5SFfnVJSef8AZ3f1ruPF/hyDxd4Q1LQbqQxR30Bj8wDJRuqt+BANKd3BPrZFR5VUfa5z2o+E/EFxotnqGg+JLqHxEpiklmubmQ2k4yC6G3BMaqRnBVQwwOeprE8WDX1+NPh3SrHxTqVrZ6ta3TywoI9kOxAP3Y2cnkkGTfg84q34SuvifY20Hh7XPD2nyLaxiEeIBqQ2SIAAG8gKXZseu0EjtUHiew8Tn4v+G9Z03wxfX+l6LbzwT3C3VqGn81AMoryqeCBndt7/AI1pzrtr+T+7oZe9yeen5/iT39xeeFNR0Xwbp8/iHxA10lxeXE73kLXjRqVGwSSNGAuX6g7gBgeoXwzD4wsPiEI4dK1qDwncWp81da1GG6lt7gZIKMJ5JCpGBgk4PpVz4heFdd1DU9G8U+DJIE13Ri4W2ujiO6hcDfGxHQ8cdvp1rS8O33jDW1EviTQoPDSxg4hTUFu5JWIIBO1QqqM5xkknHTHMp6X66/8AA/D8S326f1/XocL4ouNU03wVrmreIdevbDxbAbi5sbTT7+RkihRj5WbeMlGQrjczqfvckY4Z8T0j8S/C3wdrd+Z/tU95p7kxXEkSgy4LHarAZ54bqOxFW9J8KeKbf4T+IvC95ook1q8juVfVJLqMpqDSbtr5BL7sELh1UDA5xUuseEPFep/BDRtLGn2ia5pLWk0diLoFX8jHymTAXccH2Gcbj1LVl8nH/g/8EHdt2/vf8D/gE/xbgvvC3w7iufDuu6vY/ZruKMp9saZphJKoO+WTdLwCcYcYz9Kl+Lt5rGmS+FbrR9avLMXOt2tnNaxsqxSqzFiWIG/+EAjdgjIxzVf4m2PjTxT8N4NOtvC6y6pdXMU8kFvfRGO1WN1ba0kjIXY4/hXHX0BK/Eyz8U+JLHwt/Y3hK8lksdTg1K6SS7tU8oRk5jyZeWOc5GRjHOeA46NX/mX3af8ABF1b/uv79f8AgEevW+ueEPiZ4Vvk8VarqMGuXzWV7Y3Tr9nUFCwMUaqAmCPc9Mk85u293qtr+0W+lS61fXWnTaG94lpMyiOJzMFwqqoyAF4LZPJ55qL4gW3ifWPEng690fwle3EGlXi393uu7VGXK7fLAMvLDJzzt6YJ7J9i8Tv8fIvEn/CKXi6P/Zf9mmdrq13AmTf5mwS52j8/btRDdX/vf+k/5jfX0X33/wAiloNvr+r/ABM8c+HJvF2rrZ2qWnlzq0YniV0ZyI/k2JycbgmcAD3B4T8Uan4T8O+PoNY1G61tPCtw32Se9k3zSIY96q79Sc9/f6Vd8I2Xiey+LnirWtS8KXltputLAIJjdWrGPyUI+dVlJG7tjOOM45Ip+G/C2u6tqXj2y8U+G7rS9O8USF4bhrm3l8pdmwBgkhIboRgEe9S78un8v46fjuVK3P5XX3W1/EbrKeNL3w/DqPhvR/FUfiQLHIlxPqdoLObkFlaAXRQKQSBhN3TnPNerafJczabbS38H2e6eJWmhDBvLcgblyCQcHI4rznwpJ8UNBt7fw1qPh/TdSt7RBDDr51IRoYxwpaHazswHbgHHXvXpVvG0NtFFJI0rIgVpG6uQOp+tU7a22M1fS+55vod42q/tHeJRNkjR9Jt7aBW5C+YRI5HpngfhWn8SPhyfG0dhf6Vqcuj6/pTmSwvo84UnGVYDscD6e4yDThsG8P8A7QM986qlp4l0sIj+tzARlfqY+R67T6V0OrxeI4PF1nf6Nb2t1pq2rxXkEs5jkZiwKGP5SCR82QxAw3WpS92Hz++7/X8y27Sk15fkkcHoHxN8Q+H/ABBZeFfi9oy2tzdSrHZaxbrut7l8/LnsDnHIxjIyq17BXAeJdG1L4ix6fp2oaDcaLYWl9FeTzX0sDyv5ZyEiEMjgZ6FmIwM8GqniDxDpU/i7WdG8Q+KZPDFxZxwyaXI1+bVGDJky43Ks3z5BRty/KOOTTvda7/8ADfj/AJCtrpt/X/APSq8z+MV4+j3fgrWYDtmtvEEUJI6mOVWV1/EVZtI73VfihqunT6/qbWSabY3sCwyiFUcyPnAUD5W2DIbOQxHphPiTp7+JPFfgzQIBu8vUv7VuuMhIYB1P1Z1UfWnFe9H1X4PX8mGlpej/ABWn5o9Erz/QGk+I1lq2o3moahZ20d/NaWEVjeSWxhERKeYxjYF2ZsnDZUDAx1J9AryfT9F8dfDrxJqkPhbRLbxL4f1a8a8jjk1BbWSxkc/OCWByuf7oJ4/OVvZ9vx0/4Ia207/hr/wC7ruveJ/BXw/0fT9Z1K3vPEWp6lHpcWoRRfKBI5AlKkAbggzjGN3qOqfEOHUvAXht/FvhzU9SnlsJUkvrS9vJLiG7hLBXG1yRGRnIMYUcdK0fGngrVPGnglIZ7i3s9et7qPULMq5eG2mT7qbsAlcZBbA5JOO1N1qy8QePPCj+HdW0KXRPtLRpf3T3MMkbRhgX8nYxYltuBvVMBs9sU9X63/DT/g3GraX2/wCH/S1jG1rUdZn+L/hSPSfEF7DYa3YXFx9lkCGKHbEMFVCgsfmJ+csM89sU7w8ur+FfjdJ4bm8R6prWmahpDahjVJhK8Mol2naQoCrj+EACn+ItN8Rr8YPDWqaR4UurnRtEtprZ5o7q2QuJFABRGlBwuB1weuO2ZLyx8Sv8erXX4/C93Jo0OmtpzXQurYElpN3mBDLu2D6buvHamrXjb+9+tr/gQr2lzf3f0v8AqWvDhm+JXhq71ybVNRsRNczx6clldyW4tkjcorMEYCRiV3EPkc4x6pqut+JfDHhbw3pGrSHVPEGpXX2OWfTRGrOqqzlk80ogcqoGSQMkkDoKydE0bx78NtWvdK8OaFa+JfDl5dvc2jPqK2r2G85ZX3A7lyeNoJ6nvit7xt4N1vxR4ZsZ7O9gtPEum3i6haPktCkgGPKzjOzHGccnnHOKnSya20v+v/B7lv4mvW36fp6GXDD4xsvHWk3Ph/RPEFvo08jJq8Gs6rBcoFONskWbiRlIOcquARjiqWg2+v6v8TPHPhybxdq62dqlp5c6tGJ4ldGciP5NicnG4JnAA9x1PhvVPHmsSRw+J/DVpoEULAy3EWpLO1xjnCRqvyqT13NkDIxzkYfhGy8T2Xxc8Va1qXhS8ttN1pYBBMbq1Yx+ShHzqspI3dsZxxnHJFK17Ps/0/ruF/db9PzE+Hi395b+M/CWv6tf6tb6Tem2gu57l1uGidN21pUIYkeue/pWN8HfD4f4Gx3thquq6deOtyBLb3jOqBZmPyxSbolJ2gEhA3J5yc1v/DzT/Elp4z8XXWu+GrrTbTW7oXNvM91bybAqbdrhJGIYjB4BHXmqfgTSPGng7wJf+Hbzw5FdQ2RnW0ktb6My33mOSpCuVWNRuOSzZOOF9YbfI+7ivvtqONtn/N+Gv/AE+Fuma34k8EeHfFOr+K9ZuLuOOV0s0uAlvOd7gecNpaT8WwMDAGKw/Fup6v4b+G8mt6j4hvIfHVqyXFxaW19JNBErS4CPboTEqbDgMyjJH3ia6v4ZaP4m0z4Rr4Y1XTJ9E1W0tZYYbp5oZIyzlyrKY3Y/LkZyB7ZrDufCPii7+Ad54Ri8Nrb6x5YWaR7yIreyCQMZVYMSS+MnzNp5rSbtN8vlb7/6uRSWkVP5lj4s6Za6prnw9vJ2ulkudZhhYxXcsW1GQsdoVhtbIHzLhvernxOGoeG/+EPOi67qltbSa3a2M1sbkyCaNnLEvI2ZWJwBy+McYqXxr4e8V6r4Z8K3+n6ZaT6zoeoQ3smmrdhVdVUqUErAAnnrgDr171/iVp/jHXrHwulj4YN5dWOqQ6nd/ZryFYowhb90rSOrM2COdoB/QEbRkv8AF+Gn/BFG+7/l/HX/AIBveI9fubn4j6L4Nsrh7RLq1lvr2aLiQxL8qxo38OWzkjkAcEZrI1q+vvh1488ORW1/e3nh/Xrg2E1tfXMly9tOR8jpJIWfB6FSSOOMVf8AFvhjVr7xJ4f8beHbYLq2mRtHcabcyKjXEDj5ot4JUOpJxztz3q1d6Ne+MvEGhajq+lzaTZaLO12ttdSRPLNPtKof3buoVck53ZJxwMVMdLX76+l/8tvMctb27aetv8/wOW0G31/V/iZ458OTeLtXWztUtPLnVoxPErozkR/JsTk43BM4AHuJfBWp+JNP0Xx7osd/da9feHp3j0ya8bzJpcxb0Vm/iOfX1x0qx4RsvE9l8XPFWtal4UvLbTdaWAQTG6tWMfkoR86rKSN3bGccZxyRH4NsfGVj4h8bXk/hmXTn1qf7Vp8txd27orKm1VkCSMRng8Bh1/Fbq3938dPx3Lk/fuu6/LX5XJfAnifQ/FH2NNE8S6hBrEUwk1TS9TunaaQhcOvlyZ2gMQf3W1eMHuK9OOdp29ccZrznxB4SuPFvibRb9vDg0bUtLvYbibWPOiYSRrktFGUbe4PT51QDJPsfQruOWWzmjt5PKleNlSTH3WI4P4GnJ+7f+vl/kSl71v6+Z4v4pvdX0X4eajrOueIL2z8b2++6S0sb+SSKGPzTsVrdCY9mz+J1+rccaXxL1PXE0rwXq2ka/e2DanqVjby20YQQsJPnLMAA55ABG/aRkY5NQ2vhPxT/AMKQ1fwlJ4fCa1LDMkt495Eyag7MT5gbcWLHj/WBcetJ4w0XxrqXhXwbY2/hdri70m9tb25FveweXGsI2+XukdSznrwu0Zxk4zTjZS12vH/g/wBfqF7u/lL/AIH47f5G3r327wBp0a2us69ruoeINThtY/tU0LtCSCW8lWEcafKpwD8ucH2NOSHxjaeLtIvfDGheI4LKS52avBrOrW9xC0JP34wbmQoy5JwgAPTHat/x54XvfHPg22+wb9H1mzuI7+x+1bWMM6dFcoWHOSCVJ696j8N6p8QdWZLTxP4ZstESIjz7+LUlm+0YPPlxKCVDY/ibIB6E0o7+af4WX/BFLbya/HX/AIB3FeReI31O18P+I9Q8Ta9eaf4gje5n0a107UJAEt4x+6YwRHDg4BYyK2N3OOg9dPTivKvD/hnxPYeC/FGg3+jifVdQa6I1h7qPZfCQEIScmQFQQu1lAGODis5Xs7b2f9eppG11fuv1/D/gEXiO31zxj8CdO8R6Zq2qWWvRaZHeZ0+8ltxOdoaRSiMAcgHHGQenpW+8tl4p+HGgx6Pf6lCuqeT9muIdRmWdBjc5aUNuYqofIYkFgM1ofDXTdY0n4d6TpfiOzhs7q0tUgMEcwlwFGMsw4yfQZA9TWZ8PfBWo+FdV1aC8dDpFtdS/2JGDkxxTEPJnB6BvlAIBGD61vK3PJLa9/wCvXT8TKN+SL67f16fqGrWVwniSWHxJqtzp/he3s4YtOMOrSwTXNwSQ250cSuwG0AEkHOcE9KHwy1bVPFXgDWrW81nUFuLHU7myh1Dy1W5EaEFSRIh+bBwdy5/Hmrtro2vab8XdX1m60ttXsb+3ij0+7WeMf2eFX54yrsGCs3JKBu2RVHwHo3izwpY+Lf7Q0OOdbrVLi9s4rW7jaS580jAG4qqKMdWYE88DAzn9l+j++6/Hf/hi7e8rd191vy/Um+FGq6hrXwSjv9YvZr68lW78yedyzNiSQD8AOAOgHArC+HA8QN+zLpSeEDGuqSb0SSRlXy0NwwdwW4yFyRn06HpWh8ONO8U+F/g7Pomp+FbsapbCYQwR3dswuPNdiMN5uF27ud2OOmelYmleDPGY+A9j4Xk0WW01DTbtZLi0ku4fL1KDzWdoldHIGQQCGwO3IrSTXNL/ALd/X/PUT1at3l/wDUk1qLRPix4VsPDOv3+oafqrXNvqEdxeTXkLPGhIKPIWVWDZBVGGMcrT5NNutW+P/iOztNUuNLEmhWwkuLQL5wXe3CMwIU++D7YPIueKNF8Tat4p8Eavonh2K3g0ieUzW11dxxtArxhedm5cDHAQsT6DrV250XXtE+Kl54rtNL/tmyvtNis5ILSeOOeJ0YncFlZUKnP9/NR1jfz/ACdhS207L/0r/IzfBd1rnhT4pXngTWNYvNdsJrD+0dOvL5t88YD7Wjd/4ue/8qi8AX8el+JvinqE/MVrqZmfHosRJ/lXWaZoFzJ4xvPF+rQbLt7JbKzskdWaGEMXO5s7d7NjocDAGT1rlvAOha+PEHjVPFHhi50+w8R3LTRyNdW8oWMqU2OEkJDEHsCOvPrL5mtN+V/mrfgP3brtdfk7/iUZbrxV4n8Ew6xpWkeKotfurUXNndW+p2sdmrMNyr5P2na0fOMvGXx15r1Dw5Nqtx4a0+XxFbLaaq0C/a4UZWCSY+bBUkYz6E1514UtviV4Ghi8KxaDY+IdJtiUstXfUltvKi52rKhVmJHT5R6c967LWdY1nw3Z6c0ejvrUTOf7RuorqOH7MvUuqOcuMnAUHOB3q3b7Oz2/r8xa/a3X9f8ADHS15trMN3JqGvzeLtZvNMHmFNAg0zUJI3aNYwd4ihO6Vt2chg3TgY6+k15z4Y0TxFouv+KhqOk/b59Uu3ntNYa4j2GAjCQMCfMXZzgBSvJ5FZu9nbs/0/EtdPX+vkavwm8QX3ij4W6Lq2rS+fezRMs0pULvZXZc4H+7XF/GqR5viN8NbC4LCwl1bzJBn5WdWj25/M/ma6n4O6Fr/hj4eWmjeJbKCzltGkWNYpxKzgyM25iOB97gAnpkkZwNL4g+B4PHfh1bM3Bsr61mW5sL1V3G3mXocdx2IrWbSqqS2TuZxT5HHyaOqpoRRIXCrvIALY5IHQZ/E/nXLaTrfiuGOGz8ReFJZroALJfaZdwNbOe7YkkSRfXG09e9TeKNQ1PRvBmsawgJu4bZnjhg+cQgdWGR8zAZPTsBjuYempS10Olory651TSp/CviG/8ABXjue7b+ynuTBFfi7lglUFhJmQuYgfulMAegU12Pg20dPD9nfzX17dS31nbySC5nMiq3ljJUH7uep9Tz607b+Vvxv/kK+3nf8Lf5nQUUUUhhRRRQAUUUUAFFFFABRRRQAUVh67rz2eo2WjaYscurahuaNX5WCJfvzOMglRkAAdSQOOSK/ijxbbeDdLsluxLqOpXki2tnaxBVku5j6dlHcnoKBnSUVzcMfjaQLcTXWgw5XJsBazOQcfd+0eYO/fyvwqfwnrWp61Y3ba5piaXe2t49u9sk3mgBQCGD4GQwII4HBHFHkI3aKKKACiiigAooooAKKa7rHGzyMERQSzMcAD1qDTdQt9W0y3v7F/MtrmMSROP4lPIP4igCzRRRQAUVwOga94gk+MeueHdXv7e5sbXT47q2SC18nbvcgBiWYkgDGcgHrgV3pIVSWIAAySe1HRP+uwdWu3/Di0VV03UbbVtPivrCQS202THIOjgEjI9jirVABRRXJ+K7rx0+oRW3gO20QJGm66uNaM2wsfupGI+SQMkk8cigDrKK870HWPiRH48stG8Wr4Wa0mtZbmU6SlyZEVcKMmQgDLMOxzhq07fxRqfiXX9WsPCbWUNvo0y29zd3sLzCebGWiRVddu0Yy5J5ONp60f1+gHY0VgeDvFcHizSZp0i+z3lncPZ31qW3eROhwy57juD3BHSsL4xa9r3hf4e3et+G763tJbUqJPNtfNZw7Kg2kthSN2eVbOKdtUu/6jinJ2R3lBBKkA4Pr6VHbuZLWJ3OWZASffFSUmuhKd1c5jQfC+r2eoG88T+J59flikZrSNrOK2jtwQR91Blm2kjcT0JwBmunoqhra6g2i3P9jXcFneBN0c1xbmZFxycoGXPHHXj36Um7K/YpK7L9Fcb8J/EOpeKvhnpes63Ms17dGUyOqBBxK4AAHYAAfhzXZVcouLsyU7oKKKKkYUV5/p3iDxCvxzvPDWo6hbz6YNIN9BFDaeUUJmCqGYsxYgA8ggHPTpXoFPon3/zt+gdWv67hRRRSAKKKKACiiquqW93d6Vcwabe/2fdyRlYbryhL5LEcNsPDY9DQNblqiobOKeCxgiu7j7VOkarLPsCeawHLbRwMnnA6VNQxLYKK8+tfEHiGL47v4av9Qtp9KfSHv4YYbTyyh80IoZizFiADyNoO7p0r0GnbRPv/AJ2/QbVnb+u4UVQiv4dWiv4dLuwstrKbZ5VUMI5QoPTocbhkfUVS8P6++o3V9pWpxpBq+msouI487JEYZSVM87WweD0IYc4yVuI3KKKKACiiigAooooAo6vo9rrVkLe8DAo4lhljbbJDIOjo3Yj/ABByCRVm2jlitY47ibz5VXDS7Au8+uB0qWuQ+KGqa5oPgDUdY8OX1taT2ELTP59r53mADovzAKe+SG6dKltRTY0uZ2OvqlfaLpWqT28+p6ZZ3kts2+CS4t1kaJvVSQdp+lN0K5lvPDum3Vy++ae1ikkbAG5igJOBx1NX6uS5ZW7ERkpRuupnw+H9Ht9Wl1W30mxi1Gb/AFl4lsgmfjHLgbjxx1pml6JFp1zcXs0rXeo3WBPdSKASoztRQPuouTge5JJJJOnRSKCiiigAoqG7u4LCzmu7yVYbeBDJJI5wFUDJJNVrv7Rqvh+Q6PenT7i6t8290YRIYSwyrbDw2M9DQHUv0VDZxTwWMEV3cfap0jVZZ9gTzWA5baOBk84HSpqGC2CiiigAopCQqksQABkk9qrabqNtq2nxX1hIJbabJjkHRwCRkexxQBaooooAKK8/07xB4hX453nhrUdQt59MGkG+gihtPKKEzBVDMWYsQAeQQDnp0r0Cn0T7/wCdv0Dq1/XcKKztGstSsobhdX1X+03kuHkhf7MsPlRE/LHhfvbf7x5NaNIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACoZ7OC5kje4TzDEdyKxO0HOQdvQkEcE8jtU1FABRRRQAUUUUAFBGRg8iiigDIHhPw4LG5shoGli0u38y4gFlH5czZzudcYY5AOTWhZWNpptmlpp1rDaW0edkMEYRF5zwo4HNT0UAFFFFABRRRQAUUUUAFFFFABRRRQB5l4RvW1b4+eOJZ+TplraWUGedqEF2x6ZbmsfxNI9z+1h4Ttrwt9nt9Mllt1J+UyES5I9/lH5Ct/SNPPh349a28i7bfxNYRXED44aaD5XT67WDY9M+laXj/wNN4mm0vWdDuorHxDos3nWNxMpMbj+KKTHO1vUcimmlyPt/wU39+oS1c0uv8AwH/wDtK5D4keJ5fCPhX7TpixpqGoXkNlbyOmVWSQhd7DvtUE/gBVzTdd8QzMtvqfhG6trjGGuIry3ktScdm3iTGf+meao+PPBM3jbwVc6ZLeLBqBlS5tZhkpBMhygHfHYnqck+wT0/D7r6/gNf1+hj+PtP1Twd4TuPFXhzWNSl1DTAs91DeXkk0F5ECPMUxMSkZxkgxhcYrH8R6rrOp/EDwFLoniXUrGw8SQzTNbAR7IVFuGG0bQSfnJ+cuN2DjjFdJqVv4n8Y+DZ/DWr6G+k3F3ELe9vzcQyQFM4dogrFySAcB1XGeTxzj+LNE16L4ieDLrw94Vu7vSPDSSo8kVzbJvV4ggEavKp4A5zt9vWqjZSs+/6P8ADb8RLZ+j/wCB+pnePdI1zwVZ+HBo/jjxFcG+1+3tpF1CeOUEOxY5KorkZUDbu24yMc10WvG8+HegTXFvrWt67qGtahb2sP26aJzC8jbT5KkJGvy5IBwuQM8ZqD4s6b4j11PDcfh3w5c3xsNUg1Kd/tNvGECZzH88gJbnt8vvW5448MXHj3wL9ki83R9SV47u0afYzW06HK7tjMvsSpPXvSvaPz/D3f8AJlO11bt+Ov8AwDmL+HxnbeINJvvCWheJYR9rUapDrGrW08E0B+8VU3L7HHUbAo9u1btldv428XeItOuLq7ttM0WWO0WGzuZLaSWUqHaRpI2V8DIUAEDrnOeI/DmqfEfUiuneJvDVjpSx4WfVYdSWQTgdTFCqkqTj+JhjOcHGKy9V0Dxj4O+IWp+JfBGmQeILDXAhvtLlu1tnjmQYEiO3y4I69Tz+RotHtr+n4b+jI1e2/wDX4/oSeIvDer23wh8XWHinVW1WGGG5m0+ZJpEmEIjLIszAjeQcg5yGAGc9KpaJfr4H+A+jarpgvbi+1C0sYI45rySdVkl2oCiSvsTG4naNq8AHA6dld6ZrfiTwTq9prMVvp97qVlJbx2sNwZo4NyMBmTaNxJbkhccAc4yeR0/wT4k8SfBseEfE9nbaHcWVvFDZTw3Pns0kJBSY7QAoO0cAk8np0ovZST/u/cr3+exWjS+f42t8husReNbe/wBO1DwfoPidLxLlPt8eratay29zBjD/ALv7Syo3Qgoq966D+038X/ELWPDgurq107RLeH7SLS4aCSeaUFgPMQh1VVA+6Rktz0xVbw7qPxMu1XSfEnhzT7Ly1Ecutw6kGWUd2jhClt3+8VGTn2rO13w14u8LfEy68Y+BtPg1u31aFIdS0uW5W3YsgAWRXbjp/Xg54NLpPbX+vT9SejfXT8/zE8LWT6f+0L4it3uprlE0S28pp2LuqbzhWY8tjnk84xkk812vjjT4NT8C6zbXfm+UbOViIpniJwhIBKEEj1HQ9DXJaJoXjKD4xXXiTUNN09bG/wBOhtp9l5/qCpLYT5SZCOhJCA5yOlegatZnUdFvbJWCtc28kQJ7blI/rWc03St1s/zZVNpVb9Lr8keSeHNWg+Hn7N9r4ptftU922mxbIri8mmiEjNtTEbOVRctyEC8Cuj8SaDrGneCJ9f0jX9TbxFZWn2pnkune3uSi7mQ25PlKGAI+VQR61laB4H8Q638HpvA3jLTrXS47e1+y29xDc+e0ro2UmwAAqggcZJP+z0rZtl8Z3ngiTwxqWi+RqZszZtq63MT2jgrs80Dd5u7BJ2lAMjGQOa1qauTjv0/r8xU7JRUvn+B0vg7xCvivwZpWurH5X262WVox/A38QHsCDW1Wd4f0W28OeHbDRrHP2exgSBCepCjGT7nrUusSXsOi3smlW/2m+WBzbw7gu+TB2jJIA5x1pVGrtxFBNpJ7mB4W/wCJp4g8QeID8ySTjT7Vv+mUGQx/GVpPyFcp+z0ZH8D6vNcDFxLrl00xPUt8uc16H4b0gaD4Z0/TA29raBUkc9XfGWY+5Yk/jXK6RoWp+A9a1v8AsTSZNV0rWLv7bDFBPHG9rOwxIH8xlHlkgEFcsMkbTR8Mn6W/FfmD95X87/g1+F0Y/wAK3YfE74lxxAi2GqRMvHG8q2/+Qq/8ff8Akimt/WD/ANHJW74D8JP4W06+lvpEm1TVryS/vpIySgkc52KTyVUcA8Z5OBnFZPxn0nW/EXw6utC8N6PNqV1fMnzLNDGkIR1bLGR164wMA++KW3Ku3L+FjSm17Ry6XbCA2nxHuo/7N1e+ttN0WUwTyaZqUtu9zNtG6NhGwwi8cnkn7uBkseI7+4T4g+GfBq3d1Z6Ve2k8kkqXDia5aNQFi87O8HB3FgwY4HPXOJe6N4o0fxLpPi7wh4Xu1vb5BB4g0l7q2RJVUYWTd5u3zP7pGcj723ob/j2bxBqV5oq6d4O/tqNYXuJtOfU47O6tJThUk85SQuAXHyPkk8Him91+P3P8Oq+4zje3y0/r+u6GaP8A2zZfGi88Mw+ItVk0S206LUIoZHjnKMzlTFJLKjysDgkfOCPWvSLz/jxn/wCubfyrznwfqut6Pqiwaz8NrjQbe/lWOTUzrUeoyPIeE81ifMI7AknGR0FekzxmW3kjBwXQrn0yKmabp2XmOLXPf0PDvhv4P1fxN8D9EfTvF2q6JNAszWkenssce8SvzNxukGe24DHY9av6b8Ttb1D4d+HoJ3W28QaprH9iz3QjBETIxEkoB43bRwMY3HpitzwFpvirwR4Mt/Ckmgfa7i1Eog1KK7i+yNudmBcFhKvXkBG+vpFrHwnlPw90vTdFvY/7c0e+GqW93OCqTXO4u+4DJCsSfXHHXFaya52+l1+ev4b/ACJs7WW+v5P9bDfiGb/4b6TF4u0HUtRuILW5jGp2N7eSXMdzC7bSVEjHy2BYEbNo9sCteTWG8WfEG58N293cWunadYR3V2bWZoZZ3m+4m9cMihQSdpBJI545Zrum6x8QvD8ehazoM2i20k8L6hJPcQyLIiMHKw+W7E7ioGXCYBzgnisvxP4X8VeHviOPGvgKyt9WF1apaajpEs6wGQL910dvlBAx16Y6HNQu0u7/AC0+V/u9CnqtN7fr+dr/AIFbSdNNh+0nd2hurm4h/wCEYURGeVnkRPPxtMhO5uc/MSW561P4Us7jwp8ZdS0PVdY1jUINQsxd6Mb7UppkRAcSxbWYgsDggkE479cusND8bH4zQ+KrzSdPjs7jSEsrhBff8e+ZC5CkITIygDqqA7sA8E1q/FTQLvUtN0nVdCnS21vStRieylcZB8xhG6EdwQ2SP9mnso/NP5t/5pg7Ny+T+5L/ACsanh3TRL4h1fXReX8kU07QW8El/NJAqp8rssTMUUlww4HAAxjJzk/F3S7ybwbNrOlahqlpdaRi5aOxv5bcXEKkGRGCMM5UHB6g9D1rtNNsY9M0u2sYSSlvEsYJ6tgYyfc9amnhjubeSCZQ8cqFHU9wRgipldL3emw4tXu+p5L8X53TwnpHiTw9qesp5JiuZorHU54lnsVwZCwVwM4Zfn+9yOfTs7i2t9f8V6RPa3t8sFraC8cW1/NHHKGP7oOisFcHDnkHO0DoSKzPBPgq8svCF3onikLNEscumWy7g2bIM2wnHQsrDPsq+lW/hh4Z1Pwv4RSz1+UTXyOYVYEHEEZ2QjI/2AG+rGq0u7eq+f8ASfrcnWyT9P6/Ffcc7BrWoeNIdSuRovime3jvZraym0fUoLRIxExTd/x8xs7Egkh1I6ADuYL+48dwfAXU7zxReXmi+INLimkWa2eAtcoo+QuV3gZzztKnK9altNG8dfDvxHqcfhTRbXxL4e1W8a8SB75bSWxkc5flgQUzzgAn+u145svE2p/C3VdPh0n+0NY1aFofs1rcxiK1DLj78pTcAB1AySegHTOX8N27L7/667Fr4/n+BS8TeKdT0H4I6TqtpcOt3cQ2UM19J85gEuxXmOc5IyeTnkjOaqeNbbU/C2t+Fx4a8RazDHrWprZXsbXQu2dWUt5ifaFkVNuCSFAGD0FXL3/hIovgvZad/wAI/GurLFBYzaXeXER+1KAqyIjqXX5lDYJ6ckgYrF0q48VaNqMd/L8HbpVgBxM/iqO9e1jP3hCkjELx/ChUHpWsmvaN9L/hpp6f5mUE1TS62/HuT6hZ3k/7RsNna6jLBM3hQo97sQygefywGNgc/wC7genarXguLUtK+JHiXwXqOvaprWnLYw3lvNfXBNxF5hKuvmLtI9sYxjjFRpH4ju/jhaeLbTwtfPoUmkiwFwbm2DENJvEuwy7tvI4Pze2eKtaPZ+JY/jnq2uXXhe7g0i9so7GK6N1bEr5bE+YyCQttPOMAnpkdcJfZT/vX+9v/ACLm73cf7v6X/Uz/AIF6FZ22m63dQveh7fXb2COM387RbAwAzGX2M3+0QW96v+Ibw6T+0T4VMRIGsaZc2k4H8QjPmLn6HP51N8OtC8VeF9a1zS77TbNdGn1S4v4dRF1ueVZTkRiMDIIOMsSPQA9adeWD698frC6RAbXw3pjmSTH/AC3nJAT67Fz7ZHrRH4oPy/8AbWvzJaajNef/ALdod5f20l5YTW8N3PZPIhUXFvt8yP3XcrLn6g15H4J03xD43+HepRaj4z1m1lt9Tu4ku7OUJNIUbC7mxwnA+RNvfnnFeu3s8ttYyzW9pLeSopK28LIHkPoC7KufqQK8z+Gdr4r8M+D9ZtNb8IXiXcl9PeW8UF3auJhKwOwN5oAIySc4GBxk8Vn/ADen43Rf8vr+jMrw2PEXxF+DFvrF/wCLdU0u7tIZwr6YywmeSJmAeU4y2do+VSo65znja0LXPFvin4G6HqOlzp/a955SXd0zIhSISbZZRn5Q20E9PXAziqXw70vxV4X+Dt3oOpeEr06lH5whiju7UrP5rMQQ3m4G3POce2egytO8HeMz8GNB8P3GhSQXWjX8cl7p0l3CU1S3DsxjDK5HORkPgHHcVq7cz7Xj+t/0uS91b+9/wP8AgGta65DpHxk8PaR4b1zUNQ0nVra5W6jubua8i82IZDJLKW54IIVsDjIGamurGfwp8cNLnvdZ1m40XXUkjtbebVJ2htrwfNtKF8FWXO1TkA9BwMWPEWieKNT+IngzX9I0KGC101LiOeK6u0RrcSIFywTcDjBwELZx1A5G58UtB/t74e36xy+Re2IF9ZzjgxzxfMpH1xj8am/Koy7Xv97/AE2+Q7czce9vv/4ff5lm300ah8QLvVFvL9YdPjS3ECX8wgeYruYmHdsOFZB06kk8gGqfxg/5I94n/wCvB63vDVhcad4ftotQdZL6QGa7dVwGmc7nwPTJIHsBVXx1oNx4o8B6xollJHFcX1q0UbykhAx6ZwCcfhUVU+RxQ6bTkpHnuv8Ah3xPa/D218W6H4w1SDUNL02O5j05dosnjSMEoYgMsSB95ieemO2k/j678RS+G7Kw0zUrgapo/wDal5Bpk0UUwU7VCh5JE2ruZslW3cLjvWj9k8S6x4G/4RSfRZNJmezWyn1F7mKWDZs2O0QVt7NjOAyoOeTxzT8VeBNY0u78P698ORbnUNAtDY/YLltqXltgfu9/ZhjIJ4yc1rJrmd9r/o/1t+JEE1BLrb/L/g/gSeEYvGFj4+uIZdM1eDwlPa7oxrN/Dcz29wDyFdZpHKEf3icH0rqPG/iI+E/BOqa2sYlktIC0aN0Zydqg+24ioPDN94q1grdeJ9Dg8PJGDttI78XUkrdMsyqFVQOQAWJJHTGDd8W+HYPFvhLUtCunMcd9AY/MAyUPVWx7EA/hUTvy2LhbmuzzrX4fGz6bBf8AhLRvFUfiCNo2aS+1S0Npcrkb1aAXTIoIzjYgPv3q94x8YwaL410228btqWk6Hc2cbwXVrPLFEt5uO5JZIiDwMYBO3qSD1Evhi7+KVhDF4e1nw9ptwtsgiXxD/aQCOgwA3kBS7PjsdoJHUV02rrqSNPa3GhDxBoz2yRmBZIjM75IfckpVGUjaclweDwab022v/Xp39RLa0t7f16/5HF/E+wg1L4Ea3dS6vJrMKhrqzuorkhWUuNgPlkK4UcYII4z15q54n02fQPghe3vh/WtX0+4ttPF4JPtr3DMwi+5mbeVT2Qr04qvD8Mb63+Enirw5YrFaPrE81xY2Jl3JaK20rFu5HVcnHA3YBOM1LrUHjbV/gte6TdeFkXVryzFjHZ2t9E/ljZgyySOyqB/sruI45OTiZfDJLy/L+rjj8Ub93+n/AASr8QLzWYP2frbXdN8QajYXttptvI7wOubguEVi7FS+fmJBVgcnJzVX4lf8JD4Y8N6f44tPFWpC4tJrZZNMVlFnLG7KpUpjLNz95iT1wFzxY8VaX4s1j4CQeGbTwnd/2vLaw2ssTXdqEh8oply3m4IO04xk+oFO+JWneKvFnwmtNE03wlef2lMYWnjku7VVgMTKTlvN53Y4xnjrg8Vq2vaN9OZfd1/AiKfsoxe9n+lvxIfiHHr/AIS1HQvFVr4s1SaW61W3s7jTWZRZGKQnIWIDg8feJZveuo8Rx3svjAnxDqTaZ4TjslETW+otaST3bPjaWjZZDgYwoOCW6E9MD4o2XirxT4a0G20Twjevc299BfzpNeWqCLyy2YyfN5Y8HIyMHrnitG303xDF8VpPEd7oM97Y3unxxWivcQb9JcffRlL4wx5LRluneoXZ93+S/W9vPUpvS/kvvv8A5W+WhheGL6fxV8NfHOla3e319b6XeXVtbSzSSwztCse5BIw2ux9d3Xvml8J30Xgb9nmw8Q2P2ue8msYESOe8lmjEjuETbG77EGWzhdoOK1PB/hTxLZ3Pjm01eytbWz1q9nuLedLnzDJ5ibQAoHAHq2D/ALPeqmg+B/Eet/B2bwP4usLXSVt7YWttcw3PntK6NuSbAACqMDjJJ/2elK+nyj+Tv8ynbm8ry/NW+QzXoPG0a2uoeD9D8VLrEUyG4Gp6rava3UfR1aL7SyITjIKIuPxrpJ9Vm8T/ABEuvC63NxZ2Wl2MdxfC1nMUs0sudkfmIQyqqgklSCSRzgc0PDd/8UPLTRPEHh7TkMKeW2vpqQKSL03rAFLFsepUZ9Kq+J/DHivw/wDEceNvAlpDrP2u1W01LSp7gQNMF+7IsjfKCBjr6dDmnpdLpr+X5EatPv8A8H/K5Bo1g2m/tLXNt9quLmJfDK+UbiQyOi+f90u2WbnPLEnnkmvUbuB7mzmgiuJbV5EKrPDt3xkj7y7gRke4I9q81sND8bH4zQ+KrzSdPjs7jSEsrhBff8e+ZC5CkITIygDqqA7sA8E16XdTSW9pLNDbyXUkaFlgiKh5CP4QWIXJ9yB70P4En5/mx/bbXl+SPMPh7c6xrXw78TJeeIdSN5bateQRX+5GmVYiAoG5SoHHICjqcYNYWl2niTxP8AbXxHP4y1mzvrSxnvIvsk4QTOhc/vmILOOMbQQoGODWv4BsfF3h7wf4ntdT8H3a3l5fXN5aRR3tqwl848KW835SvU54x0yeKTwxpXivSfgDP4YuvCl3/bEVpNZxRLd2pSXzN+HDebgAbhnOD6A1Mr8jtvaP32d/xCGlSN9ry+6/+R3ngTVrnXvh/oeq6gQ11eWMUszKMBnKjJx25rj/ABzPrmn/ABY8Gx6b4gvI7XVZ50ksX2+QpSHg4UBmGWJIZiCcdMV0fwytdU034eaVpeu6VNpl5p9uls6SSxSCTaAN6mN2GD74PXjvXPePrLxPe/ErwpqOi+F7q/sNDnlluJ1urZPNEiBcRq8oJI5+9t5/OtJ29rptf8BQ/hu/b9P8zNuI/EPhT4yaVott4t1PULXxLaXBkGpbJfsskYB3xKAqrxwABjPJ3VY0Mav4T+OS+G5PEmq61pmpaU98y6pKsrwyh8fIQAFXA+6ABzUvimw8TXvxk8M69YeFL240zRo5455hdWqmTzUxlFMoOF75x3x2yuoWHieX49af4ig8K3j6PbWD6dJcfa7YE7nJ8wJ5udvI64bGeM8VMfs/P9bfoN/a+X6X/Ur2us6p440a51OLR/FUgkuJ10+40nU7e2iiVHKKdpuULn5cnzFIySAMVmeLb/x7p/wSsNT8Q6heaN4gtbqO3uY7WWHbdK8qqHZkDEHaf4GXnPHStTSdI8e/DfVrzTPDWh2nibw5eXT3FqGv1tJLAu2WVtwO5QSSNoJ6/SrHxT0fxdr3w9j0rTtFOp6ndXUVzP5F1EkFsEdW2BpGVm6AZC88k44FEbKz6XX/AAf+C+oTu7pedvxsVPH0Gv8AhPXPD3ia28VanO93q9vY3Wmu6iyMUhIISIDg8feYs3vXrdeXfE208U+JtD8Ox6N4SvJJ7fUoNQuY5bu1TyRETlM+bgseoxkY754r0y1me4tIppreS1kdAzQSlS8ZI+6SpK5HsSPehfC15v7rL9bg90/L9X+ljgdXgup/EWtN4w1i60zTiUi0KHTtRkgklPlku+yEh5H3fwkMMLwvc4vh/wAZ+Jb/APZ4XXlFzqWrxO0cr28QEzxpPtdlXH3xGCenUdK2/Duj+INF8eeJ7q/0n+0Rqc4lsdVNxGFihAwLdgTvQKcn5VYHOetVPhvoXjPwr8PW0u402xhvLe+d4Y3u9wnjabcxLKpCfKTjqemcdKUdreS/r/Mp2/H8LP8A4BoeBtd8P+JZba68HeJ7m7tYY3N1p15dvNMGbozeaTIMEEYzs546Cu9rzxPCD6n8T9M8U2+gHw9JYCZbyZ5It+oBk2qMRMwKg87nw3AG309DpvZMjqFFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGdrOi22t2scdwXilgkEtvcwnElvIOjqfXkgg5BBIIIJFXoFkS3jWeQSyqoDuF2hj3OO30p9FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcV4m8BahqfiB9e8L+K73w7qkkCQTMkKXMEqKSV3RPxkZbnPeu1ooA5jw94W1WxaO48VeKLrxHdxHMZe2itoYzz8wjjHLYOMsW9sV09FFO4BRRRSAKKKKACuX0fwvrEGryXviXxTca2kczSWVr9jit47YHIGdgzIwBIBJxznGea6iijZ3DpYKKKKACiiigAooooA53xf4RTxXa2fl6ne6Ve2E/2i0vLNwGjfaVOQQQwIJBBrJ0fwV4qSUr4s+IF5rdnx/osGnQWauMEEOyZcj2BX3zXcUULQNxFVUQIihVUYAAwAKWiigCO4SWS2kS3lEMrKQkhTdsPrjvVTSNHttGtXhtdzvLIZZ55DmSeQ9XY9z+gAAAAAFX6KACiiigAooooAK5f/hF9YuvE1xeav4puLvRjKstto6WcUSRlcEB5QN8gyAcZHvkV1FFHW4dLBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXN+OvGdr4I8Pf2hcQtdXM8q21naRnDXEzfdQenuewqOz0XxReQw3WseKJ7G6IDPZ6ZawfZ0Oc7SZY3dvQkMuccAULUNjqKK5zw3P4jGs6vY+JpbSdIDE9lNaQmMSRMG5YEt8+VIODjoQBmujoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKqarqlpoulT6jqMnl29uu5yAST6AAckk4AA5JNRWF3qEumNd3tj5cr5eK0jYGRVxwrEkLv9ecDpk4yQDQorlvCPjNvFGra/YS6XJp8mi3S2z+ZMHMhK5zwMAenJyPTpXUkgAknAHU0dLgFFcp4Q8e2njHXNesdPtZI4NHmjiFxIcfaN6k7lXHC8cHJ3Ag1JL4tuL7Xb7SvC+nRanNpZRb+We6NvHGzDPlqQjl5Mc4wFGRlgeKAOnorJ8N+I7LxRo66hp5ZQHaGaGQYeCVTh42HYg/h3HFa1GwBRRRQAUUUUAFFFFABRWLqeutomqW41ONF027kWCO7U/6qVjhVkHox4DDuQCOhO1R0uAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4z8atyfEj4aS3Q/wCJeuqkSMfuiTdHtz+R/I17NWD4y8Iab438Oy6Rq3mIrMJIZ4jiSCRfuuh7Ef41S0mPx1pscNlqP9i6zFGAp1E3EtrM49WhETqWxjo4B9qI6R5fNv77BLV83lb8/wDM6uiuQ8b/ANp6d4Nu7+2Se+uVkha6jtFKubYSKZUjAOc7N3fJyfYDzjxNq/gS++HOqah4MvZbK1nurVRDGstjbGYSYYIhCB2KF9wG4fLk8gGha/16f16h0/r+v+Ae7UVQ0ex02ys2fRkjW3u3NyWifckjPyXByRz14471foAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArifEF/5OuTx/8ACR+MLLG39xpvh/7TAvyj7sn2OTd6n5zg5HHSu2ooGebf2p/1N/xA/wDCV/8AvdXolqd1nCd8kmY1O+VNjtx1ZcDB9RgY9BUtFBPUKKKKBnm3xFv/ALX8SPAXhl+be7vpL6dOz+Qm5Af+Bc49hXpNea/EaxNp8SPAPiZh/o9pfSWM7Z4Tz02oT/wLj8RXo88y29vJNIHKxqWYRxs7EAZ4VQST7AEmmrcnzd/69LA/j+S/X9bnnXw2/wCShfEb/sLRf+iRXW6o/wDbF8dChLeTsD38inG2M9IgfV8HPooPTIriPhpeyDx/4zkudK1mzi1bUEns5bvSriFJUWPBJZkAXkdGIJrc8QfB3wJ4p1yfWNe0L7Vf3G3zZvtk6bsKFHCuAOAOgpK9o+i/JCVry9X+ZlfDtVj+KPxIWNQqre2oUAYAHkVU/Z9le88H63qFxk3N5rt1LMx6lvlrN+HXwm0LRvih4lvm8PXFrDpl3CdFmlecIFMXzlCzYkGT1O7FdD4Zspvhtqmv2E9hqF3pWo37X+nS2Vs9xhpB88LBASmGHDNhcHqOapaW/wAKX/pIrb2/mv8An/mUvhTKYviR8SbCH/j2j1ZJ1ABADurb/wBQK9Uri/hx4VutBttX1TV08vU9ev5L6eEMG8hSfkiyOCVXrjjJOK2fFXg7QvG2lx6d4nsfttrHKJlj8548OAQDlGB6E1Lukl2SX4IrRyk+7Zt1znjG/wBdtYtLtfDdq7y398lvcXax+Z9ihIJaXaeOgwCeMkZB6FfCXgLw14FhuYvCum/YUumVph58ku4rnH32OOp6Vi/Ew6wtx4f+y2+oXGg/bf8AicxaajvO0ePk+VPnKbvvBeSPbNGl18gV7P5lbQ/E2pWXxgn8G3WtjXLRtM+2pPMsK3EEgcKY28lVXGOeVB571cbXdR8SfETWvC+najNo0GjW0EklxbxRPNPJKCwx5qsoQAc/Lkk9RWD9hu7H45aLe6J4WvI9GGiPZxyRW6wwwnzN2WBxsGP4SN3otQ+NNYk0v4k3NzF4d8WC5jso4YtS8MWUVy0yMSzCUPuXAIwoZcj5iDyKelo38/zdv0G95W8v0v8AqXtA8da/bJ4vn8VXVhLaeFZJI5Ft7F0luQE3o/meaVBI4KhOveqOueNPEcOhR6z4fm16+1VQjtoh8MXK2kwJG5VkNuHBCk4YyYOOnOKl0b+xPFnhPXvCNloniHw/fatDNK8uv2TRSXUjAAy7skNgleARgdBirHhLxt4rsLO28NeI/A2ty6xaRiD7dbIhspwvyiQzMwC56kAE+3ajy62Xz7/iLTfzf6WOm8YQ/wDCRfCfVhLBJbPdaU8oimUq8L+XuAIPIZWA+hFSfDnXZfEvw30LVrlt89xZoZm9XHysfzBo8b376R8Mdaurtlkmj02RTgYDyFCoAHuxAx70fDfQ5vDfw20LSbpPLuLezQTJn7rn5mH5k0L7Xy/X/gC1tH5/odNRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHM+JPBsvieO7t7rxLq9tY3ShWsreO02JgDlWeBnByN2d2QemOMV7Hwp4jjidL7x9rUm1yInit7EZTtuDWxO4dCcnOM8ZwNPxL4otvDcdkjwyXV7qNwLaytIsBppDz1PCqACST0A7nArOvPFWt6JBbSa/wCGhtubqK2Eml3v2lITIwUNJvSNlGT1VW7etC12Blj/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FrpKKAOb/wCEX1f/AKHvxB/340//AORaP+EX1f8A6HvxB/340/8A+Ra6Ssca4154hl0rSo0l+xlTf3D52Q7hkRjH3nI5x0UEE9QCAU/+EX1f/oe/EH/fjT//AJFo/wCEX1f/AKHvxB/340//AORa04P7a/4SC6+0/YP7H8lPs3l7/tHmc79+fl29MY565rRoA5v/AIRfV/8Aoe/EH/fjT/8A5Fo/4RfV/wDoe/EH/fjT/wD5FrpKKAOb/wCEX1f/AKHvxB/340//AORa4fWfAnxW0/UbqXwN8QYGt7uYzSpq9pF5gYqB99YWB+6MAKoA7V65RQBwei+CfFvkw3Pin4g6hcanGGCtp9lZxRRhsZGHgbcePvcfQc1sf8Ivq/8A0PfiD/vxp/8A8i10lFMDh7/wDq2r3apqnjfWJtPgkjmhh8iy3GVTkMxFuFIBxhSDyAc11WlWFzp1q0V5q15qrs5YTXiQq6jAG0eVGi44zyM8nnphuo38tve6faWyq0t1MQ24Z2RqpZm6/QfVhWH4j8by+HvFGhaTJo00sesXn2SO7MyKiHbuJwMk+wOM4PTjKXRA+77HWUVU1bVbPQ9IutT1SdbeztIzLNI38Kj+f0rmf+E7ns7Oy1XXtIGm6JqDxpBdNdb5YfM+4Z49gEYJIGQ74yM45wLV2QbK52NFYfiLxTbeH5LC0ETXepanN5FlZxsFMrAZZiT91VHJPYdASQKi0vxQ8uvnQNetItO1fyPtMUUNwZ4p4s4JjkKISQcZBUEZ7jmhag9DoaKKKACiiub8f6/qnhbwXf61o1naXcljE00qXUzRgIoJJG1TuPTg7frSbsrsaV3Y6SiuYsfEWpXHgXSPEP2KO5M9nFdXlvBkMAyBmMQJOcZPyk5I75679hf2uqadb32nzLPa3MYlilQ5DqRkGrlFxbT6EpppPuWKKKKkYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHDfE/wNqHi/T9PvfDuoDTte0ac3NhM33C2OUbg8HA7H3BFc14f+L0q6tF4U+LGiSeH9WlZUiuCD9lumBGCrducdCV9x0rvPEOoazp2uaRLpelXGpWTeal+kDoDEp27ZMMRuII6DnBbANcp8RbWH4meGT4c0vSNQa7e4jIvL7TZraOxw2WkDyqu47Qwwm7OfQ5ojo7dG/6f9aDeu/3/wBf8Oem0VyVzq+tz3Woaf4VNjLNoqxJNFeo7PdOybtgYMojyCvzneMk/LxzCviPxJeeOdR0C0tNMtls7W1u0eZ5JGdJHIdTjAVgEbGNwzj14e7sha2uzqtRvF0/S7q8flbeF5T9FUn+lcR8E2kuvhfZ6rdMHvNWnnvbmT++7yt/IAD8K7fUbNdQ0u6s34W4heI/RlI/rXD/AASEtr8L7TSrxBHeaTcT2NxHn7rpK38wQfxoj9r5frf9BS2Xr+mn6jvDmu+Ip/it4l8P6rqNrcW1lZwz2ghs/KVDIWPzDcWYgYH3gDjoKyfDeqePfE8/ivR18Q2Fnc6ZqP2WPUl00MEUIDhIS/Uk5Jdmx0weyeH9TmX49eJL2bRdchsLuyht4LyTSbhYpHiBLc7OBycE8HHHUZb8M9VltvE/jefUNE12xhvdRa+tZLjSLhRNEEwcfJ97jIX7xzwCaUdUr/yv8/8AIqWjdu6/9J/z/E6D4UeJtW8SeGb5PEckc+paVqU+nT3ESBBOYyPn2jgE57cU34va14h8NfD+91vwzf2tpJZqDKs1r5rOGZVG0lsKRuzyrZ46Vj/BWa6jXxPb6hpGrabJda1c38P27T5oFeGQrtIZlAzx93Ofar3xxa4uPhbqWladpuo6je34RIYbGyln+7IrEsUUhRgd8Z7Zom9E/JfpcdO3PZ7Xf3X/AMjL8eeIvG3hPStP8Xpq1idJjlgjutH+xgtIkhCljNnO/nOFCgZ/ixy/xrrvjfwhq2ja9LrNjNpF9qMNjLoqWQHlLIT8wnJ3Mwx6KPaqHxYvrjxB8F7Sw0rQ9duL66a3YWqaRcb4/LdS+8FPlxjjPXqMjmpPi/qU+s+FPDqaPoevXsy6lbXzxRaRcbo44y27dlPlbP8ACee/Q5q9E/8At63y0/4Jmrtf9u/ir/8AAOv8WeJby18YeHvCumzfY5ta895L3YrNDHEmSEDZUuSRjIIAB4NZFtrPizT/AIsR+DpdYtbyyewGox3d7p4e4dBJteMmJ4kU+jbD7g94/iTq0bHw3eL4c16/iLyXEVzpNmTf2bhRtxE+GUHJ3blI4wRzVDwt4w0m38RPfap4b8cQ6ndxC2/tfX9JEYcAkpCPKARMseAFGTjJJxUx316X/wCB/XX5lPb7vz1/D+tD0Kz/ANO8VX12eY7GNbOLjo7YkkP6xj6qa5D4n/8AI5fDv/sO/wDtNq7Xw9aS2ehwC6XbdTbp7gekjkuw/AnH0FcB8Tr6STxr4OFrpWs3aaVqgurya10q4mjijKEZDKhDdei5IwaW0ors1+eonrGTXZ/loN/aHuJI/hlFbJny7zU7aCbB6puLY/NRWv8AGa3hf4J+IY5AAkdoGTjoVZSv6gVo/EHwv/wn3w9utNtZGguJkS4tHkRoykqkMm4EZXkYIIyMmsDxSdU+IHgpPCkelahp99emGPVJbm3ZIrRAQ0hWUjZKTtIHlluvOKTi3BwW9/0S/C3yLTSnGfRL9b/j+hzXh/UbnWPjd4KN/lvK8ILcoD2kkGHb6kVt/EmU2nxm+GtxAxE0lzcwMADyjKoP4c1q+IvCs2k+MPDXivQraW4j0mBtPvLWEZke1ZcBlH8RQ87RyR054oOjy+M/iZo/iaS1urXSdBt5Ra/a4HgkuJ5OCfLcB1VVHVgMk8DHNa3TnFro3+bf4p2M0rRafVJfgl+D1/E7q7S5ks5ksZo4LlkIilliMio3YlQylh7ZH1ryvwjq3j/xn4d1+CLxDY6ff2GsXFmt+NPWQbYwoCpGTgAnJLMXPOMHt6rdXKWdpLcSrKyRIXYQxNK5A9EUFmPsASa8o+EmqTaVY+LDq+h67YmbWLnUYVm0i53SwuVxtATlv9kc98YBrNfa9P1X/BLey9f0f/AHeHdd8eePvhwLzTdasNB1GzkmgublbIXBuJY2I+VWO2NSAMnDHk4AxyybxXd+Nf2W9V1zUo447ufS7lJhGMKWQshIHbO3NM+E2oTaH8ONZg1fRNetLhL24uBBJo9xvkSVvk2AIdx9QOnU4HNc/wCHn1Cy/Zf1Dw5c+HtfTWDFcWy2n9j3G52ld2Uj5MbcHk546HkjJPWnL0T+bWv/AAwR0kvVr5dP+HPXvh9/yTXw3/2C7b/0Utcz8JL14rrxd4ddgY9G1uZbdR/BDIS6r9AS1dD8OJ2k+HWiQzWt5Zz2tlFbzQ3lrJA6OiKGG1wCRnuMg+tc98JLOSa88X+InjCRaxrcxtmB/wBZFESgb6Ehq1qa1pvpr+aM4/wo+q/JnpFFFFZFhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHI698ONL13xEmtrqOsaTelVjuH0m/a2+1ov3Vk28kDPUYPvV6w8Iwaf4uufEEWpXzy3FvHbG2fyvJWNM7VGED8FiclieeeOK6CihabA9dwrF/sJ7PxJJq2kypD9sKjULdx8k+BgSDH3ZAOM9GAAPQEbVFHUAooooAKKKKACiiigDivFXh7xg/iRNf8E61YxTi1FtJp2rQs9u437twZPmQ+uM5wPSrGh6X4wvvLfx3faPtidZFs9GgkVGZTlS8kjFiAQDgBeRySOvW0ULQHqFFFFABRRRQAUUUUAFFFFABRRRQBnazZXmpWn2O0uhaRTZW4mTPmhMchOwY/3j07DPSzYWNtpmnwWNhCsFtbxiOKJBwqgYAqxRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXFax8XvBPh/WP7L1zVptOvN20Jdadcxg843BjHtK5/iBx711V9qltp+ltqE3nS26qGza28lwzA9CEjDMw57A8c0dL9A626luisbw54r0nxXavc6HJdTQIcebNYzwK3UfKZEUNjBzjOO9Vr3x54dsdWk0w3sl3fxf621060mvJIv99YUYp+OKNtAOiorH0TxbofiOWaHSNQjmubf/X2rq0U8P8AvxOA6/iBVbVPHOhaPrw0W7lvJNR8gXH2az024umEZJAY+VG2BkGgDoaK4iz+MHgzUNUm0ywvtQur+33edaQaNevLHtODuQRZGDwcjircfxM8Ly6Rd6nFdXz2tlMYLpl0q6LW7hdx3p5W5QB3IA96Olw62Osori9J+Lfg/X4pJNCutS1NIiFkaz0S9mCE9ASsJxWv4e8Z6H4qur620W6mluNPKrdQz2k1u8RbJUFZEU84NOzC5u0UVn65rlj4d0mXUtVaZLSHmR4baScoPUrGrEAdzjA71LaW4bmhRXLaZ8R/DOs+HrnXNKuby6021x5lxHpd0QecHaPLy+Mc7QdvfFTeFPH3hzxusr+GLye9ih4eb7FPFGDx8u90CluRwDmqs72FdHR0VzWpfEDQdK106NdnUm1HYXW3g0i7mMijGWQpEQwGQCQSAeKseEvF+neNNNuL7SEuUht7p7VhcxeW29MbvlPI645weDxSWuw3pubtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRUdxN9ntZZvLkl8tC/lxLuZsDOAO5o2DckoqnpGo/2vo9tf/Y7ux+0Rh/s17F5c0Wezrk4PtVym1Z2DcKKztY1f+yEtW/s+/vvtNylviyg8wxbjje/Iwg7ntWjSAKKKKACiiigAooooAKKz9d1q18PaPPqd+ly9vANzi2t3mcD12oCcDqT0A61H4a8QWnirw3Za3pqTJa3sfmRLMoVwMkcgEjt60AalFFFABRRRQAUUUUAFFFFABRRRQAUUVS1fVIdF0ua/uormWKEZZLW2eeQ844RASfy46mi9g3LtFY/hXxPY+MfDdtrmkrMLO5LiPzkCsQrlc4BOMlcj29K2KbTTsxJ3CiiikMKKzoNX8/xBdaV/Z9/H9mhSX7ZJBi3l3Z+VHzywxyMcZFaNABRRRQAUUVzmk+ONL1rxbf+HbSG+jvbCISzG5tWhXaW2jbvwWB6ggYI6GjrYNlc6Oiis7RNX/tqwa6/s+/0/bM8XlX8HlSHa2NwGT8pxkHuKANGiiigAooooAKKKzrTV/tet32m/wBn38P2NUb7VNBtgn3AnEb5+YjHPHGRQBo0UUUAFFFFABRRRQAUUUUAFFUtX1WDRNKn1C7juZIYF3MtrbvNIR7IgJP5cdTVTwp4nsfGXhq213SVmWzui/l+eoViFcrnAJ6lc/SjcNjYornfEfjfS/C9pfXWpQ3zwWKoZ5LW1aYLuDHB2524C5JbAG5eea1dH1SHW9DsdVtFkSC9t0uI1lADBXUMAQCRnB9TRvqGxdoornNd8c6V4d1/TNHv4b43OqTpBbvHaOYSzHABlOEyMEkAk47UdbBsrnR0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHl/xY+HNt8SLn7AzCLULbTnlsZycBJPMHDf7J6H8+1cZ8CviTe6Tqj/AA38cb7a+tHMNi855BH/ACxJ/VT3HHpXsxuYD8Qlt/Oj88aYzGPcN2PNHOK84+O3wok8U2K+J/DKmPxBpy7isXDXKLyMEc716qfw9MKMuRJvZ3v971BrnbXVWt9y0L/xK8VXfg74FzXulP5N3M32WGRTgxl3ILD3Azj3qP8AZw0eCx+EtvqITN3qlxLPPKeWfDlFyfov6mkvvCl58Rf2a9P07zM6pNYQ3MbynG6ZfmwfTdyPbNM/Z51gReB38J6orWetaJcSRzWc/wAsgVmLhtp5x8xH4e9XGPK6kXv+n/Dik7xg/wCrnHftGXM/g34geFvF2gt9m1FkkSR1480RlcBvUEOQfave9GW1voY9dgTEupWsLM3+wFLKP/Hz+deF/GXTZ/iv8U9E8JeGj9oTS0ZtSu4/mjtfMYZDMONwVOnckD1x9A2ltHZWUFrAMRQRrGg9AowP5UoaUte7sOf8RW7a/p+B84fCH/k6Txj/ANvv/pQte7+INOtrTw54juoIwkt5ZyPMQPvMsRUH64AH4CvBfg/NE37UXi5lkUiT7bsOfvfv1PHrwK+gfFkiReDNZeRlRFsJiWY4A+Q1FT/do/4f8zX/AJiJf4j5z/Z78baJ4N8DeJ59X1K1gufOR7e1klAknIQ4CpnLc4HFfS8Gn26alLqaRhbm5hjilYD7yoWK/lvavnr9mbS7LXvAfizSb9Y5YrmaNXRgCQChAbHseh9q9yi8V6fP4yj8M2FzFc3cNq1xdiM7vIUFVUEg8MS2cegPtW097ddPyOaHw/N/mXNOvtUudV1GDUNH+xWlvIq2l19qWT7WpGS2wcpg8YPWtGWNJonjlUMjqVZT3BqC21KxvLm5t7O8t7ia1cJcRRSqzQsRkBgDlTjsas1nurGnU8u+DIbw/J4l8CXJG/QtQZ7Yf3rab50Pv3z9azvg5qEOmeOPGPhWKNobR7xtU00OAPMhdijFcfw5UY9jT/iJDqfhz4uaDrugxM76/bSaLPt6LIRuikI77Tkn2Q0z4iWUngLxZ4K8UaHZvOluP7Dngi6yo64iBPswP44pxd7SfX3fn/w6j94SW6X+L/P/ANuXyPSNOUX3iTUNRIyluBYwH1x80hH1YhT/ANc68u+HviLVNF8J+JD4e8N3PiC8XxFfO0Ec6QIi7xyZH7+iqGPsOtevaRY/2Zo9vas+940zJJ03ueWb8WJP41538Eby3k8O+KNkyEReIb1nIYYALAg/THelte3SP6oT1s7df0Z0+i/EDS9a8AWviuOOaO3ucItsQDKZS/liIc4LF+B257VV1Px5d+Gta0y28V6NFZWOrXItbW9tr3z9krfdWVDGuzOOqlx7968l0yGS8/Zpsb20tF1WDTNca9u7IIJBPClwxdSvcbSDg9q9B0e6+D2qxWdx4e0zwrdX05Vra0gs7cXO/qP3e3epHUkjjGauy5vnt5WT/wA/uHL3dPXX0bX+T+ZcufibqCeM9Q8MWfg3UbjUra0+1QRm5gX7Qu/ap3biqKeTlmB7bSTit2PxJqU0NpZroqR6/Na/aZ9PlvB5doM4+eZVbgtkAqpzg8YBrlbG5h/4ag1SESKZD4ciG0HuJskfkRWT4wbw9onxuW7+IWl2FzomsabHb2l9qFqssVvPGzEoSwITIbOeO1Qto+d/wv8A5C6y8rfjb/NndeGPGy65r+qeHtSsTput6Vsa4thN50bo4yrxyYXcOR1UEelbPiDW7Xw5oN3q1/nyLZNxAIBYkgBQSQMkkDk96xPCieBzqUsngWx0IkRbbi80eGEKvIxGzxjknrjPGOeorS8XxaLceE76DxQqnSZkEVzvbaqqzBdxbI2gEg57YzRLbQcdxtrrOqrfWdrq2jJb/bHcJNa3fnxxhULDeSiEMcdACOvzdM17vxHqdz9sPhbSINUSylaGZ7i9NuHdfvLHiN9xB4OdozkZ4NcTpWneIPh5420DSdM8Qza/4Z1h3iSzvCJJ7NVQsHWQcmMYA54GQO4NYfhBvAWla1r/AIe+JWl6Ba61b6lPcR3esWsI+1wSOXRxJIMHqRjP9aN9uz/Cwtlr5fqdbqPxms4PhqnjLStDvtQswzR3CeZHEbWQMF2SZbdyxAyqtxzVrUvHnim00/UdVt/A23SLG0a7W6v9VSB51UZIWJEkYHHI37ffB4rm/it/YEP7P2uHwxZ2Nlpks0JgayiSOK4Pmx5dQoAOcEZ77c9K7zxbE+o/CnWI7JTM9xo8oiVOS5MRxiibtCUl0/yuaQScop9f80ZmsfEK90/4UWvjez0WC5iezjvLi0lvjE0aOAcKwibeQT3C/wBKTXviY2gHw40/h+6kt9dkt4luxOnlRPLyVwMuSFyfuAHpn04HUfFeh6h+ywdN0/U7e7v4dEhjmtYJA8kJUKG3qOUGRjJxnjHWrnjPWtMuvCvwtuLXULaeEa3YgvFKrgFEwwyPQnB9D1rRxXtXFbcyXybaMbvlT8pfekmddL8T59O8aWui+IPC2oaXZ6gHGnX7yJKbllGSpjTJQkYwCdxz0FO074kXreP7bwx4j8K3ehHUUd9MuJrqKb7SEGWDBCQhx2yffFZfxUnij+IPw3EkqIf7YY4ZgONgGfzIFR+Pp4o/j58N1eVFP+m8Fhn5owB+Z4qKdpNX7tfhcuXX0v8Ai1+h6rXK3Hi2/u4r6fwto0erW2nyvDPJLdmDzXT76wgI+8g8clRnjPBrqjyDXjvwp8Z6N4T0rUPB/jDUrXRtV0m/n3DUJlhWeN5C6yKzEA53euehqd215D2V/P8AzN7Wvi7BpngCw8W2fh/ULywvMK5Zki+zuX2bXBJcndkfKrDj6Vs2/jDUI/7SvNe8N3Oj6TbIhtLqa5ikkvCxwFEKElCSQACcnI4B4rk/jbq9re/B2W9ikX7K9/amGTPEyiZTuX1BwSPUDPStj4x2V1qPwuuJNOsxqBtZre8e02bxcRxyK7LjuMA8c5xVO1m/O3otPyuSr8yXl+r/ADLWtePbzwteafJ4p0SOz0rULlLWK8gvfOeGRx8omj2KFHBGVZxV3UPF1y3imfw74b02DUdStLZbm6+1XZtookYkKAwjcljjONuMdT2rlNHvvg1rWn211o2leFJ7y4AMFgtlbrdGTsvl7dwOe+MDrnHNaEOsvrnxQ8QaNFLFocWkW9ubm5iRBdXysCw/eMPliXJHAzljgrRbp6hfS/p+ZbtfHl54g+HOq654e0+KDUtPaeCW11CUhIpYvv8AzIDvA6jGM+orO8FeLPEUXwjtfEGr6Mmo/wCiC5Bsr0NNOCSzu6SLGqY64Vn9BXOfC+6sX8GfEHSrK6E9wup6i6xmYySGMqArMSSTnHDE84PXBrS8B+JNGuv2fEtbbU7aWex0KT7VGkgJtyEYYf8Aun0BxntUz0hKS7Rf3ptlRV5KL7tfirG9ffE1rP4UWvjePw/c3UM9uJ5LeG4jHkKehZmwSM4HyqTz0qrr/wAVbrQE0/Urnwnet4duGiS41Y3MaiFpMAbYj87rk43EKO4zxXK3d3b/APDG6P50e06Skedw+/vA2/XPGK1PjDdW5/Z3SQTRlJUsfLYMMP8APGePXgE/hWrSVRropJfeyI3lCPdp/hY67xl46fwhfaNA2i3F5Bqt7DZrdrNGkcbyNjBGS5IALfdxwBnniLxF8Qj4d8caR4euNDu5E1TzPKvVkQq2yMswVFJYtnaMEL97OeK574z3dvHp/gh3mjVW8SWTglhgqMkn6cin+PrmGP44/DdHlRW33vBbnmIAfmeKmKTsn3a/BMvS1/7t/wA/8jY0L4h3t947fwv4h8MXWg3Utu11YtNdRTC4jU4OfLJCN7Zb61q3fiPU7n7YfC2kQaollK0Mz3F6bcO6/eWPEb7iDwc7RnIzwa5fxBcwL+0f4ThMqCT+ybv5N3POMfntP5VyvhBvAWla1r/h74laXoFrrVvqU9xHd6xawj7XBI5dHEkgwepGM/1qFql6P8Hb8hPRv1X4q/5nrPg3xdp/jfw1DrOlCRIpGaN4phh4nU4ZWx3FY3xC8cav4IWyubXw9b6np91PHbPcvqJgMEjtgF18pvk6fMD36eu54WTQ00lj4VsbK00x5S0TWMKRxT8DMihQAQTxnvj0xS+LvDsHizwjqWiXWNl5A0asR9xuqt+DAH8KcnbVIcddGReIdZ1nSdNsZdN0izv7y5njgkt3v2hVWbqVfym3Ack5C8An2rNuPGl/da1quleGNHt9SudGRDfm4vjboHdSwjjIjcu2B3Cjkc9cZHww1u98W6ZZS6vFJHd+H0exuw643XikozA98IM8cfvCO1GkauPE3irxXE9zHoNlpN2Le5jtgsVxeEJjzZZfvKhGAu3B+X72OKctLpeb+Wn4f5oS219Pn/X5GtbeKrPxr8Jb3XdOilhhubC4HlzABkZVZWBxx1BrkPC3inUPBn7OOha7ZaVb6lb2djvuY5b1rdwu/A2YjcMee5X8aq/CrVNPH7Pmq263kRe0jvzODJkxAs5G89iRzzyetRW0b3n7G+y1XzmGkMSE5PyuS35AGlP3edr+7/7cNL95GL7yX4o7jxz4+vfB3g618SQaNBf2kgi8+N74wyRmQqF2jymDDLc5K9O9b+pa49veQadptqt5qdxC06QvL5caIuBukfDFRuIHCsSTwODjyL4qeLtB1z4BpFo2qW1+8f2IzLbyBzBh0/1mPuHjGDgnn0NWvFmoeGLf4p6P4g8V22m6t4U1fSRZW+oTwJdW9vcLIWB3EEDIJGfY9gatpXt5tfhdfiRFuyflf8dfw1O90Tx4l54i1Pw9r1iNK1jTYBdSRpP58MsB/wCWkcm1SQO4Kgg0+w8X399pVrrCaIH0q/eAWksF2JJtkrBQ8se0BANwPys59QOcVdBX4ei5uZvBunaBMY7Z/tVzo8MB2J/cZ4x1bH3c9s1wt1o918O9PsfEvww8RyXfh26uoVOgTv8AaIpVlcLiBuqn5icDn1PGKUbNpPy/P9f8xvZv+tv6/A9vrjbrxxfXN/rNv4X0aHVE0NvLvnuL77MTJt3FIh5b7iB/eKDPGeuOyFeY6Pq6+K7jxdJNcpoNhp1/LaTW1oVgmuWVNvnTS/eG7gLt2nCj5j0rN3s7dFf8i109TS1H4pQW/wAL7fxvpmh3uoWM0JmeNZI4zAAcfPubP3uPlDeuKt2Pjm/mWbUdT8NXOmeHo7IXS6nPcxlpGOPkEA+cZzwSAT6DNeUaRqdjL+xxfW8V1E8tvbSJMgfJjZrgkKfRiCDjrgg969A8f2N1rvwEddGh+2S/Yra5SALv89EKOVx3yFPHetJpRlLsmvud/wDhyI3fKurv+FjR17x9feFFtdQ8S6CtpodzMkJuor3zJrZn+6ZYtgAGcglXfFduCGAIOQehrybQ9S+DGvaNb3dlpHhQ3c6jbpzWNut0ZP8AnmIiu4nPHAx36V6vGMRKNgTAHyjovtQ1ZWYk7nOT+Kbq91bUNM8K6dDqVzprKl3JdXZtoUdhu8sOEcs+MEjbgZHOeKj8P+MrTxVY6tbC3lsdT0xmgvrCcgvC2Dg5HDKw5DDrXK/C6Y6D468a+GNXfy7+fVX1S1DnH2iCXGGXPXbgA+lWPDmmNc/Ffxx4hsx/oEttDZLInKzzInzkeu3hc+uR1BrOWsPWN/w/z0Ndpej/AF/y1OW+G3jHWfDnwQ0SXRfB99r0FuJnvJoZ0hESec5OxWy0rY7KMe+a3PiB8Q729+D1v4l8Em3NnqDxwyy3EjJLEHcIVVQpG7JIJJ46gHirHwR1SwsfgXp8t5dQxJYicXW5x+5Ilc4Ydjg9PeuN1zQ7jw/+zNM17A9oJ9XTUPIcYNvE90rKCOxC4yO2a2nrVd+6/F/5fkY68vu76/k/1/M9Y1XxddeHdJ0865p1uNV1K8Wys7OzuzKkkjdMyvGm0YBJ+U4xxk8UzR/GlzceNpvCev6VHp+qJZi+ia1ujcwSw7tuQ5RGDBuMFfxrG8U+OtPurnwva+H5tNvF1XUTBDq0iieG0dUySh6GQhioweCSDnBFYfm2Gi/tJabHd61JdzSaC8LS3U4Z5JvN4QKuFViBnaij6VMdZWfW/wCEb/n+ZX2b+S/Ox22heN5NY8b6x4bn0S50+XS4EmLzzRsZg5IUgISACADy2ecECsmx+J2oapea9p2neDtQl1bSJEiFi11CrSMylstJuMaKBjncxOeBxVXw7dW7/tGeLoUmjaQaXaAoGGcjOePbcPzFN+HFzBL8WfiSkUyOwvrY4VsniLaf1BFTFXS9G/xsEnZ/Nfir/mbPhf4l2Wu+E9Q1fUbGbSrjS7prO+snYSNHOCBsUjG/JYAdMk0a149vPC15p8ninRI7PStQuUtYryC9854ZHHyiaPYoUcEZVnFeU3EEuq+DviU2lQJqbWfisXslmFDieKN0ZlK9wQp45zg13Gj33wa1rT7a60bSvCk95cAGCwWyt1ujJ2Xy9u4HPfGB1zjmnHWz9NPVJ/5/cOS5W16/g/8AhjtdT8Ryxaz/AGLodnHqOqiD7RJHLceTFBGTgGRwrEbjnACknB6DmuK8LXdxd/tC+ImvbQ2dwmiWySxb96g7ycq2BuXng4HuAciqVr4ktfBHx98SR+LbiPT7PXra2l0+9uW2Q/uk2tHvPA5J/wAkVJoHibRrn9o3Vni1G38u/wBFt47ORpAFuiHJ/dk/f9sZzgkcUo/FF97/AJMVTRSXp+aPVL64mtbCae2tJb2WNCyW8LIrSH0BchR+JFcr4e8fyeIvAdz4ktNBumeCaWIWCTxmVvLbaTuYqo6EkZPTjNdizBULMQABkk9q8o+D17av8HdVmW4jMcd5fs7hhhRuZsn8CDUttKT7K5aWsfW34Mst8XtQufANt4q0XwXeahZmN57wi8jjW1iUkEgsMyNgZwq4HTNeg6Jq9tr+g2OrWG77NfQJPFvGCFYZGR6815Z4FuoB+ygZDMgSPSLtXbdwp/eDB967L4USJJ8I/DJjYMBp0Skg9wuCPzrWSSlNdmvxv/kZxbcIyfW/4W/zI/EPxCPh3xtpOgXWhXjRao7rFfiRCjbELMFRSzls7Rghc54zjmla/E+5j8ZP4e8Q+E9Q0ieeBp9NJljna9VeCuIyQrc9NxwOSRVD4i3UEPxe+GySyojG7uuCeeYgo/MnFReMpol/aJ+H6tIgb7Ne8FhnmPj88VMFzW87r7lcueiuuyf42Nvw58RLzU/G8/hbxH4YufD+o/Zzd2okuo51uIQ2M7k4Vv8AZBPQ81c8L+OX8R+Ldd0KfRbjS5tGEJk+0TRuz+ZuI4QsoG0A/ePXHGK5nU7iFf2pNFjaVA58PyqFLDOfMY4/IE0ng6WK4+OnxIgimQyNFZKAG5BERB/IkUR1jfyf4Ow2kub5fjb/ADOluvGmoT6dean4Z0NdW06xeRJZXuzDJP5Zw/kIEbzMEMPmKZI4z1rN134sQaV4U0bxFaaDf3um6s0SrNuRPJMjYCsuS5br91SDgc81z3wi8caH4c8H/wDCJeLdTs9E1jQ55beeG/nWDzAXLK6liAwIPb69xV34y6tbXHgHR70uI4H1y0aNnON6CTO4A9iBn6c0WV0lqm1+LJez8r/h/wAMdOPG15p9hq2p+K/DtxoWl2ez7LNLcxTS3m44AEcZJRs4AUnnI6c1BrPjvUPC8MOpeKNAWz0SWRI3vILzzpLXdgAzR7AFGTglGfFZ3xwsb+6+HqXumRPcNpV/b6hLDHyZI42y31xnP4VY+ImpWHiT4Mag+lyR3y6xaCKwSMhjNK+NiqPUHn2wc9Km7s2ujtb7vz1+4dldLv8A1+G/zLfib4hDw34k0XTZdFup7XV5lii1FJUMWSCxAVSXJxjA2jOeDVJfifcWnjaPQPEXhW/0lL2N5NMuGlSc3mwZZdkedjegJJ9cVz/jKFNAvPhNpl/dKZ7XUYonZm5YrDsJ/wC+iB+NXPiJNEnxs+GqvIinzrzgsB1jUD8zxVpLmtvq1+CJTbV3p7t/z/yNnRPiNe3fjweFvEfha70C5uYGuLCSW6jnFwi/ezsJCt7Zb8OK05PFd7qN/qNn4S0uDU30yUQ3Ut1eG2i8zbkxowjcswBXPAAz1zkVynim4hT9pHwUjyornT7wBSwzkrx+eD+VL8IJ20bVvFnhPVmEWqQavNfRo5wZ4JSCsi56jjnHTvSjql6P8JW/IG2m/Vfir/nodPovjGy8XeHNXNvDNZ3th5ttfWNwAJLeQKeDjIIPUEcGsP4CuqfA3QnchVVJiSew856qeGrAJ4w+JHidHVNKvAkMUmfklaGEiRwehAYkZ9Qao/CeXzv2fNA0+Fx5uoSSWfytyA0zmT6ERhz+FOOsXbdqP43CW67Jv9DZ8YoZPgZ4p1CQYl1KyuLtsjB2sv7sH3EYQfhXS/D7/kmvhv8A7Bdt/wCilrP+LLRW/wAHfEwYrGg06RFycDJGAPzwKv8Aw8dX+GfhtkYMP7Lt+Qc/8s1oVrSt/d/9uE73jfz/AEOb+KXiHxJo+r+FbPRIbFrXUdWhhkM1w8byMDvCHCMEQ7eWG49sVS+KNxcR3nw9uNVhit518QxNNHbSNOqnY/CsUUt/3yD7VL8Zbq306/8AAt/fTJb2lv4iiaaeRgqxjY3JPYe9VvihrWm3l/8ADu+tbyGa1l8RRNHMjDa64ZdwPdckcjjkUodP8S/9tFUv73+F/wDtxvWnxGvB8QLXw3r3he80ePUlkOmXk1zHJ9p2DcwZEJ8s46Akn1ArbvNfv5ry8s/DOm2+pXFiyrctdXhtolcru8sMEcl8FTjaB8w5zxXIfEO4hj+L3w2jeVFf7XdnaWAODEAP14rndPbwZo3xM8VaR8TdM0Zbm9vjf6dqOr2kRSaB1A2CVxgbSMYz60lql8/nZr9PyNJK2vp+v+X4ndaZ8UNK1Hwjfa09vNbTafd/YLqylZQ8dzvCBN2dpBZhhumPTBrcs9X1X+0LWy1jR0tpLlZHE1rdefCm3GFLFEbcc5xtxweeK5q4svh3e+CdStobDSoPDN5LFDNc2CRwwSyM4UMHTAO1ivzg8HjsaxtBs/EfgHx/o3h2LxDN4i8O6tFN5Ud5h7mxCLuD7xyyEkLk4AyABT3f9dri6XOwvPFGpzW11d+GdFh1S0s5JI5XmvfIaVkOHEICMHwQV+YoMjg96veEfFWn+NPC9prujmT7NcqfklGHjYHDKw9QQa8g8BN8PtNj1Hw58R9M8PWniDTr2bzLjWbSFDdxtIWSQSSD5sg9M5wBXsXhlNHTRVPhqxtbPTGctALSFY4pR/fVVAGCc4Pcc9DQtr+gS3t5sw/EPxCPh3xtpOgXWhXjRao7rFfiRCjbELMFRSzls7Rghc54zjmla/E+5j8ZP4e8Q+E9Q0ieeBp9NJljna9VeCuIyQrc9NxwOSRVD4i3UEPxe+GySyojG7uuCeeYgo/MnFReMpol/aJ+H6tIgb7Ne8FhnmPj88UQXNbzuvuVxz0V12T/ABsbfhv4iXmp+N5/C3iPwxc+H9Q+zm7tRLdRzrPCGxncnCt/sgnoeaju/iRdPpus6voWhx6hpGhzSw3k8l95MrmIAyGKPy2DBefvMmSOPWsnVLmFP2o9FRpUDnw/KoXcMk+Yxxj1wCazo9WXxd8L/FOsz3SaNYr9uiTSrIrAfMAIzO4+dpGIzgFQQ2CG61Dl7nN5P8HYpRXPy+a/FXOl8W/Em80LwNp/i3RPD66vpV1FHLK0l4beS3WTG1ivltkc8nPHuOa6DWdd1PS/CcWp2+m2d3fOYl+yC/ZY2ZyFCpL5R3csAMqM+1c98NU0zxN8ENJ0xpI7u2k0tLS6VDuCkphlJ6bh3HUVl/DO61G7aLwlrCSGbwfO8U8zKds4AxbHPQ5RmbHYqp71tKKU5QXR/h1/T7zJP3VL+r9D0+1a4e0ia9ijhuGQGWOKQyKjY5AYqpYe+B9KloorMoKKKKACiiigAooooAKKKKAMT/hC/Cw1T+0x4a0f7f5vnfa/sEXm+ZnO/ftzuzznOa265vR/HOl634svvD1pDfx3thEJpvtVo8C7S20Y34Jz1BAwR3rpKOi7B1fcbHGkUYSJFRB0VRgCs/VfDmh69s/tzRtP1LYcp9stUm2/TcDitKigCtYadZaVaLa6ZZ29nboMLDbxLGi/QAAU69sbTUrKWz1G1hu7WYbZIJ4w6OPQqeDU9FD13DY5xPh34KjdXTwfoCspyGGmQgg+v3a1NW0LSNet0g1zSrLUoY23pHeW6TKrYxkBgQDg9av0UAc3/wAK48Ef9Cb4f/8ABXB/8TV/SfC+gaBNJLoWh6bpkkq7ZHs7SOEuOuCVAyK1aKAK1tptjZ3NzcWdnb28104e4liiVWmYDALEDLHHc1ZoooAiltoLh4nnhjlaF/MiZ0BMbYI3LnocEjI7E0s1tBchBcQxyiNxIgkQNtYHIYZ6EdjUlFAEV1a299aS2t7BHcW8yFJYZUDo6nggg8EH0NY9v4G8JWkc6WnhbRYEuI/KmWLT4lEqZB2theRkA4PoK3aKAMzSfDWhaAZToWi6fphmAEv2O1SHzMZxu2gZxk9fWnaf4d0XSbye70vR7Cyubg5mmtrVI3lPXLMoBPU9a0ScAmuc8NeOdL8VavqunabDfRT6UYxcC8tWgIL7iAFfDdFzyBwRT1bDoT/8IR4U/tL+0P8AhGNG+2+b532n+z4vM8zOd+7bndnnPXNad/p1lqtm9pqlnb3ttJ9+G5iWRG+qsCDVmil0sHW5XsdPs9Ls0tNMtILO2jGEht4hGi/RQABU7osi7XUMM5wRmlooAoWGhaRpVxPcaXpdlZTXJ3TyW9ukbSn1YqAT+NJqWgaPrMkL6xpNjfvA26Frq2SUxn1UsDg/StCigDN1Xw5oeuxwx63o2n6ikGfJW7tUlEeeu0MDjoOnpU+m6Vp+jWS2ej2FrYWqkkQWsKxICep2qAKt0UAZsXhvQ4ILqGDRtPjivH8y5jS1QLO2c7nAHzHPc1BqHg3wxq86Tar4c0m+lRBGj3NjFIyqCSFBZTgcnj3rZqkuq2pmvkd/LSxKieaQgIpKhsZz2BBOfUUAZ914G8JX0iPe+F9FuXjjWJGm0+JyqKMKoJXgAcAdqLvwP4Tv7s3V94X0a5uGxmabT4nc4AA+YrngAAfSp9E8U6L4jnvYdEv0vHsJBFchFYCNyM7ckYJ+nTvVjVdZsNEtln1K48pXbZGiozyStjO1EUFnbg8KCaL21AvAYGBwKzr/AMPaLqt5Bd6ppFhe3NucwzXNskjxHOflZgSOnan6VrVhrdu8unTF/LbZLHJG0UkTYB2vG4DIcEHDAHmqmp+LNG0i8NpeXMhnVQ8kdvbyTmFDnDyeWreWvB+ZsDg80bMCbVvDWha/5X9u6Lp2p+QCIvtlok3lg4zt3A4zgdPSrWnaZYaRYpZaTZW9jax52QW0Sxxrk5OFUADJOalgniureOe2lSWGVQ6SI2VZTyCCOoqSjbQNzOs/D2i6dqE1/p+kWFreT/664gtkSST/AHmAyfxp1zoWk3upQajeaXZXF9bjEN1Lbo0sX+65GR+FX6KAK1pp1jYNO1jZ29s1zIZZzDEqGVz1ZsDk+5qnJ4W8Py6fNYS6Fpr2c8vnS2zWcZjkkzney4wWzzk81n6l470rSvGmm+GLmG++36kxWBxasIThSxPmNhTgAZ25IJGa6WjpcNnYwf8AhBPCJsRZHwtov2USeaIP7Oi8sPjG7btxnHGeuKWXwP4TmsoLObwvo0lrblmhgfT4ikRb7xVduBnAzjritLUdTtdKt1ku3OZHEcUaKWeVz0VVHJP9ASeBVpSWQMVKkjO09R7UAYU/gXwldRQRXXhbRZo7ZPLgSTT4mES5J2qCvAyScDuTRc+BPCN5Ksl34V0SeREWNXl06JiqqMKoJXoAAAOwFb1FAGLP4M8L3Wpf2jdeG9Imvtwf7VJYRNLuGMHcVzkYGD7Va1LQNH1mSF9Y0mxv3gbdC11bJKYz6qWBwfpWhRQAiqEUKgCqBgADAApaztY1/TdBiifU52Qzv5cMUUTzSzNjOEjQFmOATwDgDNTaXqtjrWnR32l3KXNtLnbInqDggg8ggggg8gjmgCaC2gtt/wBmhjh8xzI/loF3MerHHUn1qq2haS+sDVn0uybUVXYLw26GYL6b8bse2asm7gF8LTfmcxmTYAThc4yT0HPTPXBx0NV11i0OtNpUjNFd+X5saSLgTJ3ZD0bBOCOo4yMEEgEMnhjQZtLfTZtE06SwkkMr2rWkZiZyclimME55zjNSaX4f0bQ7eW30XSbHToZjukjtLZIlc4xkhQAeK0KKAMyHw3odvZGzt9F0+K1aUTmBLVFQyA5D7QMbs8565q1d6dZX9g1jfWdvc2jrta3miV42HoVIwRVmigCpYaVp+l2IstMsLaztBnEFvCscYz1+UACo00HR49XOqx6VYpqJXYbxbZBMV9N+M49s1frK1XX4dMuI7OG2uNQ1CWNpo7G02ea6KQGb52VQAWA5YZzgZNF9bh5GrVD+wtI/tdtV/sqy/tFk2NefZ084r6b8Zx7Zqr4Y8UWPivTZLuwiuoDBM1vPb3cJjkhlX7yMOmRnqCR71rTSrBBJK4dljUsQiF2IAzwoySfYc0PTUFroZVx4Q8NXenxWF14e0qezhcyR28llG0aOerBSuATk5NXNL0fTNDs/sui6daadbbi/k2kCxJuPU7VAGeOtYnhvx/pPinT9WvNMg1ARaTO0E6S2jiUuqhiFiGXJGcYwDkYxU/g/xnpnjawu7zR47pIrS7e0k+1Q+UxdQCflJyPvY5AOQeKdn+oPzL9t4d0Wz1WXU7TR7CC/m/1t3Faosr/VwMn8TWjRRSAz9W0DR9eiSPXNJsdSjjbciXlskwU+oDA4NXYYYreFYoI0ijQYVEUBVHoAKfRQBmv4b0OXWF1aXRtPfUk+7eNaoZl+j43dz371dubaC8tZLa8hjnglUpJFKgZXU9QQeCKloo6WDrcz7jw/o13pCaVdaRYz6dGAEs5LZGhUDphCNox9KemjaZFdW9zHp1ok9tGYoJVgUNEh6qpxlQfQcVdooAxbfwZ4XtNS/tC18N6RBe7mf7THYRLJubOTuC5ycnP1ptn4I8KadcGfT/DGjWsxRkMkGnxIxVhhhkLnBBwR3rcooAyNK8JeHNCujdaJ4f0vTrhkKGW0so4nKnkjKgHHA49qms/D2i6dqE1/p+kWFreT/wCuuILZEkk/3mAyfxrRooApano2l63brBrOm2moQq25Y7uBZVB9cMCM1JFplhDdm6hsreO4ZFQzJEocqBgDdjOBk4FWaKAIbyztdRs5bTULaG6tpl2yQzxh0cehU8EVkQ+B/CdvZ3FrB4X0aK2utvnwpp8QSXacruULhsHkZ6Vu0UAYSeB/CcVhLYx+GNGS0mdXlt10+IRyMv3SV24JGTgnpmr+laJpWg2zW+h6ZZ6bA772is7dIVZsYyQoAJwBz7VeooAxdR8GeF9YvmvdW8N6RfXTgBp7mxikdsDAyzKScCm3Pgjwpe3xvbzwxo1xdMQTPLp8TOSAADuK54AH5VuUUbbBvuYcngnwrLqR1GXwzo73xk843TWERlL5zu3bc7s85606x8G+GNL1Bb/TPDmkWd4pJW5t7GKOQZGDhgoPIJraoo22Dczrzw9ouo6hDf6hpFhdXkH+puJ7ZHkj/wB1iMj8KZq3hjQNfkjk13Q9N1N4gVja8tI5igPUAsDitSigCvY2FnpdjHZ6baQWdrEMRwW8YjRBnOAo4FVLLw3oem6hLf6doun2l5NnzbmC1RJJM9csBk/jWnRR1uHSxjan4P8ADWt3n2vWfDuk6hc7QvnXdjHK+B0G5lJxUd34G8JX9x9ovvC+i3M21V8ybT4nbCgBRkrnAAAHoBW7RRsBh3Hgnwrd6gb+68M6PPeMwc3ElhE0hYdDuK5yMDmreq+HtF10RjXNIsNSERzGLy2SbYfUbgcVo0UAU73SNN1LTTp+o6fa3dkwANtPCrxnByPlIxwQKr6X4Y0DRGJ0XQ9N04ltxNpaRxZOCM/KBzgkfjWpRQBR1XQ9J162S31zS7PUoEfesV5bpMqtjGQGBAOCefenaXo+maHZ/ZdF0600623F/JtIFiTcep2qAM8dauUUAVr/AE6y1Wze01Szt722fBaG4iWRGwcjKsCDWfqXg/wzrFwk+r+HdJv5o4xGkl1YxysqDooLKcAZPFbNFAGFdeBvCV9Ikl74X0W4eONYkaXT4nKoowqgleABwB2q7qmgaPrlvHBrWk2OowxHdHHd2ySqh6ZAYECtCigCMW0CwLAsMYiUYWMINoHsKq6doek6Q876TpdlYvcNvma2t0jMrerbQMn3NXqKAM7UfD2i6vdQXOraRYX09ucwy3NskjRHOcqWBI5HatEAAAAYA6AUUUAYuo+DPC+sXzXureG9IvrpwA09zYxSO2BgZZlJOBTbnwR4Uvb43t54Y0a4umIJnl0+JnJAAB3Fc8AD8q3KKNtg33MR/BXhWXUzqMnhnR3vjL5xumsIjKXznfv253Z5znNWo/D2ixX1zexaRYJd3Y23E62yCSYYxh2xluPWtGijyA5zWtZt/BOm2FvpnhjU7+3kkEEVrodkjLB6Fl3KqL79KueH7OeOG5v7+3Fte6jN50sW4MYwFCohI4JCqM4yM5wTWvRQAUUUUAFFFFABRRRQAUUUUAFFFFAHk0mp3Gl/H/xHLYaXc6rdtoVsIbS3KqXO9uruQqj3J+mTxXSeC/iKPEuo6ho+t6PP4e13TVElzYXEokHlno6SAAMvvjv3rI024hg/aU1uKeVI5LjQrfyVdsGTEhzt9ce1QanoU3ib4r65qejnbFbeHJNKa6X7r3MjMQgPQlBjPoSBUptQXpL8G/10+YWTk76ax/KP/D/I3tW8d39j4cfxNZaCt74fiiM7zfbNly0I/wCWqQlCrLjkZdTjtXU6RqtprmjWmqabJ5tpeQrNC+MZVhkcdq8Z+Ht98KpvB9rY+LNI8L6Xr2moLW/t9Vs7eKYypwW+cZfdjORnk17JoyWsejWyadZJYWgT9zbxxCNUT+HCgDbxzjHGa0aSvbUV2/Ipar4iNrrEOi6VarfatNA1wIXl8qOKMHG+RwrFQW4GFYk544OKXh3xmdV1PWNJ1jTm0rUtHCNcr5hkgaNgSskcpVdy4B6qCMHiuQ1jX7fwP8fG1DxG4tNI13So7aC/lOI45onYlGbouQ2cnA5rqNc1Ky8c+Dtd0vwnqNrqLz6fNCLm0nWSNJGTCoWU4yc9M8Dr1FQ3aHMtd/wZSV58r02/Qibxzqd1oB8RaH4dOoaGEaUObvy7qaNSfnjh2EMCBkBnUkdqreIfitY6V4HsPFekabPrGl3pVRPHKkawlmCgPuO4HcSOFOMHOKZ8KvEWnz/CKw+1TR2z6Na/Y9RimYK1s8Q2sHB6cDPPrXmuraXJ4b/Zhjj1IG0+16vHdQwTfKYo3uQyrg9PkG7HbmtHFKfL0utfV2/Faoht8nN110+X6PT5nperfE260TxNplrqfhW9t9D1O5Szt9YknjG6Z/ujyRl1U+rYPtU2u+Otc0X4haT4c/4Ru1ltdXdltdRfUyi/Iu5wyeScNjoMnPHI5xkfGy6t49A8LM8yKreIrJlJYcgEkn6Yra+LGg3Gs+CJLzSh/wATbRpU1KwYDJ8yI7iv4rkfjUJpK8tk7P0svyuXa+i6r8df8jZ1TWNWtPE2mabp+l2t3bXis81xJfGJ4FQjc3l+WwYfMoHzDJOOBzWff+L9TOl3OreHtDj1PTbRpBJJJe+RJMIzhzCnlsHGQwG5kyRxwQaXwdqa+L9LfxRCjwxahbpFaK4IKIB8xwfWQtz3Cqa8x+HEvw4stDk8PfEDS/Ddh4j0iZ4LttXtII2uBuJWQPIPnyCO5PfoRQ01eL3X9fgJNNc3Q7bWPi/ZWPhHR/EumaNe6lpeqSRxi4R0UQuz7djLkuWGG4VSMjGeap+OPGvjWx8C+ItRs/C6aLHZxg293f36PJJG3BdYow21xxgMw657YrP+KUujWXwx0RtItbXTdN/t21e3igjWJGTzSS6qABg8t9Dmup+MqmT4N+JNgz/oZb8AwJ/SlO3LJ+b/ACT/AFKh8cV6fm0XdL1690vwbaXfiGyt4pnWGG1gsbprhrhnChBl448MSenIA5LYzVa88dXeg+JtM0vxXpENjBq8xgsby1vTcKZOySgxoUJ4xjcM9+9cX481bTdc+GXh/WNKFt4h0zQr20udUtokFwjQiMq6sOQSobJU9OpArf0ab4R6lJYz+GNO8K3d/K6PbQWlpbi5Q5B3FAu9NvUkgYxWr1m79/w0/wCCZR+Ben4/1Y6e98SXMmtXOj+G7CHUr6zjR7pri6NvDBu+6hcI7byATgKeMZIyK434a3El18XfiNLNbvbSGayDxOQSpERB5HBHHB7iqPhTxZYeDPil400XxneQ6W+oXw1Cyu7xxFFPEVC4DtgfKAB17H0qX4ea/pdx8bvHsSXsKy37WclpG7BWuFWE5ZFPLDGDkdiD0qaeuveP6rT5foXPRNdmju/Heq6rofgfVdU0GK1ku7S2eZftTsqKFUknAU7iMcDgH1FYvgXxJfW3wrstc8Xi0trSHTYrk3cd08zyrs3M7qY12seOFLcnr67XxAjeb4beI4413O2l3AAHc+W1eX3TxeM/2W00fwveRX2oWek2rT29s+9lMe1mjbHRiEb5TyfSpTSjL5fLe7Lsny+d/wBDu9T8eano2ir4h1Hw0yaAUSSSWO733cEbY+d4Nm0AZydsjEDt1rsLO8t9QsYLyylWa3uI1kikQ5DqRkEfhXF3vifSPEHwUutWiljntbzS3i8pTljKybfJx137jt29c1q/DrRrvw98ONC0rUc/arWzRZQTna2Mlfwzj8Kpqzku3/B/y/EyTuovvf8AT/Mz9Q+Ij6b8QYPC9x4evg1xBJPBciSNhcBB0RVJPJ4+bbjqeKpaV8ULu48Raj4f1rwlqGma1bwfabSxWeOdryInaCHUhFOeuWwOctxVTxDd26ftIeEoXmQSnSrsBM85PT89p/KoLiaIftVWiGRN3/CNMu3cM584nH1xzUwV+W/W/wCF/wDIp/a8rfjb/M3/AAd8QLnxD4k1Pw9rvh6fw/rGnxrObeS4SdZIWOA4dePqBkD1PNS/8JtfalLqb+FdGj1W10m4e2upZbzyGeRAC6wrsbeRnHzFBnjPeud0u4h/4ai1uLzU8w6BCAu4ZyJASPyIrN0XxHpXhXVvEdr4e8SeGo7O71WaR4Na1UWstpOcCUqm1jIm4HAOzoecHNG8U+tn96dg6v1X3NXO88IeOrXxh4ebXLbTb6w04IXSe8aHEgUkNgRyMRtKnO4LWl4ahkTRI7i4UrcXrNdShuqmQ7gp/wB1SF/4DXJeG9K0nTPhxpXhvw/q1vrMF7cGGa8t5FdJcs0k5+UkAEBlxnjIFeh9OlVKybt/X9foI83+GoC/EH4jBQAP7WiPH/XIVWgvW1v9pu4tJ2zBoGi5gjPRZZWXc/12kCp/hpIknxC+I2x1b/ibRdDn/lkB/MGmS2DeHf2iV1e5CpY+ItL+yRzHOBcxkEIT0yyLkeuDUw3h6f8AtontP1/9u/yI9Xvn0D9o3S/JZlt9c0aWO4jHR3gLOrH3A4z6GnfAm4bWvBup+IrsmS71rVZ55mbngEKq/QAYApZtMPij9oKLUoAsmn+HtLe3mmU5X7TKW/dg+oQ5I7ZHrSfB6NPCHh3W/DGryR2s2h38zsZG2hrZ/nSbn+EjPPsRRHSOvZ/+lf8ADfIqe+ndf+k/18xfgveTRr4s8PyMTBouuTw2qn/lnEzFlQewOfzroPiJ46k8A6D/AGqdDutTtwwWSSKaONIiSFUNk7uSeqq2O9Yvwb0W4tNN1/XruJov+Eh1ea+gR1IbyCx8skHpkZP0IqP9oKaOH4Oaj5rqm64tguT1PnKcD8AT+FPrBP8Aup/gmNWcpW7v83Yu678Tp/DuuaempeGL6LQL6dLZdZaZNokb7v7r74Xr8zbenANJf/E680jxbpthrPhO+sdG1W4W0s9Wlnjy8zfdDQj5kB9WIP8As9ayvjrcwf8ACudKkM0YSTVrNkYsAGG7OR+HNJ8cLiGIeB2klRV/4Sa1fJYD5RnJ+nIpwV5JP+a35f5kXuv+3b/n/kS/EL/ktXw0/wCu17/6KWvUa8r+Ic8S/G74ao0iB/OvDtLc4MYA/M8V6pSXwL1f5mk/iXovzZwHhrUD4o+K3iS8l+a18PbNNs16hZGG6Z/qflX2A96nuPiPJa/EGTwrN4bv1mFnJdwSeZGxugGCqI1UkfMc8uV2gZIHbG+EsB07xl8RNOmP79db+0kYx8kq7lP5U69uoB+1BpkJlTzD4ckUJnnPm5x+QJ/ClHXkXdf+2t/mJ2XO+z/VL8i7o3xQvL7VtV0PU/COoWGv2KLLDpqzxzG6jbO1hICEXpySdo6ZJq/4I8fT+KNW1XRdZ0GfQda0rYbizknWdSjjKsrrgH8u/U1z1pNF/wANVX6eYm7/AIRpF27hnPnA4+uOaXwrcQt+0j43iEqFzYWmFDDPCjP5ZH5046280/wb/wAhPaXlb8bf5m+fHd7f2uo6j4a0NdT0zTJpYZ5nvPKlmaP7/kR7GD4OR8zJkjjPWtXwd4th8aaHHq9lpt7Z2U6hoJLtoT5w5BIEcjkYIwQ2D7V5roHiLTPDlvrel+H/ABT4Zj0661G5aJdY1RbeexYnD4iwfMXeGKglDjHPNei/D7StI0TwJpmm+HtRh1Oxtoyq3cMiusrZJZsqSOWJ4zxRH4b+n/BFLSVvN/8AAOe8Yk6T8WvCviLU5lt9Et7W7tprqVtsVvK4BUux4UNjGTxkAd6h+Gclxpeh+JdWuYJUstS124udMtyPmmRyApUH++wJHtz05r0skAEk4A6msewH9sX66rIP9FiyLFf7wIwZvx5C/wCzk/xcKOmnl+bv+Y3/AF8lYjsbvT9KvktNU1SyTW9SPmmB7hRJIQPuxqTkqo4GB6k8k1l/FKGVPAN7q1kdmoaKP7RtJAOVePkj6Mu5SO4Y15pqZYeA/it/bZ/4nH9rnyf+emMR/ZNnf02475r0bxlcTwfA7V5dX+W6/sNxOP8ApoYcEf8AfRpSbUOZbpJ/hdfcXFL2ii9m2vxs/vudNoOrRa94e0/VrYYivraOdR6BlBx+tZGs+LXtPFFv4Z0Wyiv9ZntWvDHcXJt4YoVYLuZwjnJJwAFPQ5xTfhpYy6b8LvDlrcgiWPTodwYcglQcfhmsnUdal1L4uP4ZtXg0l7fSxcy6iI0N1Ohf/VRMwIVRjLHB9sEZrSokqjiu7/Uyg707vsv0NPw347g1rTdam1GzfTLjQZ3g1CJpBIqFF3FkcAblx0JAPsKksfFGpXNlZahNoarYahJCLaS3vBK6JJjDyrtAXqPuM/OOnUcF8Pr/AEO08U/EmxuLwXkLXfmtE8xmkmhEHztkkkr1GenIHoKibR9Q+G8mj6p8PfEcmp+GdQvoYP7EuJPtC7JWAzbvyeOuPQEknmpjq4+fL+P+f+Y3s7dOb8P8v8j2mvH7e+8Un9ojUhHpelyTpoUaiF9VlWNYvOOGDfZydxPVduP9o17BXmFhd25/af1WETRmT/hHYl2bhnIlyR9cEH8aI/Gvn+TFP4H8vzR1t74omfXrjQvD1jFqOp2sKTXInuDBBAGPyq0gRzuIBIAU8DnGRUfhjxpFr2q6jot9ZvpmuaYV+1WUjhwVYfLJG4A3ofXAPqBXJ+E528PfHTxfpersIm13yL7TZHOBcKibXVT3K+nXA9KuWWmNqH7Q1/rlmR9jsNFSxuJF+687SFtmfVVAJ9MiiOtr9V/X46FPS/lb9P01KnwY/wCQh49/7Ge5/pUHwavrbTPC/jO+v5lgtrbxFfSyyN0RV2kn8qk+Ck8U1949aKVHH/CS3DZVs8HGD9ODXI+G9NufE3wT+JGn6I4mup9bvHiWNsmQBkfaP94AgeuaV7Ruv5F/7aXJKVSz/nf/ALcemX3jzU7Hw+viZvDTSeH/AChO8i3f+mJEefMMGzbjGGx5m7HbtTfFPxAu9H0nR9Y0HSbXWNI1SWGIXj6gYBCZWARmHlN8nIyeoPajR/FOlaz8Gl1V5YzANNMVzETykgj2tER13buMdTketZnhrwJdP+zzb+E9W3Jey6e3D9YZWJkQfVWK/lVStFy7Jr5rW/5GcLyUb9b/AC2/zNTxx461XwbqejRDQ7S7sdVu47Jbt9RaLyZXz95fJb5eOCD+ArcvtX1SDxVY6Zaaba3FpcRNLPcveskkCqQCfL8shvvLj5xnnpjNeeT2tx8XPhPJM8bJe21gEgDZXbqCYLn8GRVB/wBpxXVfDXWJfFmgp4ouoXie8git1RxjAjHznHvK0n1AFFrXXb8un4/gHRPv+fX8PxRPb+NLy90ifXNP0ZbvRl3iKWG8Bnk2uVLeXt2hOCc7y2P4c8V1teI6voj+E9Du/HPwn8SPBZ+Ybi60OdxNbTuW+dFGSUkJONo5zwMV7TayvPZwyyxmJ5I1Zoz1UkZI/Cl0G9JEtFFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAo6pomla5biDW9Ms9RhU5Ed3bpKoPrhgRVq3toLS3S3tIY4IYxtSOJAqqPQAcCpKKAM6fw7ol1q0eq3Oj2E2oxDEd5Jao0yD2cjI6nvWjRRQBV1HTLDV7NrPVrK3vrZ/vQXMSyI31VgRT7KwtNNs47TTrWG0toxhIYIwiKPQKOBU9FAGZP4a0K61ZNVutF0+bUYxhLyS1Rpl+jkZHU96NX8NaF4gaI69oun6mYciI3tqk2zOM43A4zgdPStOigDCuPA/hO7t7eC68MaNPDaoUgjk0+JlhUnJCgr8oyc4FbFtaW9nZx2lpbxQW0SCOOGJAqIoGAoUcAY7VLRQBHbW0FnbR29pDHBBEoWOKJAqoB0AA4AqlfeHtF1O+gvdS0iwvLq3/1M9xbJI8X+6xGR+FaNFHW4GXq3hjQNfkjk13Q9N1N4QVja8tI5igPUAsDirVpplhYaaun2Nlb21kilFtoYlSNVPUBQMY5NWqKOlg8ytY6dY6ZYpZabZ29paoMLBbxLGij2UDAqvpvh/RtGmmm0jSLCwluDume1tkiaQ+rFQM/jWjRQBR1HRNK1hoW1fTLO/Nu++E3Vukvlt/eXcDg+4qWDTrK2uprm2s7eG4nOZZY4lV5DgDLEDJ4AHPYCrNFAARkYPIqrYaZYaVbmDS7K3soWcuY7eJY1LE5JwoHJPerVFAGZF4a0KDWH1aDRdPj1KT794lqgmb6uBuPQd606KKAMS58FeFr3Um1C88NaPcXruHa5lsImkZh0YsVzngc0h8E+FTqf9onwzo5vvN877UbCLzfMznfv253Z5znOa3KKFpsBhx+CvDFrqH9o2fhnRotQVzKlylhEsgc/wAW8LnOe/WvL4r61huTD49+DN9qmuzSkzX9lo8F9DMSxAbzWI2jGOG6Dr617ZRQM5Pwf4astOuLjVLbw5a+HvtSIqWMMcatGBnLMI/kV2yAQpPCrknt1M8EV1byQXMSTQyqUkjkUMrqRggg8EEdqfRQ9RLQxdN8GeF9HvVvNI8N6RYXSAhZ7WxiidQRg4ZVBrTvbG01OzktNRtYbu2lGJIZ4w6OPQqeDU9FG4EFlY2mm2cdpp1rDaW0QxHDBGERB6BRwKg1DQ9J1aaCbVNLsr2W2bdA9zbpI0TeqlgcH6Veoo63AKzNX8NaF4gaI69oun6mYciI3tqk2zOM43A4zgdPStOigDCm8DeErm3t4LjwtossNspSCOTT4mWJSckKCuFBJJ47mi58C+ErwQi88LaLOIIxDCJdPiby0GcKuV4UZPA45rdooAwbnwJ4RvJVku/CuiTyIixq8unRMVVRhVBK9AAAB2ArdACqAoAAGAB2paKAOY1PRrjTfFg8UaPCZ3ltxa6jaIQGnjU5SRc8b0y3HGQxHUCrR8GeFbjUBqknhnSGvXkE/wBpfT4vN35zuLFd27POeua3aKNgepiR+CfCsOpDUYvDOjx3wk80XS2EQlD5zu37c5zznrUcXgvw3ptwb/RvDOi22pRhmhnjsIo2DkHncq5Gc8ketb9FLpoB4na3thHLHbeNvgtqGoa9K3+k3trotveQzuTgv5zEAA+hPyjHavR/B2gwaRBdXNrolvoCXzI/9m26ooiwuMsE+Tee+3I4HJrpaKq4uo2WKOaJ4pkWSN1KujjIYHqCO4pQAqgKAABgAdqWikMo3GiaVealBqN3plnPfW2fIupbdGli/wB1yMj8KxvE2lT+LJk0OaB4tHSWOW/mkGPtIUhhCgzkgkDcx4x8oySdvT0UAAAAAAwB0Aqjf6HpOq3NvcanpdleT2x3QS3FukjRH1UkEr+FXqKAKsWl6fb3FzcQWNtFNd4+0yJCoabAwN5Ay3HHNRQ6DpFtqsmp2+lWUWoSjbJdpbosrj0LgZP51fooAK5//hAPB32n7R/wieh+fv8AM83+zYd27Od2duc55zXQUUeYeRS1TRtM1u1+za1p1pqFvnd5V3AsqZ9cMCKfHplhDpv9nRWVulj5Zi+yrEoi2EYK7MYxjjGKtUUAYdp4I8KWHnfYfDGjW32iJoZvJ0+JPMjbqjYXlTjkHip9J8K+HtBuHn0PQdM02aRdjyWdnHCzLnOCVAyPatWigDMHhvQhrB1caLp41I9b0Wqecf8AgeN361p0UUARW1pb2cJis4IreMszlIkCjcxLMcDuSSSe5NLb28FpAsNrDHDEv3Y41CqO/AFSUUAZ7eH9GfVItSfSbFr+FdsV0bZDKg9A+MgfQ1oUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFNd1jjZ5GVEUZZmOABWbp3ibQdXWY6TrenXwg/1ptruOTy/97aTj8aANSiiigAooqvdX1tZNCt1MsbTyCOJTy0jHsAOT6+wBPSgCxRRRQAUUUUAFFFQQ31vO1yI5QfssnlzEggK20NjJ4PDDp/SgCeiq9nqFlqCymwu4LoQv5chglV9j4B2nB4OCDj3FN1HU7DSLNrzVr23sbZPvT3Mqxov1ZiBRsBaoqK2ure9tY7mznjuIJV3RyxOGVx6gjgiqt9ruk6XdW9tqeqWVnPcnbBFcXCRtKfRQSC34UdbB5l+iiigAooooAKKxF8Y+HpPFX/CNxarby6xtZms4yWdAoBO7HC8EdcVp2l/a34l+yTrKYZDFKo6xuOqsOoP17EGgCxRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRTXdY42eRlRFGWZjgAVm6d4m0HV1mOk63p18IP9aba7jk8v/e2k4/GgDUooooAKKKr3V9bWTQrdTLG08gjiU8tIx7ADk+vsAT0oAsUUUUAFFFZ2ia9pviKwa90a5+026TPAz+WyYdG2sMMAeCOvSgDRooooAKKKKACiiigAooooAKKyfEPijRPCmni98R6nb6fbsSqtM2C5AzhR1Y4HQAmtG1uYryzhurZ98M8ayRtgjcpGQcHnoaAJaKxb/xj4a0md4dW17TtPkVzHtvLlINzAKTt3kbsBlyRnGcdasaR4j0TxAJToOsafqYhx5v2K6SbZnOM7ScZwevpRuBpUVXmv7W3vYLSedY57jPko3HmY6gHoTjnHXHNWKACiiigAooqtfalY6XbmfUr23s4QMmS4lWNR+JNAFmigHIyORVZtSsU1BLFr23W8kBKW5lXzGAGThc5OARQBZopskiRRtJKyoijLMxwAPUmqWla9pGuxSSaHqtjqSRttdrO5SYIfQlScGgC/RRVa+1Kx0u3M+pXtvZwgZMlxKsaj8SaALNFAORkcis1vEehprA0ltZ09dSbpZG6Tzj/AMAzu/SgDSooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPMvjjPqNl4Z0rULeyl1DSbLU4rjV7SIZMtuuSQR3XOMg8dM8ZrSjufB3xc8Lxy6PNZ3rWzpNBkBZbOVSCuR95OmPQjPUV1Wo6zaadqOnWV6yodSkeGEu2AzhS233yAfyryX4qfDfTvDNhc+PfA0reH9csWErLattiu8sAUKdMknoOCeoOc0J8u+1/u2Hbm23se10Vg3Hiyw0nTbWXXnkt7l7dJriKK3kmNuCOWk2KdiAgje2F4PNJc+OPDdpfS2cmqwvcQxJNLHCrSmNHKhWbYDgHcvXsc9OadtbEp3VzfJwMnpXC/D3UP8AhLbjVfF0/wA8ct1JZacvJ8q2ibaSB2LuCxI64UdhXZ3yPLp1xHF994mVecckHFedfs+Ap8GNLhfiSGa4jkXurCZ8iiP2n2X5/wDDfiN/CvX9P6+417f4q6Bd6hqtjBb6s11paoZYDp0gmkZ87USIjzGOF3fdxgg564j034taBq3h+51Gys9XkurWZoJdIWxZr5ZAMlfKXPr1zgdyKzfCuw/tB+OvulxZ2OPXGw5/pUPw6H/F5viZ/wBfNn/6KNEVdfK/4pfqOfuv5r8Vc7Hwd410rxxo8moaP9oi8iVoLi3u4vLlt5B1R15weexNZ918SdLtrGbVEsNSudDt2ZZ9Yt4ka3jKsVY7d/msoIxuVGHv1rnPhSiy6/8AEiJ2wra/KGIOCAV61V8N6ZrVv8JrjwfpOmjVrW4hubaw1kTRJbNC5bDyKW8wEZP3UYHAOealu6uuyf3r+v6Q7JSs+7X3M9FsPFGmanoE2s2ZuRZQxmQyXNnNb7lC7tyiVVLLjuOPel0XTAPDsMOpwRyyzk3FxHIoYea7eYRz6MePoKyINFGi+FPDvhFJjOFWKCWTGN0UKhnJHo20L/wOuuq5JJu239f18iE3ZXPMfgfDHb6Z4shgRY4o/E14qIowFAK4ApdB1BvFHx88RfaiXtvDFrDbWcTHKrLKNzyAf3sDbn0+tO+C3/Hn4w/7Gi9/mtQ+ELF9C+P3jWC6Gz+2ba2vrRif9Yi5R8e4Y/y9aa+KP+Fffyr9LjltL/F/7d/ww7S9YPhr43eI9ABK6Zd6Yusxw/wxSg7Zdo7bsbj789zS/B5U8WeAr/xDrca3Vx4jup2uBKA2IQxjSL/cUA4HufWq8GkyeIf2g/Ed/ESbSw0NNMeTsJpPn2j3CnJ9MirfwJU6V8LxpF9iG70a8uba7Rj/AKthIWyfbDA59KmNuTXt+F3+nKEr307/APtv+d/mT/BfXLvU/CmoaZqM0k8+hanPpolkOWeND8hJPU4OPwre8U+PdI8H3lha6tFfF7+eOCF4bRmj3u20AyHCA9TjdnAJx0zy/wADNOmi8L6xrEysE1zWLm+t93Voi2Fb8cE/TFP+N+z+wvDQk27T4ksshumNzU3fmjfry3+drgkve8ub8Lmsfir4ei8Ww6Ddx6jZm5DG21C6tGitLkqMkRyNjdxzuxtPGDzS6f8AFLRL/wAZR+G5LPVrC6uAxs576xaCG92jJ8pm5IA7kAHtmsL4yj/ib/D/AP7GaAfhg074lHHxW+Gmf+f+5/8ARa0o62v3t+X+YPrbtf8AP/IXXAP+GlvDBxz/AGLdfzrT8d3w8Ia5oviiH5IZryPTdTUcCSGTIRz7o+MH0Zh3rM1wj/hpbwwO/wDYt1/Oj9oFGm+E81vCcTz31rHD6lzKuMUobQ9fzk0J/FP0/wDbUenUUyFWWCNXOWCgE+pxT6AWqCiiigYUUUUAFFFFABRRRQAUUUUAFYmoa9qNlfSQW3hPWNQjXGLm2lswj8Z4Ek6tx05UdK26xNQ8Jadqd9Jd3NzrCSSYyttrd5AgwMcJHKqjp2FAyt/wlGr/APQieIP+/wDp/wD8lV0UTtJCjvG0TMoJjcjKn0OCRkexIrnf+ED0j/n88Qf+FHqH/wAfroooxDCkaFiqKFBdixIHqTyT7nmgnqOooooGeZfHGfUbLwzpWoW9lLqGk2WpxXGr2kQyZbdckgjuucZB46Z4zWlHc+Dvi54Xjl0eazvWtnSaDICy2cqkFcj7ydMehGeorqtR1m007UdOsr1lQ6lI8MJdsBnCltvvkA/lXkvxU+G+neGbC58e+BpW8P65YsJWW1bbFd5YAoU6ZJPQcE9Qc5oT5d9r/dsO3NtvY9rorDn8UWelaXZza4ZYbmW3WWWCC3kneLgbmZY1YqgPBYgAetRTePPDENy9v/a8EsscKXDpbhpSkblQrnYDgHcpyexz05p21sSndXOhJwMnpXC/D3UP+EtuNV8XT/PHLdSWWnLyfKtom2kgdi7gsSOuFHYV2d8jy6dcRxffeJlXnHJBxXnX7PgKfBjS4X4khmuI5F7qwmfIoj9p9l+f/DfiN/CvX9P6+417f4q6Bd6hqtjBb6s11paoZYDp0gmkZ87USIjzGOF3fdxgg564j034taBq3h+51Gys9XkurWZoJdIWxZr5ZAMlfKXPr1zgdyKzfCuw/tB+OvulxZ2OPXGw5/pUPw6H/F5viZ/182f/AKKNEVdfK/4pfqOfuv5r8Vc6nw38QdG8UeGbrWtNjv8AZZu0VzaPaObmGRRyhiXJLc9BmrXhjxjpXivw7JrmnmaGxjkljZ7pPLI8s4ZiCeBx3wfUCuN+EZ/4qb4if9jDJ/KuT0yK7uf2XPFCaZueb7VekiPklBPlxx/s5qbq1/7qf32/zGo+9y/3rfn/AJHpt78SdK02G1vtQsdRttGu3SOHWJIk+zsXOFyN/mKD2ZkC+/NGsfE3QdD8UQ6BfRal9tmR3i2WEhWXau7EZx+9J4ACbuTireiax4f8VeAbXUQ1pd6VJbo8izKrohUAlWByAVI6HoRXLeJpEb4/eAmYFN9hfbVYYIOxTj61fLafJ6/k3+hlze5zen5r/M6i18c2E2g2upXthqmlveXBtrawv7Qx3UsmTgLHknkDOegHJwM0WHjiyuPEMWhapYX2iapOhktrbUFj/wBIUdSjxu6MR3XduHpiuV8dXUmm/GzwDe3pK6ZJ9qtVdj8iXDphc+56D8al+Lmny6hqvgZdOB/tFPEETxMvVYlVmlP0wBmiNnZ93b01t/wfT7y3pddlf9f+B6m0fidoI8T3ugtFqSXtlbtcSK9hIu9QwUCNSN0hYn5dqkHBwar6T8WfD+r2uosltq1te6dII5tLuLFxeFmyV2wrktkAnjoOTisqMof2o5wdu4eF1xnr/wAfFJoIH/DSvirj/mD2v86lK6j5p/g3/kEtL+Vvxt/mdP4M8faT43t706fDe2N1YSeXd2WoweTPbk5xuXJAzg96iuviHYQafJqlvpmp32ixbvN1W1iRoUCkhmClxI6jB+ZEYd8157BDfXPjz4ywaSWF9JYW62+w4bebdsY9812/wovrLUvg3oRjKGGKwW3nU/wsg2uCO3INN/DzLsn99/8AIdrSs+7/AE/z/AqfFq/tNW+BGu32nzx3NrcWIkiljOVdSykEV0+i3cVh4D0+7uG2xQabFI59AIgT/KvG7Oyn0/8AZE1pJtwt5BPJZh+ogab5Pz6j616lD/pXhLwzpS8/bYbfzcf88kjDvn2OAv8AwOi2skv7v6/kS9436c36fmc98SrFoP2fNcF7GpuZLU3MwbnbK8gdvyJwPoK7HwPGkPw/0BIkCINOgwFGB/q1rD+NP/JGfEv/AF6f+zCt7wWc+A9BI5H9nW//AKLWiP2/l+opXvH/ALe/9tLWv6PDr2iXFhOWQyLmKVDh4ZBysinsynBB9qx/hx4nm8WeCLW+vQq38LPa3qqMATRttb6Zxn8a6C2v4Ly4uoYCWNrIIpW7B9obb9QCM/WvOPgVFINC8S3BbdBceI7x4MdNu4DI/EGiO7Xlf8V/n+Q5bL1t+D/yOm8dePLbwDpq6jqej6re2OcSXFhHE6wknADBpFIz64I96sXfi77Ne6Lax6Fql0+rp5iG3EDLbgAEmU+aMABhyu4dgSSAdDxANPk0G6t9XhFxa3KGBrfGTOX+UIB6nOK85+HD3PgbxRJ4H8UOZJ5oRLot7JIX822X/l23HHzRkngDkHPpRHV2f9eX6+n4uWiuv68/6/4b1ivL/wBoGxtJPhRf3cltE1zHPbBJig3qPOXgHr/EfzNeoV5v8ff+SOal/wBd7b/0elEfij6r80NdfmejRf6lP90V5lq1haWf7R3heS0tYYHm0q8MhjQLvOQcnHXlj+demxf6lP8AdFec69/ycR4T/wCwTe/zWj/l4vn/AOksz/5d/d+aO51fRbHXbVbXVYRc2gbc9s/Mc3oHX+Id8HjOM15/pXhXw9bfGmK/8EnTrBLCwki1e0sGRFdnI8pTGvAIwzE4HRa9NkjSWNo5UV0cFWVhkMD1BFeS614A0zw98XvCGq+CrKLTLi4mmjv7a0XZG9uI8s5QcAAkDjGSy96I6TX9dLFy1i/621PXK8v/AGgbG0k+FF/dyW0TXMc9sEmKDeo85eAev8R/M16hXm/x9/5I5qX/AF3tv/R6UR+KPqvzQ11+Z6BNFJPprwwzGCSSIqsqjJQkdQPUV5x8Qfhj4Mi+G2sTQ6NZ2V1Z2klzFqEUQFwJUUsGaX7zEkc5JzmvTYv9Sn+6KwLyBPFk627DdosEgaYnpeOpyEHrGCMnsxGOmczJX0Qqbsk2S+CpNRl8CaI+ubv7RaxhNzv+9v2DOff1rcqKC4huUZraRZEVihZDkZBwRn2PFS1cnzSb7iirJIKKKKkYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBn6toOk66kKa1p1tfLA2+JbiMOI26blz0b0I5HaqMHgvRIL5Ltobq5kjffEl5fz3McTdikcjsiEdtoGO1b1FGwbnBa9B4v0bxldaj4f0K18R6bq0EMFxbTXy2zWrJuG7LBgyENyACc9qk07TdXi+K/wDaMuhyW+nDRo7EXEUsPkrIHLkKu/ftGdoO0c9sc13NFC0s/wCtmv1B6pr+t0/0CuN0XTj4K8RahaCJv7F1m7N1bSouVtbh/wDWRtj7qsQGU9Mkg4+XPZUULe4dLHK6d8NvDGk+IptdsLa9j1O4BE1ydUunaUEYw+6Qhh6A5xgY6Ck0n4aeGND1S71LS7a+gvb1StzP/a12zTZBGWJlOSMnBPIPIINdXRQG5xlr4G0TwNaavrHhLR7qbUpoJJHtzqM8n2x8EgMJHZSxP8RGeT615HYWXwEvJIrbWNEvrbXpQDPpzW2oJMJCNxURx/KPYDjFfR9FHXUfQ5TwR4ZtNE0/daWt1a2yM66fb3kzySWtuwTKfMSQCybsEkgEDjoOlvLSO+s5bWdpljlXaxgmeFwPZ0IZT7gg1NRTbvuStDnfDXgPw/4RuJ5fD9vdWxuGZ5UfULiVHZsZco8jKWOB82M+9aGr+H9N1xYv7RgcyQkmKeCZ4Jos9dskZV1z3wRnvWlRS3GU9M0qx0ayFpplslvCGLlV5LMTksxPLMTySck1Q1LwdoWrXr3V9ZM0koCziOeSJLkAYAlRGCyjHGHDVt0UdbgNjjSGJY4kVEQBVVRgKB0AFc94o8A+HfGclu3iS0nuxbENCi308SIwz8wVHVd3P3sZ966OigDlNZ+GnhjxC9k+tW19dtYBRbGTVbvMRXowxL9//b+8e5o1f4Z+F9e1K01DV7a+ubuyCi2mOq3SmHAABXEow3AJYck8kk11dFAHLXPw38M3niiPxHcWt42rxYEd0NTulZAP4QBJgL1yuMHJyOTUGq6aPGfibTQ8THRtEuvtTu6kC5ulBVFUEcqmSxbpuwBnBx2FFC0t5AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcp4mv/AAxdXgsfEWi3+pNaMHjxoF3dxoxUEMjpEybgD1U5ByODmsiC48GwXyXbab4quZI33xJeaXq9zHE3YpHIjIhHbaBjtXoLMqKWchVUZJJwAKgs9QstQWU2F3BdCF/LkMEqvsfAO04PBwQce4oXkD8zg9TuPFEXiZfE3hDQ/wC3tO1S0SzuLC/kbTprcxvJiTEyZ2ne2RtyeCMg1JY2mq6d8R5NYu/D01rpcGhLaGSzMcsaMrGQrHGjeawA+UYjBJHC4rW1nwp4AtFuNV8Q6D4bgWSQyT3l9Z267nY5LM7jkknqTyaW28BeAL21jubPwp4buIJV3RyxadAyuPUELgihaa9v1v8A5hLX52/C3+SJf+E80j/nz8Qf+E5qH/xiuS8P+ItN8I69q1vFYa6ND1K4N7DJ/YF8v2adyBJEQYQcM2GXGeSwOOM+o1QOu6SusDSW1SyGpFd4szcJ5xX12Z3Y98ULcOhwGnWXgHSfEU2u2GleLY9TuARNcmw1p2lBGMPuUhh6A5xgY6Ck0mw8A6Hql3qWl6X4ugvb1StzP9h1pmmyCMsSpyRk4J5B5BBr08nAyeBVHTtc0nV5J00nVLO+e3fZMttcJIYm9G2k4PsaPIH3Z55pOm/D/QpL+TSdJ8XWsmoqVu3Sx1rdNk5LElfvdfm+8Mnnk1c8LN4H8F209v4b0fxLaW9wd0kLaPq0yE+oWSNgCe5GM8Z6V3t9qFnpdm93qd3BZ20Yy81xKI0Ue7EgCnWd7a6jZx3en3MN1bSrujmgkDo49Qw4IoA8xsdC+F2m+Ijrlj4P1SLUN29XHhzUiiN/eWMxbFPHUAVPq1r4D1vxFHr2o6X4tfU4hiK5j0/WojCMYwgRQEBHUKBnJ9a9Noo2tboHfzOM1bxD4W17TG0/WdG1q9tWwTHN4a1BuR0IPkZBHqOar6VqvhTRpRLZ6f4nkmVSiz3mjardSIpxlVeWNmVeBwCBXd0UAeZJZ+Ak8WHxKuleLBrBbJu/7P1nJGc7cbcbP9jG3HGMUWVn4C0/xNJ4htNK8WpqsuRJdNp+tM0g9GBUhh6AjAwMdBXptFGwbnmWi2ngLw/4gl1zStJ8VxalPnz7iTTtZlM3GPnDoQ//AAIHFTFfAn2+4u49D8RQm6YtcwQaLqsUFwT1MkKxiNyc8llOa9HooA4DxHeeDfFmjppWu6T4knsFIP2eLRNVgQ46AiOJdwHYHIFS6Pq/hTQYLaHTdO8TKlrE0MHnaLqs5jjJBKgyRMcfKvHbAAruqKNgPPvE114O8YWotfEOm+Kbm2AwYI9K1eGN+QfmSONQ3IGNwOO1Ura08E2dpHa2kHjuC3iUJHDEmvqiKOgCjgD2r06igDzb/hJdC8LeF5tI8GaRrwupN7wxS6LqLHe7fNK7yRFmALZPU9h2q74U1nw94S8L2Oi2Np4haO1jw0h8N6hmVzyzn9x1LEn8a7yincDg9b1Lwl4iurG51XT/ABQ8uny+bbNDpGrQ+W/97EcagnHHOeCR3NUfEUPgTxXq1rqWu6R4puLuz/49pE0vWIvJOc5UIgCnpyBk4HoK9KopAcynjnR441RbTxEQoABbw7qLH8SYcn6msLxRN4L8ZW6QeI9L8UXUCciBNJ1eGMnOQWSONQxB6EgkV6HRQGxyGm+K9B0nT47O0tfFDQx52m50TVJ35OeXkiZj+J46Vg3lr4Fv/ES69c6d4wbVEzsuVstbRowTkqoCgKv+yAB7V6bRR1v1DpY4TX9T8I+J4bePWdK8RzfZZPNgeLQ9UhkifGMq8cSsODjrVjTvEXhrShm00/xI0hQI09xoWpzyso6AySRMxAyeprs6KAOIuNa8KXXiO016fSfED6lZxPDBP/YGpDYjfeG0Q7Tn3FU/FE3gvxlbpB4j0vxRdQJyIE0nV4Yyc5BZI41DEHoSCRXodFAHEx694bi0F9GFr4rezdGjbzNJ1Z5drdR5rRmTv/e47VxH/Cufg1/0JviD/wAFes//ABNe20Udbh0sYHg+bRYtHj0rw3Y39jZaeixxxXen3NthTnG0zopfockE4zz1Fb9FFNtt3YbaIKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUARz28N1CYrmGOaMkEpIoYEg5HB9xmvNfgfDHb6Z4shgRY4o/E14qIowFAK4Ar06vNPgt/wAefjD/ALGi9/mtVDeXp+sQl8K9f0Y3QdQbxR8fPEX2ol7bwxaw21nExyqyyjc8gH97A259PrT9B1GTRPj1rvheIkafqOnpq0MP8MUu7ZJtHbd94+/Pc1B4QsX0L4/eNYLobP7Ztra+tGJ/1iLlHx7hj/L1p2lWMmq/tKa1rEOWtNJ0iKwd+3nO3mbR7heT6ZFEfsejv9zv/wCTBPeXqv0/T9TrPiD4hk8KfD3Wtagx51pas0OenmH5V/8AHiK5ey8NLJ+z4LcszX8+mf2gbvJMhuynmibd13B8HPXit/4o6HceI/hdr2l2SGS5mtWaJB1d1IYD8SuKyLTX7ZP2dk1ZX2pHoG3G7kSLFs2/XcMfWspX5Jtb6fr+pcfjgvX9P+CchrHji88V/DPwBYtOUn8V3sVrfuh2l40bEwGOm4jB9iRXTfFy5PhHTvD3ifSlW2fStRht5BGuA1rJ8rxHH8PCkDsQDXFXXhS78LfDz4W6jfQsg0PUopL8MceQk75Jb0wxUH0rs/jlaS654d0Pw7ZgyXOraxBGqKedi5d2+gAya6JfHp/P+Hu/pf8AExjfl1/l/wDkv+ALZagfFH7QmoWk7b7Lwxp8ZghblRcTYJlx/eCHaD2yfWn2Woy6F+0Ld6DCduna3pQ1ARfwrcIxVmUdtyjnHUgGoNAsG0H9o3xELhSseu6ZDc2shPDmLCOo9xwcehpy2Mur/tNSahCC1romhrBM4PCzSuxCfXac/lWcfsej/X9f0Ll9r/t3/wBt/S/4np9FFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAhvLSO+s5bWdpljlXaxgmeFwPZ0IZT7gg1h+GvAfh/wjcTy+H7e6tjcMzyo+oXEqOzYy5R5GUscD5sZ966KihaaoDN1fw/puuLF/aMDmSEkxTwTPBNFnrtkjKuue+CM96m03SbHRrH7HplslvBksVXq7HksxPLMT1JOT3q5RQBzfg/wrZ+F475dMtXsLS7m85bRrl5tjHO5iWZgCxPIU44Hcmpv+EJ8P/wBofbP7P+bzfP8AI86T7P5ud3meRu8vfnnft3Z71vUySWOFQ00ixqWCgs2ASTgD6k8UdQGXdpb39nLaXsEdxbzIUkilUMrqeoIPUVm6V4V0fRrw3VlbSG42lFluLiSdo0OMohkZiicD5VwOOlbFFGwGfq+hadrkcS6lAXaFi8M0crxSwsRglJEIZDjjKkU/StHsNEszbaZbiGNmLudxZpGPVnZiWZj3ZiSau1XstQstTgM+m3cF3CrtGZIJVkUMpwy5B6g8EdqALFFFFABRRRQAUUUUAFFFFABRUN3e2thbPcX1zDbQIMtLNIEVR15J4FSRSxzwpLC6yRyKGR0OQwPIIPcUAOopkc8UryJFIjtE2yRVYEo2AcH0OCD9CKfQAUUwyxiYRGRfMKlgm75iPXHpzT6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArE1Dxbp2mX0lpc22sPJHjLW2iXk6HIzw8cTKevY1t1iahoOo3t9JPbeLNY0+NsYtraKzKJx2MkDNz15Y9aBlb/AITzSP8Anz8Qf+E5qH/xiuiikE0KSIGCuoYB0KkA+oPIPsea53/hF9X/AOh78Qf9+NP/APkWuiiRo4UR5GlZVAMjgZY+pwAMn2AFBPUdRRRQM82+NXiG68O6BpExa5i0ebVIotXntSRIlvySMryoJABI57d6uN4R8La74WS88B/Z7FXZJo7jRZBAtwVIJSXZgOCMgh89fWuu1N9PnMWlapFHNHqIeMQzKGSXC5KkHrxk49jXjPjH4e3fwohu/G3ww1Oawt7ciW/0WZy9vNHkZ256Y9Dk+hHShNR377/d+A2ubb7v66nutFZTeI9MtNHsdQ1m9tdLS8RCgvJ1i+ZlB2ZYjJ56VZutZ0yycJe6jaW7EBgss6ocEhQeT3JA+pFNpp2JTTVy5XE+Er9fGmsaj4hm+fT7G7ez0qMnKDy/lknx/eZsqD2VeMZOevvvM/s658nPmeU2zHrg4rzr9nzP/CltK3/6zzbjfnru858596I9X2/X/hvxG/hXm/0Oli+JHg6dNReDxFYyRaYivdypJmOIMSo+f7pJIIwCT09RTIPib4NufCcniWHX7U6TE/lvcNuUq/8Ad2Ebt3ouMmua8L2sD/tC+OJHhRnjtrF0JX7rGMjI98cZqD4cWlvH8ZfiOEgjUQ3ds0QCD5C8RLkehYgZ9aIq6+V/xS/UcrRfzX4q53Wl+NPDmteGZPEGnaxay6TGCZbpm2LFjrv3YKn2IB5p3hXUfDup6K114Ra0OmmeQF7SLy42kDfOegByf4u/XJriPg+iRa/8QoolVI18Qy7UUYA47CuV0u6vLD9l3xPPpjNHMt1ejcnBVDPhyPT5Sam6tfyT++3+Y1H3uX+9b8/8j1p/HnhyK9htpdQMYuJBFDcvbyrbSuTgIs5Xy2bPYNmkvviB4T0zWZNJvtfsYb6JGeWEy8xKq7iXI4Tjn5sdvWmx6V4c8W+ALC2uba3vNEltoZYkztQKoBUgjGMYrk/FMdtdfH3wCzxpIn2K9kj3r0IRSpGe4q+X3uX1/K/6GXN7nN6fn/wTstN8b+HNX8OLr1hqkUmmPKYUuGVk3Pu27QGAJJPAAHPbNSaT4v0XWtQk0+zupI76NPMazvLWW1m2f3xHKqsV/wBoDFcb40vXj+OHgG1vf+QfILt4wR8puBHhT9QDx9ab8XbWVNd8C6npYxqkWvRW8bKPmaF1PmKf9nC80o2dvN2/G35/gW9Lrsr/AK/15nWL8QPCcmp3thHr9k9xYQvNdhZMrAiEKxdvurgkDBOfyNQ6b8SvB2r6FeazYeILR9PsW23MzEp5RzgZDAHntxz2zXLi1gm/ahmMsKOV8NI43Ln5hccH6io9Bs7YftK+KcW8X/IMtZ/uD/Wfd3/72CRnryaS1UfNP8G/8glpfyt+Nv8AM7nwv4x0DxpprX3hjUo7+3R9jlVZGQ+jKwDD8RzUN9478OabK63d+6xRuUluktpXtoWBwVedVMaEHghmGK8xtZbvT/HHxmk0Rdl3HZQSwLGv/LT7O5yB655+tdx8M4dP1T4KaFb7I5bS40xY51IyGJXEmffduzTfw8y7J/ff/IdrOz7v8Lf5lL432en6n8Gtaup7e3uzBbia1mZFfy2JHzo3Y4PUdjXW+H5o7bwTpk8zBY49Pid2PYCMEmvFrEXafsh61DdyNLFALiG0kc5LQrNhfw4OPbFepr/pHgXw/pa9dSgt4HH/AEyEYaT80Vh9SKLfEl/d/G/9Ml7xv05vwscf8UPD2n3vwN1bVtW023l1PyGvI55YlMtu0jq21W6jA2rwedtdj8N/D+kaJ4G0l9I0y0s5Lqwt3uJIIVR5m2A5dgMsck9fWqPxp4+DHiTH/Pp/7Mtb/gv/AJEPQf8AsHW//otaI7Tt5fqKV7xv5/8AtpJ4k0X+2dLYW8httQgBksrtB80EuOCPUHoR0IyDVbwN4nXxf4OstX8sQzyKY7mEH/VTIdrr+DA/hituO5hmnmhjcNJAQJAB90kZA+uMH8R615n8C/OGieJ9/wDqP+EkvPI9NuRnH45ojrdeV/xS/X8By6Pzt+D/AMvzPUaKKKQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDjPF8vhzUdRtrbXLXX5J9MmE9vLp+mX7LHIV4ZZYIyGwGIxuI5II4xWRNcaJfyBddv/GmsWSyCRbC78O3Swgg5XPl2iM4BA4dmHHOTXpEkiQxtJK6oijLMxwAPUmqGleIdF10SHQ9XsNSERxIbO5SbYffaTihAzhNZ1+8sfFX9s/8IrrWvaFq2nrZRpa6ewuLZ1kferwy7GVHDD5jgfKO2KrabYadY/E24mfwxe2unL4digkVtKlmUujFxGXVGEjiMKOC3ICgk4FdTrnhn4eWPnan4l0TwxbedIXlu9QtLdPMdjklncckk9Sckmls/A3w91G0jutP8L+Gbq3lG6OaDT7d0ceoYLg0R017f8H/ADCWt/O34W/yRP8A8J5pH/Pn4g/8JvUP/jFcZ4P8S6T4K1DVNGltdbi0y8vmutLkbQb1ctKCzwBTFuJUqWHGNrexr1eq2oXFjbWok1SW3hgEiAPcsqrvLAJy3Gd2Me+KFv8AgHSx5fpFjoWj+M73xPDrPjye/wBQUJdCfw9OY5VAwo2iyGNvGMY6d8nJoNjofh7xDqmtWmt+PZrzVh/pjT+HZ2WRgpCvtFkACueMceoI4r1mijbT5A9dzyPw9puheGbrWLjTdc8fGbWGaS6ebw9O/wC9P/LVR9iwG5Ptz04GLXg238MeC9Gu9JtZvGOpafdszPbal4eu5FBb75BW1U/N3BJH616lRR/w3yD/AIf5njmieGvBWgag0mnT+Pl07cXXRjp2p/YlJOT+7EALD2YkHPIq5rdpoWueM7PxM+r+OrS+sFZbNLbw7P5durLhgFeybOe+4n+Ver0U7vTyDv5nA+JNS8KeK9NitNY0/wASObeVZ7eeLw/qMcsEq9HRhBwf09qZp+qaJbXtve6nN4u1q7tQwtp7/wAOXeYQwwdqxWqLkjjcQWwSM4Neg0Utg3PJ0stBT4gnxj/a/js6kyeSUPh248ow7s+Tt+x52++d3fdnml0600PTvHFz4rTWPHc2oXaCKdJfD1wYpIx91NosxgDjGCD78nPq9FG1vIHre55P4fstA8PeLr/xHFqvjq8vNSAF6l34euDHcYGFyq2a4x22kflxU1lbeGdKa5g0W58a6bpl07PNpdtoN75BZs7ipa1Mkec9I3UemK9SooA8z8Tjwv4m8Hp4Yx4s0rSlVY2g03w5eJvRcYQlrVsDgdMe9XdE1bRNFgsI2l8XagbC3a3gkvPDt4WCHb12WqgkBAAcZxnOc139FO71fcOx5v40utE8b6Q+lXt74zsbCZds8Fj4dulEwyCNzPaMwxj+Ej3zVXT5LbS9Mt9PsfFnxBjtbaJYYkPhhmKoowBuOnknj1NepUUtgPNLbxZo3g3w7cWenjxRquqXTyzQ/b9FvBPeTkZxkwKvAA6AYUVp/DBNO0fwza6BZx6mbqGNri6nu9JurVJZWbMjBpY1BJZuFznA6cGu1MUZmEpjXzApUPt+YD0z6cU+ncAooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcB8Xv7Qg8N6dqNnYSanY6dqUV1qVjEMtPbrnI2/xYO1se1V49WsPiF4h8L6x4KlEtvp0rTXl+q7RHE0ZX7Mc8lmJUle20E/w51viBq9zZTeHtLhka2ttZ1NLO6ulYqUj2s2wMPulyoXPUZOOcGuV1nwgnw98faFr3gb/AEG21fUI9P1PSY+IJlYH94qfwsoBPH6c5cN/n+Nl+G3/AAwS2+X4a/juWPEniKHwV8ZotV8WwuuiahYR2ljqTLujsZgzF1bj5N+Vyf8AZHYHHQ+D7OaXxT4g1+1Q2+j6oYDaxFdvnuqkPcbewfKgZ5IUH0qjdLb+M/iTrfhjxJapPpOm2MEkFlKDtuWl3bpSO+3aFHocnrjFP4daVfeDPHOt+DYb2a90C3tYr6w89tz2nmMymHd6fKSPYfWiO1n52++/9f5hPdv0v+Fv0/4Y9M6da8d+L3maxo+k6qXYWNvrlnHZIrECUmTDyn1B6L7ZP8Qx6J40sdd1LwrdWfhaWyi1CYqoN8zrEU3DepKfMMrkcc89R1rx34nR/FGLwxpkevr4NSzTVbRYF04XQYSh/wB2Du42Z645x0pR+Jeq/NA/hfo/yPoCiszw7/bv9hw/8JZ/Z39q5bzv7M3+Rjcdu3f83TGc981p03owCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFXUtLsdYsXstVtIbu2cgtFMgYZByD9QeQe1UdM8K6VpNws9tHczTICI5b29muniB6hGldigOOi4rYooAytX8M6Trk0U9/bOLmFSsd1bTyW86KTkqJY2VwDjkA4NWNL0ex0aB4tPg8vzCGlkd2kklbGNzuxLOcADLEmrtFGwGZonh3SvDqXaaNa/ZlvLl7qceYz75W+83zE4z6Dil1vw/pniOzitdZtvtMMM6XMa+YyYkQ5VsqQeD26VpUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==" /></p><p>Where 113.12 is the molecular weight of creatinine.</p><p>For women, this result should be multiplied by 0.85.</p><p><strong>NOTE: </strong>These formulae cannot be used for creatinine clearance in children.</p><p>In practice, this will mean that most patients will be maintained on 0.125 to<br />0.25 mg digoxin daily; however in those who show increased sensitivity to the adverse effects of digoxin, a dosage of 62.5 microgram (0.0625 mg) daily or less may suffice. Conversely, some patients may require a higher dose.</p><p><strong>Neonates, infants and children up to 10 years of age (if cardiac glycosides have not been given in the preceding two weeks):</strong><br />In the newborn, particularly in the premature infant, renal clearance of digoxin is diminished and suitable dose reductions must be observed, over and above general dosage instructions.</p><p>Beyond the immediate newborn period, children generally require proportionally larger doses than adults on the basis of body weight or body surface area, as indicated in the schedule below. Children over 10 years of age require adult dosages in proportion to their body weight.</p><p>Oral Loading Dose:<br />This should be administered in accordance with the following schedule:</p><p>Preterm neonates &lt; 1.5 kg&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 25 microgram/kg over 24 hours<br />Preterm neonates 1.5 to 2.5 kg&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; &nbsp;30 microgram/kg over 24 hours<br />Term neonates to 2 years&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;45 microgram/kg over 24 hours<br />2 to 5 years&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 35 microgram/kg over 24 hours<br />5 to 10 years&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 25 microgram/kg over 24 hours</p><p>The loading dose should be administered in divided doses with approximately half the total dose given as the first dose and further fractions of the total dose given at intervals of 4 to 8 hours, assessing clinical response before giving each additional dose.</p><p>Maintenance Dose:<br />The maintenance dose should be administered in accordance with the following schedule:<br />Preterm neonates:<br />daily dose&nbsp; &nbsp; &nbsp; &nbsp; =&nbsp; &nbsp;20% of 24-hour loading dose (intravenous or oral)</p><p>Term neonates and children up to 10 years<br />daily dose&nbsp; &nbsp; &nbsp; &nbsp;=&nbsp; &nbsp;25% of 24-hour loading dose (intravenous or oral)</p><p>These dosage schedules are meant as guidelines and careful clinical observation and monitoring of serum digoxin levels (see Monitoring) should be used as a basis for adjustment of dosage in these paediatric patients groups.</p><p>If cardiac glycosides have been given in the two weeks preceding commencement of Lanoxin therapy, it should be anticipated that optimum loading doses of Lanoxin will be less than those recommended above.</p><p><strong>Use in the elderly:</strong><br />The tendency to impaired renal function and low lean body mass in the elderly influences the pharmacokinetic of Lanoxin such that high serum digoxin levels and associated toxicity can occur quite readily, unless doses of Lanoxin lower than those in non-elderly patients are used. Serum digoxin levels should be checked regularly and hypokalaemia avoided.</p><p><strong>Dose recommendations in renal disorder or with diuretic therapy:</strong><br />See Special Warnings and Precautions for Use.</p><p><strong>Monitoring:</strong><br />Serum concentrations of digoxin may be expressed in conventional units of nanogram/ml (ng/ml) or SI units of nanomol/L (nmol/L). To convert ng/ml to nmol/L, multiply ng/ml by 1.28.</p><p>The serum concentration of digoxin can be determined by radioimmunoassay. Blood should be taken 6 hours or more after the last dose of Lanoxin. Several post hoc analyses of heart failure patients in the Digitalis Investigation Group trial suggest that the optimal trough digoxin serum level may be 0.5 ng/mL (0.64 nanomol/L) to 1.0 ng/mL (1.28 nanomol/L).</p><p>Digoxin toxicity is more commonly associated with serum digoxin concentration greater than 2 ng/mL. However, toxicity may occur with lower digoxin serum concentrations. In deciding whether a patient&rsquo;s symptoms are due to digoxin, the patient&rsquo;s clinical state together with the serum potassium level and thyroid function are important factors.</p><p>Other glycosides, including metabolites of digoxin, can interfere with the assays that are available and one should always be wary of values which do not seem commensurate with the clinical state of the patient.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lanoxin is contra-indicated in intermittent complete heart block or second degree atrioventricular block, especially if there is a history of Stokes-Adams attacks.
Lanoxin is contra-indicated in arrhythmias caused by cardiac glycoside intoxication.
Lanoxin is contra-indicated in surpraventricular arrhythmias associated with an accessory atrioventricular pathway, as in the Wolff-Parkinson-White syndrome, unless the electrophysiological characteristics of the accessory pathway and any possible deleterious effect of digoxin on these characteristics
has been evaluated. If an accessory pathway is known or suspected to be present and there is no history of previous supraventricular arrhythmias, Lanoxin is similarly contra-indicated.
Lanoxin is contra-indicated in ventricular tachycardia or ventricular fibrillation.
Lanoxin is contra-indicated in hypertrophic obstructive cardiomyopathy, unless there is concomitant atrial fibrillation and heart failure but even then caution should be exercised if Lanoxin is to be used.
Lanoxin is contra-indicated in patients known to be hypersensitive to digoxin, other digitalis glycosides, or to any component of the preparation.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Arrhythmias may be precipitated by digoxin toxicity, some of which can resemble arrhythmias for which the drug could be advised. For example, atrial tachycardia with varying atrioventricular block requires care as clinically the rhythm resembles atrial fibrillation.</p><p>In some cases of sinoatrial disorder (ie. Sick Sinus Syndrome) digoxin may cause or exacerbate sinus bradycardia or cause sinoatrial block.</p><p>Determination of the serum digoxin concentration may be very helpful in making a decision to treat with further digoxin, but toxic doses of other glycosides may cross-react in the assay and wrongly suggest apparently satisfactory measurements. Observations during the temporary withholding of digoxin might be more appropriate.</p><p>In cases where cardiac glycosides have been taken in the preceding two weeks the recommendations for initial dosing of a patient should be reconsidered and a reduced dose is advised.</p><p>The dosing recommendations should be reconsidered if patients are elderly or there are other reasons for the renal clearance of digoxin being reduced. A reduction in both initial and maintenance doses should be considered.</p><p>Hypokalaemia sensitises the myocardium to the actions of cardiac glycosides.</p><p>Hypoxia, hypomagnesaemia and marked hypercalcaemia increase myocardial sensitivity to cardiac glycosides.</p><p>Administering Lanoxin to a patient with thyroid disease requires care. Initial and maintenance doses of Lanoxin should be reduced when thyroid function is subnormal. In hyperthyroidism there is relative digoxin resistance and the dose may have to be increased. During the course of treatment of thyrotoxicosis, dosage should be reduced as the thyrotoxicosis comes under control.</p><p>Patients with malabsorption syndrome or gastro-intestinal reconstructions may require larger doses of digoxin.</p><p>The risk of provoking dangerous arrhythmias with direct current cardioversion is greatly increased in the presence of digitalis toxicity and is in proportion to the cardioversion energy used.</p><p>For elective direct current cardioversion of a patient who is taking digoxin, the drug should be withheld for 24 hours before cardioversion is performed. In emergencies, such as cardiac arrest when attempting cardioversion the lowest effective energy should be applied. Direct current cardioversion is inappropriate in the treatment of arrhythmias though to be caused by cardiac glycosides.</p><p>Many beneficial effects of digoxin on arrhythmias result from a degree of atrioventricular conduction blockage. However, when incomplete atrioventricular block already exists the effects of a rapid progression in the block should be anticipated. In complete heart block the idioventricular escape rhythm may be suppressed.</p><p>The administration of digoxin in the period immediately following myocardial infarction is not contra-indicated. However, the use of inotropic drugs in some patients in this setting may result in undesirable increased in myocardial oxygen demand and ischaemia, and some retrospective follow-up studies have suggested digoxin to be associated with an increased risk of death. However, the possibility of arrhythmias arising in patients who may be hypokalaemic after myocardial infarction and are likely to be cardiologically unstable must be borne in mind. The limitations imposed thereafter on direct current cardioversion must also be remembered.</p><p>Treatment with digoxin should generally be avoided in patients with heart failure associated with cardiac amyloidosis. However, if alternative treatments are not appropriate, digoxin can be used with caution to control the ventricular rate in patients with cardiac amyloidosis and atrial fibrillation.</p><p>Digoxin can rarely precipitate vasoconstriction and therefore should be avoided in patients with myocarditis.</p><p>Patients with beri beri heart disease may fail to respond adequately to digoxin if the underlying thiamine deficiency is not treated concomitantly. There is also some published information indicating that digoxin may inhibit the uptake of thiamine in myocytes in beri beri heart disease.</p><p>Digoxin should not be used in constrictive pericarditis unless it is used to control the ventricular rate in atrial fibrillation or to improve systolic dysfunction.</p><p>Digoxin improves exercise tolerance in patients with impaired left ventricular systolic dysfunction and normal sinus rhythm. This may or may not be associated with an improved haemodynamic profile. However, the benefit of patients with supraventricular arrhythmias is most evident at rest, less evident with exercise.</p><p>In patients receiving diuretics and an ACE inhibitor, or diuretics alone, the withdrawal of digoxin has been shown to result in clinical deterioration.</p><p>The use of therapeutic doses of digoxin may cause prolongation of the PR interval and depression of the ST segment on the electrocardiogram.</p><p>Digoxin may produce false positive ST-T changes on the electrocardiogram during exercise testing. These electrophysiologic effects reflect an expected effect of the drug and are not indicative of toxicity.<br />Patients receiving digoxin should have their serum electrolytes and renal function (serum creatinine concentration) assessed periodically; the frequency of assessments will depend on the clinical setting.</p><p>Although many patients with chronic congestive cardiac failure benefit from acute administration of digoxin. There are some in whom it does not lead to constant, marked or lasting haemodynamic improvement. It is therefore important to evaluate the response of each</p><p>patient individually when Lanoxin is continued long-term.</p><p>Patients with severe respiratory disease may have an increased myocardial sensitivity to digitalis glycosides.<br />Patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interactions may arise from effects on the renal excretion, tissue binding, plasma protein binding, distribution within the body, gut absorptive capacity and sensitivity to Lanoxin. Consideration of the possibility of an interaction whenever concomitant therapy is contemplated is the best precaution and a check on serum digoxin concentration is recommended when any doubt exists.</p><p>Digoxin, in association with beta-adrenoceptor blocking drugs, may increase atrio-ventricular conduction time.</p><p>Agents causing hypokalaemia or intracellular potassium deficiency may cause increased sensitivity to Digoxin; they include diuretics, lithium salts, corticosteroids and carbenoxolone.</p><p>Patients receiving Digoxin are more susceptible to the effects of suxamethonium-exacerbated hyperkalaemia.</p><p>Calcium, particularly if administered rapidly by the intravenous route, may produce serious arrhythmias in digitalized patients.</p><p>Serum levels of digoxin may be increased by concomitant administration of the following:</p><p>Alprazolam, amiodarone, flecainide, gentamicin, indomethacin, itraconazole, prazosin, propafenone, quinidine, quinine, spironolactone, macrolide antibiotics (e.g. erythromycin and clarithromycin), tetracycline (and possibly other antibiotics), trimethoprim, propantheline, atorvastatin, ciclosporin, epoprostenol (transient) and carvedilol.</p><p>Serum levels of digoxin may be reduced by concomitant administration of the following:</p><p>Adrenaline (epinephrine), antacids, kaolin-pectin, some bulk laxatives, colestyramine, acarbose, salbutamol, sulfasalazine, neomycin, rifampicin, some cytostatics, phenytoin, metoclopramide, penicillamine and the herbal remedy St John&rsquo;s wort (Hypericum perforatum).</p><p>Calcium channel blocking agents may either increase or cause no change in serum digoxin levels. Verapamil, felodipine and tiapamil increase serum digoxin levels. Nifedipine and diltiazem may increase or have no effect on serum digoxin levels. Isradipine causes no change in serum digoxin levels. Angiotensin converting enzyme (ACE) inhibitors may also increase or cause no change in serum digoxin concentrations.</p><p>Milrinone does not alter steady-state serum digoxin levels.</p><p>Digoxin is a substrate of P-glycoprotein. Thus, inhibitors of P-glycoprotein may increase blood concentrations of digoxin by enhancing its absorption and/or by reducing its renal clearance (See 5.2 Pharmacokinetic Properties).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data are available on whether or not digoxin has teratogenic effects.</p><p>There is no information available on the effect of digoxin on human fertility.</p><p>The use of digoxin in pregnancy is not contra-indicated, although the dosage and control may be less predictable in pregnant than in non-pregnant women with some requiring an increased dosage of digoxin during pregnancy. As with all drugs, use should be considered only when the expected clinical benefit of treatment to the mother outweighs any possible risk to the developing foetus.</p><p>Despite extensive antenatal exposure to digitalis preparations, no significant adverse effects have been observed in the foetus or neonate when maternal serum digoxin concentrations are maintained within the normal range.<br />Although it has been speculated that a direct effect of digoxin on the myometrium may result in relative prematurity and low birthweight, a contributing role of the underlying cardiac disease cannot be excluded. Maternally administered digoxin has been successfully used to treat foetal tachycardia and congestive heart failure.</p><p>Adverse foetal effects have been reported in mothers with digitalis toxicity.</p><p>Although digoxin is excreted in breast milk, the quantities are minute and breast feeding is not contra-indicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since central nervous system and visual disturbances have been reported in patients receiving Lanoxin, patients should exercise caution before driving, using machinery or participating in dangerous activities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are listed below by system organ class and frequency.<br />Frequencies are defined as: very common (&ge; 1/10), common (&ge; 1/100 and &lt; 1/10), uncommon (&ge; 1/1000 and &lt; 1/100), rare (&ge; 1/10,000 and &lt; 1/1000), very rare ( &lt; 1/10,000), including isolated reports. Very common, common and uncommon events were generally determined from clinical trial data. The incidence in placebo was taken into account. Adverse drug reactions identified through post-marketing surveillance were considered to be rare or very rare (including isolated reports).</p><p><strong>Blood and lymphatic system disorders</strong><br />Very rare:&nbsp;Thrombocytopenia</p><p><strong>Metabolism and nutrition disorders</strong><br />Very Rare: Anorexia</p><p><strong>Psychiatric disorders</strong><br />Uncommon: Depression<br />Very rare: Psychosis, apathy, confusion</p><p><strong>Nervous system disorders</strong><br />Common: CNS disturbances, dizziness<br />Very rare: Headache</p><p><strong>Eye disorders</strong><br />Common: Visual disturbances (blurred or yellow vision)</p><p><strong>Cardiac disorders</strong><br />Common: Arrhythmia, conduction disturbances, bigeminy, trigeminy, PR prolongation, sinus bradycardia<br />Very rare: Supraventricular tachyarrhythmia, atrial tachycardia (with or without block), junctional (nodal) tachycardia, ventricular arrhythmia, ventricular premature contraction, ST segment depression</p><p><strong>Gastrointestinal disorders</strong><br />Common: Nausea, vomiting, diarrhoea<br />Very rare: Intestinal ischaemia, intestinal necrosis</p><p><strong>Skin disorders</strong><br />Common: Skin rashes of urticarial or scarlatiniform character may be accompanied by pronounced eosinophilia</p><p><strong>Reproductive system and breast disorders</strong><br />Very rare: Gynaecomastia can occur with long term administration</p><p><strong>General disorders and administration site conditions</strong><br />Very rare:Fatigue, malaise, weakness</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The symptoms and signs of toxicity are generally similar to those described in the Undesirable Effects section but may be more frequent and can be more severe.</p><p>Signs and symptoms of digoxin toxicity become more frequent with levels above 2.0 nanograms/mL (2.56 nanomol/L) although there is considerable interindividual variation. However, in deciding whether a patient&#39;s symptoms are due to digoxin, the clinical state, together with serum electrolyte levels and thyroid function are important factors (see Dosage and Administration).</p><p><strong>Adults</strong><br />In adults without heart disease, clinical observation suggests that an overdose of digoxin of 10 to 15 mg was the dose resulting in death of half of the patients.</p><p>Cardiac manifestations<br />Cardiac manifestations are the most frequent and serious sign of both acute and chronic toxicity. Peak cardiac effects generally occur 3 to 6 hours following overdosage and may persist for the ensuing 24 hours or longer. Digoxin toxicity may result in almost any type of arrhythmia. Multiple rhythm disturbances in the same patient are common. These include paroxysmal atrial tachycardia with variable atrioventricular (AV) block, accelerated junctional rhythm, slow atrial fibrillation (with very little variation in the ventricular rate) and bi directional ventricular tachycardia.</p><p>Premature ventricular contractions (PVCs) are often the earliest and most common arrhythmia. Bigeminy or trigeminy also occur frequently.</p><p>Sinus bradycardia and other bradyarrhythmias are very common.</p><p>First, second, third degree heart blocks and AV disocciation are also common. Early toxicity may only be manifested by prolongation of the PR interval.</p><p>Ventricular tachycardia may also be a manifestation of toxicity.</p><p>Cardiac arrest from asystole or ventricular fibrillation due to digoxin toxicity is usually fatal.</p><p>Hypokalaemia may contribute to toxicity (see Warnings and Precautions).</p><p>Non-cardiac manifestations<br />Acute massive digoxin overdosage can result in mild to pronounced<br />hyperkalaemia due to inhibition of the sodium-potassium (Na+-K+) pump.</p><p>Gastrointestinal symptoms are very common in both acute and chronic toxicity. The symptoms precede cardiac manifestations in approximately half of the patients in most literature reports. Anorexia, nausea and vomiting have been reported with an incidence up to 80%. These symptoms usually present early in the course of an overdose.</p><p>Neurologic and visual manifestations occur in both acute and chronic toxicity. Dizziness, various CNS disturbances, fatigue and malaise are very common. The most frequent visual disturbance is an aberration of colour vision (predominance of yellow green). These neurological and visual symptoms may persist even after other signs of toxicity have resolved.</p><p>In chronic toxicity, non-specific extracardiac symptoms, such as malaise and weakness, may predominate.</p><p>Children<br />In children aged 1 to 3 years without heart disease, clinical observation suggests that an overdose of digoxin of 6 to 10 mg was the dose resulting in death in half of the patients.</p><p>Most manifestations of toxicity in children occur during or shortly after the loading phase with digoxin.</p><p>Cardiac manifestations<br />The same arrhythmias or combination of arrhythmias that occur in adults can occur in children. Sinus tachycardia, supraventricular tachycardia, and rapid atrial fibrillation are seen less frequently in the paediatric population.</p><p>Paediatric patients are more likely to present with an AV conduction disturbance or a sinus bradycardia.</p><p>Ventricular ectopy is less common, however in massive overdose, ventricular ectopy, ventricular tachycardia and ventricular fibrillation have been reported.</p><p>Any arrhythmia or alteration in cardiac conduction that develops in a child taking digoxin should be assumed to be caused by digoxin, until further evaluation proves otherwise.</p><p>Extracardiac manifestations<br />The frequent extracardiac manifestations similar to those seen in adults are gastrointestinal, CNS and visual. However, nausea and vomiting are not frequent in infants and small children.</p><p>In addition to the undesirable effects seen with recommended doses, weight loss in older age groups and failure to thrive in infants, abdominal pain due to mesenteric artery ischaemia, drowsiness and behavioural disturbances including psychotic manifestations have been reported in overdose.</p><p><strong>Treatment</strong><br />After recent ingestion, such as accidental or deliberate self-poisoning, the load available for absorption may be reduced by gastric lavage.</p><p>Patients with massive digitalis ingestion should receive large doses of activated charcoal to prevent absorption and bind digoxin in the gut during enteroenteric recirculation.</p><p>If more than 25 mg of digoxin was ingested by an adult without heart disease, death or progressive toxicity responsive only to digoxin-binding Fab antibody fragments (Digibind&reg;) resulted. If more that 10 mg of digoxin was ingested by a child aged 1 to 3 years without heart disease, the outcome was uniformly fatal when Fab fragment treatment was not given.</p><p>Hypokalaemia should be corrected. In cases where a large amount of Lanoxin has been ingested hyperkalaemia may be present due to release of potassium from skeletal muscle. Before administering potassium in digoxin overdose the serum potassium level must be known.</p><p>Bradyarrhythmias may respond to atropine but temporary cardiac pacing may be required. Ventricular arrhythmias may respond to lignocaine or phenytoin.</p><p>Dialysis is not particularly effective in removing digoxin from the body in potentially life-threatening toxicity.</p><p>Rapid reversal of the complications that are associated with serious poisoning by digoxin, digitoxin and related glycosides has followed intravenous administration of digoxin-specific (ovine) antibody fragments (Fab) when other therapies have failed. Digibind&reg; is the only specific treatment for digoxin toxicity.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mode of Action:-<br />Digoxin increases contractility of the myocardium by direct activity. This effect is proportional to dose in the lower range and some effect is achieved with quite low dosing; it occurs even in normal myocardium although it is then entirely without physiological benefit. The primary action of digoxin is specifically to inhibit adenosine triphosphatase, and thus sodium-potassium (Na+-K+) exchange activity, the altered ionic distribution across the membrane resulting in an augmented calcium ion influx and thus an increase in the availability of calcium at the time of excitation-contraction coupling. The potency of digoxin may therefore appear considerably enhanced when the extracellular potassium concentration is low, with hyperkalaemia having the opposite effect.</p><p>Digoxin exerts the same fundamental effect of inhibition of the Na+-K+ exchange mechanism on cells of the autonomic nervous system, stimulating them to exert indirect cardiac activity. Increases in efferent vagal impulses result in reduced sympathetic tone and diminished impulse conduction rate through the atria and atrioventricular node. Thus, the major beneficial effect of digoxin is reduction of ventricular rate.</p><p>Indirect cardiac contractility changes also result from changes in venous compliance brought about by the altered autonomic activity and by direct venous stimulation. The interplay between direct and indirect activity governs the total circulatory response, which is not identical for all subjects. In the presence of certain supraventricular arrhythmias, the neurogenically mediated slowing of AV conduction is paramount.</p><p>The degree of neurohormonal activation occurring in patients with heart failure is associated with clinical deterioration and an increased risk of death. Digoxin reduces activation of both the sympathetic nervous system and the (renin-angiotensin) system independently of its inotropic actions, and may thus favourably influence survival. Whether this is achieved via direct sympathoinhibitory effects or by re-sensitising baroreflex mechanisms remains unclear.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Intravenous administration of a loading dose produces an appreciable pharmacological effect within 5 to 30 minutes; this reaches a maximum in 1 to 5 hours. Upon oral administration, digoxin is absorbed from the stomach and upper part of the small intestine. When digoxin is taken after meals, the rate of absorption is slowed, but the total amount of digoxin absorbed is usually unchanged. When taken with meals high in fibre, however, the amount absorbed from an oral dose may be reduced.</p><p>Using the oral route the onset of effect occurs in 0.5 to 2 hours and reaches its maximum at 2 to 6 hours. The bioavailability of orally administered Lanoxin is approximately 63% in tablet form and 75% as paediatric elixir.</p><p>Distribution<br />The initial distribution of digoxin from the central to the peripheral compartment generally lasts from 6 to 8 hours. This is followed by a more gradual decline in serum digoxin concentration, which is dependent upon digoxin elimination from the body. The volume of distribution is large (Vdss = 510 litres in healthy volunteers), indicating digoxin to be extensively bound to body tissues. The highest digoxin concentrations are seen in the heart, liver and kidney, that in the heart averaging 30- fold that in the systemic circulation. Although the concentration in skeletal muscle is far lower, this store cannot be overlooked since skeletal muscle represents 40% of total body weight. Of the small proportion of digoxin circulating in plasma, approximately 25% is bound to protein.</p><p>Elimination<br />The major route of elimination is renal excretion of the unchanged drug.</p><p>Digoxin is a substrate for P-glycoprotein. As an efflux protein on the apical membrane of enterocytes, P-glycoprotein may limit the absorption of digoxin. P-glycoprotein in renal proximal tubules appears to be an important factor in the renal elimination of digoxin (See 4.5 Interaction with other medicinal products and other forms of interaction).</p><p>Following intravenous administration to healthy volunteers, between 60 and 75% of a digoxin dose is recovered unchanged in the urine over a 6 day follow-up period. Total body clearance of digoxin has been shown to be directly related to renal function, and percent daily loss is thus a function of creatinine clearance, which in turn may be estimated from a stable serum creatinine. The total and renal clearances of digoxin have been found to be 193 &plusmn; 25 ml/min and 152 &plusmn;24 mil/min in a healthy control population.</p><p>In a small percentage of individuals, orally administered digoxin is converted to cardioinactivate reduction products (digoxin reduction products or DRPs) by colonic bacteria in the gastrointestinal tract. In these subjects over 40% of the dose may be excreted as DRPs in the urine. Renal clearances of the two main metabolites, dihydrodigoxin and digoxygenin, have been found to be 79 &plusmn; 13 ml/min and 100 &plusmn; 26 ml/min respectively.</p><p>In the majority of cases however, the major route of digoxin elimination is renal excretion of the unchanged drug.</p><p>The terminal elimination half life of digoxin in patients with normal renal function is 30 to 40 hours. It is prolonged in patients with impaired renal function, and in anuric patients may be of the order of 100 hours.</p><p>In the newborn period, renal clearance of digoxin is diminished and suitable dosage adjustments must be observed. This is specially pronounced in the premature infant since renal clearance reflects maturation of renal function. Digoxin clearance has been found to be 65.6 &plusmn; 30 ml/min/1.73m2 at 3 months, compared to only 32 &plusmn; 7 ml/min/1.73m2 at 1 week. Beyond the immediate newborn period, children generally require proportionally larger doses than adults on the basis of body weight and body surface area.</p><p>Since most of the drug is bound to the tissues rather than circulating in the blood, digoxin is not effectively removed from the body during cardiopulmonary by-pass. Furthermore, only about 3% of a digoxin dose is removed from the body during five hours of haemodialysis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data are available on whether or not digoxin has mutagenic or carcinogenic effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Ph Eur<br />Starches&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Ph Eur<br />Hydrolysed Starch&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;HSE<br />Magnesium Stearate&nbsp; &nbsp; &nbsp; &nbsp;Ph Eur</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                60 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amber glass bottle with low-density polyethylene snap-fit closure Pack sizes: 28, 50, 500 tablets</p><p>Amber glass bottle with a clic-loc child resistant closure Pack size: 56 tablets</p><p>White opaque PVC/aluminium foil blister Pack sizes: 30, 60, 90, 120 tablets</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen Pharma Trading Limited 
3016 Lake Drive,
Citywest Business Campus, 
Dublin 24,
Ireland
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>